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ABSTRACT 
Clopidogrel is a thienopyridine antiplatelet prodrug that was approved by the US FDA in 
1997 and quickly supplanted ticlopidine as the primary drug therapy for reducing 
atherothrombotic events.  It is converted to its pharmacologically active metabolite H4, which 
irreversibly inactivates the P2Y12 receptor on platelets, through two sequential reactions that are 
catalyzed mainly by CYP2C19.  Common clinical practice involved the coadministration of a 
proton pump inhibitor (PPI, including omeprazole, esomeprazole, lansoprazole, pantoprazole, 
and rabeprazole) with clopidogrel to decrease the risk of upper gastrointestinal bleeding.  This 
practice was formalized for high risk patients by the American Heart Association (and others) in 
2008.  By 2009, numerous publications described an unexpected decrease in clopidogrel 
efficacy when coadministered with PPIs, prompting both the US Food & Drug Administration 
(FDA) and European Medicines Agency (EMA) to issue recommendations discouraging the 
concomitant use of PPIs and clopidogrel.  Proton pump inhibitors are also metabolized by 
CYP2C19. It seemed reasonable to conclude that, despite their relatively short plasma half-
lives, PPIs might competitively inhibit CYP2C19, thereby reducing the efficacy of clopidogrel.  In 
2010, as numerous publications emerged, both regulatory agencies restricted subsequent 
warnings to only omeprazole and esomeprazole.  The interaction between clopidogrel and PPIs, 
and the potential mechanisms responsible for it, continues to be a subject of much debate in 
2015. 
This dissertation describes research that contributes to the progress made in 
understanding the basis for the interaction between clopidogrel and PPIs since the time of the 
initial regulatory statements, and in particular, why only omeprazole and esomeprazole are 
implicated in this drug interaction.   
The initial studies in this dissertation identified omeprazole (a racemic mixture of R- and 
S-enantiomers) and esomeprazole (the S-enantiomer) as not only competitive inhibitors, but 
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more importantly, metabolism-dependent inhibitors (MDIs) of CYP2C19 in human liver 
microsomes (HLM), human hepatocytes and recombinant CYP2C19.  In contrast, lansoprazole 
and pantoprazole did not cause metabolism-dependent inhibition (MDI) of CYP2C19.  In 
addition to its clinical relevance, these observations are important because they underscore the 
importance of using a low concentration of enzyme and a short incubation time with the CYP 
marker substrate in order to detect MDI of CYP enzymes in vitro.  In many previous studies of 
CYP2C19 inhibition by omeprazole or esomeprazole, the concentration of HLM was too high 
and/or the substrate incubation time was too long to detect MDI. The kinetic parameters for 
CYP2C19 inactivation by omeprazole, namely kinact and KI, were determined and used in a 
physiologically based pharmacokinetic (PBPK) model to predict the degree of CYP2C19 
inactivation under clinical conditions.  Omeprazole and esomeprazole were subsequently shown 
to be irreversible MDIs of CYP2C19, which explained why the decrease in clopidogrel efficacy 
could not be prevented in clinical studies by simply separating the doses of clopidogrel from 
omeprazole or esomeprazole. 
Subsequent studies demonstrated that, like the parent drug, two of the three major 
metabolites of omeprazole are also irreversible MDIs of CYP2C19.  The kinetic parameters for 
CYP2C19 inactivation by these metabolites were determined and, along with those for 
omeprazole and esomeprazole, used in a mechanistic static model to predict the reduction of 
H4 formation from clopidogrel under clinical conditions.  The model slightly overpredicted (by a 
factor of 2) the ability of omeprazole to block the conversion of clopidogrel to H4, its 
pharmacologically active metabolites, but otherwise established that inactivation of CYP2C19 is 
the likely mechanism for the clinical interaction between omeprazole/esomeprazole and 
clopidogrel. 
Esomeprazole and its two inhibitory metabolites, namely omeprazole sulfone and 
5-O-desmethylomeprazole, were subsequently determined to meet several criteria for 
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mechanism-based inhibition (a special case of irreversible MDI).  In addition, studies were 
initiated to test the hypothesis that the mechanism of CYP2C19 inactivation by esomeprazole 
and its metabolites involves the formation of a benzylic radical (on the 5′-methyl group) that 
binds covalently to the heme moiety.  This hypothesis was based on the observation that the 
5′-methyl group is present on the pyridine ring of those compounds that irreversibly inactivate 
CYP2C19, namely omeprazole, esomeprazole, omeprazole sulfone and 
5-O-desmethylomeprazole, but absent from those compounds that did not inactivate CYP2C19, 
namely lansoprazole, pantoprazole and 5′-hydroxyomeprazole.  Based on this hypothesis, the 
investigational PPI, tenatoprazole, which contains a 5′-methyl group, was correctly predicted to 
cause MDI of CYP2C19 whereas ilaprazole and rabeprazole, which lack a 5′-methyl group, did 
not cause MDI of CYP2C19.  These results suggest that the investigational PPI, tenatoprazole, 
but not the clinically used PPIs ilaprazole or rabeprazole, may compromise the therapeutic 
effectiveness of clopidogrel.  
Finally, studies were performed in an attempt to provide direct evidence for the proposed 
mechanism of inactivation of CYP2C19 by esomeprazole, namely the formation of a heme 
adduct.  The potential for the formation of a heme adduct in incubations of esomeprazole in 
HLM was evaluated by UHPLC analysis with UV/VIS detection and high resolution mass 
spectrometry (HRMS) with post-acquisition mass-defect filtering to identify heme and heme-
containing adducts.  Incubation of esomeprazole with NADPH-fortified HLM resulted in a 
substantial decrease in the amount of heme detectable by UHPLC with either UV absorbance or 
HRMS and appeared to show the formation of a heme adduct based on mass-defect filtering 
and isotopic distribution.  However, the putative heme adduct was subsequently identified as a 
dimer of esomeprazole sulfone (a metabolite of esomeprazole formed by CYP3A4/5).  Although 
an adduct between heme and a metabolite of esomeprazole was not ultimately identified, the 
potential for an unusual analytical artifact was revealed; namely, that sulfur-containing drugs 
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can be converted to metabolites that closely resemble a heme adduct based on mass-defect 
filtering and isotopic distribution. 
In summary, this dissertation supports the hypothesis that irreversible inactivation of 
CYP2C19 is the mechanism by which omeprazole and esomeprazole reduce the efficacy of 
clopidogrel.  This property is not shared by lansoprazole, pantoprazole, rabeprazole or 
ilaprazole. These findings support regulatory agencies’ recommendations that, in order to 
reduce the risk of gastrointestinal bleeding, clopidogrel should not be coadministered with 
omeprazole or esomeprazole but should be coadministered with other PPIs that do not 
inactivate CYP2C19.   
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1.1. The cytochromes P450 in drug metabolism 
The human cytochromes P450 (CYPs) are a superfamily of 55 functional heme-thiolate-
containing proteins that catalyze the biotransformation of a large number of endobiotic and 
xenobiotic compounds, the latter of which includes drugs, pesticides, and other commonly 
encountered small molecules (1).  Nearly 80% of all oxidative metabolism of currently used 
drugs is catalyzed by one or more of the major “drug-metabolizing CYPs” (i.e., CYP1A2, 2A6, 
2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 2J2, 3A4, and 3A5), with CYP2D6 or CYP3A4/5 involved in 
the metabolism of the majority of orally administered drugs (1-3).  CYPs are expressed 
prominently in human liver endoplasmic reticulum (microsomes), which is the major site 
involved in drug elimination, but they are also expressed to a significant extent in many other 
tissues, with the next most important site for drug metabolism being the intestinal mucosa (1,4).  
Because CYPs represent the rate-limiting step in the metabolism of many drugs, they play a key 
role in determining the potency and duration of action of these same drugs.  Therefore, a 
decrease in the activity of these enzymes can lead directly to type A toxicity (defined below), 
especially upon repeated dosing, thus allowing accumulation of a “victim drug” (defined below).   
Relevance of drug-drug interactions to toxicology 
To appreciate the relevance of adverse drug reactions to the study of toxicology, certain 
definitions must first be considered.  Much of the current literature attempts to use various terms 
to describe the same thing, and to some extent the choice of term depends on the intended 
audience or other context of the particular communication.  For instance, the FDA frequently 
uses the term “side effects”, but generally only in information intended to be disseminated to the 
public at large, because the term “side effect” is often used informally to refer to any adverse 
drug reaction (ADR) (5).  In contrast, FDA-approved drug labels (a.k.a. prescribing information) 
do not use the term “side effects” and instead use the term “adverse reactions”.  Alternatively, 
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some authors use the phrase “adverse drug event” when describing any harmful or unpleasant 
event that occurs while a patient is taking a drug, so it has been suggested that this term is 
confusing and should not be used (6).  For instance, adverse events encountered during the 
course of drug therapy can include any untoward or unplanned occurrence (e.g., unplanned 
pregnancy while a patient is on an oral contraceptive, an accident, or deterioration in a 
concurrent illness), and may or may not be due to the drug therapy itself (6).  The term “adverse 
drug reactions” (ADRs) will therefore be used in this dissertation as defined by Aronson: “an 
appreciably harmful or unpleasant reaction, resulting from an intervention related to the use of a 
medicinal product" (6).  ADRs can occur in monotherapy, the majority of which are predictable 
from their known pharmacologic mechanism of action (7), but they can also occur when 
combinations of two or more drugs are coadministered (i.e., ADRs resulting from drug-drug 
interactions).  Drug-drug interactions can be pharmacodynamic in nature.  For example, drugs 
that have antiplatelet activity and drugs that impede vitamin K absorption potentiate the 
anticoagulant effect of warfarin without necessarily impacting its pharmacokinetic disposition, 
and can lead to serious ADRs.   
The relevance of increased toxicity resulting from pharmacokinetic drug-drug 
interactions to public safety has been indirectly addressed in a number of studies.  To estimate 
the impact of drug-drug interactions on public safety, the overall number of ADRs of any kind 
must first be considered.  The frequently-cited study by Lazarou and colleagues on the 
incidence of ADRs in hospitalized patients over the 30-year period from 1966-1996 suggests 
that over 2.2 million serious ADRs occurred annually during this time, with 106,000 deaths occur 
per year in the U.S. alone due solely to ADRs (8).  If still true, it would mean that ADRs are the 
fourth leading cause of death in the U.S. ahead of diabetes, pneumonia, and automobile 
accidents.  It has also been estimated that over 350,000 ADRs occur in U.S. nursing homes 
each year, six percent of which were life-threatening, and 51% of which were judged to be 
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preventable (9).  Importantly, these estimates do not include the number of ADRs in ambulatory 
settings.  While there may be many reasons for these ADRs, it is reasonable to hypothesize that 
many are caused by an increased or decreased exposure to victim drugs by perpetrator drugs 
(i.e., other drugs, genetic polymorphisms or other factors that alter the disposition of the victim 
drug).  Certain statistics underlie this hypothesis.  For instance, 69% of all patient visits to 
primary care physicians result in a prescription, with 21% of those visits resulting in four or more 
drugs being prescribed (10).  In total, there were 3.9 billion retail prescriptions filled in 2013, or 
approximately 12 prescriptions for every person in the U.S (11).  Most importantly, the rate of 
ADRs increases exponentially after a patient is prescribed four or more drugs (12).  While many 
of these ADRs result from pharmacodynamic interactions, there are also many cases that 
suggest a pharmacokinetic origin.  For instance, it has been found that a known 
pharmacokinetic drug interaction was the suspected cause of the ADR in 26% of cases in one 
study (13). Leape and colleagues also estimated that known drug-drug interactions represent 
3-5% of all in-hospital medication errors.  Even if many of these interactions are 
pharmacodynamic in nature, the fact that most pharmacodynamic interactions are easily 
predictable from their pharmacological action underscores the importance of pharmacokinetic 
drug-drug interactions which can be difficult for a clinician to predict from the more obvious 
characteristics of the interacting drugs.   
Types of drug-induced toxicities 
The types of toxicity caused by drugs and/or their metabolites have been historically 
classified according to various systems.  More recent systems propose four major types (A, B, 
C, and D, define below) (5,6,14,15).  Some ADRs can be difficult to classify or overlap with 
other categories, so two additional categories, types E and F have also been proposed (5).  In 
type A toxicity, there is a pharmacological basis for the effect, one based on the 
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pharmacological target of the active drug (type A1) and the other based on off-target 
pharmacology (type A2), but in either case, the toxic effects are “selective”, and for the most 
part, dose-related and predictable on the basis of their pharmacological mechanism of action.  
This type of toxicity can be thought of as an extension of pharmacological effect, and can occur 
when the drug, or its pharmacologically active metabolites, reach supratherapeutic 
concentrations at the target as in overdose situations, or even with typical dosing in so-called 
poor metabolizers of the drug (16,17).  Examples of type A1 toxicity can include the 
extrapyramidal effects of dopamine receptor agonists, gastrointestinal bleeding due to inhibition 
of cyclooxygenase-1 (COX1) by nonsteroidal anti-inflammatory drugs, or hypotension upon 
administration of propofol.  Type A2 toxicity occurs when the drug or its metabolites bind to and 
alter the activity of an enzyme or receptor that is not the designated pharmacological target.  A 
very well-known example of this type of toxicity is the binding of terfenadine (a non-sedating H1 
receptor antagonist) to the rapidly-acting delayed rectifier (IKr) potassium channels in the heart 
which can lead to QT interval prolongation and fatal torsade de pointes (18).  Most side effects 
are examples of minor Type A toxicity, and many inhibitory pharmacokinetic drug-drug 
interactions cause Type A toxicity. 
Types B, C, and D toxicities are typically thought of as nonselective.  Type B toxicity 
refers generally to toxicities that do not necessarily display typical dose-response relationships, 
are observed in very few patients, and are therefore frequently termed “idiosyncratic” or 
occasionally “bizarre”, and are generally not described as dose-dependent.  Strictly speaking, 
however, “idiosyncratic” toxicity refers to toxicity that occurs due to a known genetic 
predisposition, for instance, the prolonged muscle relaxation and apnea that occurs with a 
standard dose of succinylcholine in individuals that possess a genetic polymorphism for 
butyrylcholinesterase that confers a low activity or complete lack of this enzyme (19).  Type B 
toxicity is, however, frequently referred to as “idiosyncratic” in the contemporary literature, in 
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spite of the fact that an underlying genetic predisposition may not be known.  Type C toxicity 
refers to cases in which the drug or its metabolites reacts chemically with tissue 
macromolecules, and is both dose and time-related (20). Type C toxicity is not frequently 
associated with drugs with notable exceptions including alkylating agents used in cancer 
chemotherapy, which are designed to react directly with macromolecules in tumor cells.  
Additionally, in some cases, drugs can be bioactivated to chemically reactive species that 
covalently bind to proteins, which is the case with the CYP2C9 inhibitor, tienilic acid, which was 
withdrawn from the market due to formation of an electrophilic thiophene sulfoxide within the 
CYP2C9 active site and subsequent formation of anti-liver and kidney microsome antibodies 
(anti-LKM2) (16).  Type D toxicity has underlying mechanisms that are similar to types B and C, 
although the response is time- but not typically dose-related.  The effect can be quite delayed 
(e.g., months to years), and therefore includes the toxicity caused by carcinogens and 
teratogens.  Type E toxicity refers to so-called “end of treatment effects” (e.g., discontinuation 
symptoms after prolonged use of selective serotonin reuptake inhibitors, rebound hypertension 
after cessation of clonidine, opioid withdrawal syndrome, etc.) and the effects are generally 
ameliorated by reintroduction of the drug. Type F toxicity refers to adverse events that result 
from “failure of therapy”, which can have different causes as described below (5,20,21). 
Type F toxicity, or failure of therapy bears special mention here because this type of 
adverse drug reaction is frequently the result of genetic polymorphisms when a prodrug must 
first be converted to an active metabolite.  For instance, codeine must be O-demethylated to 
form morphine (predominantly by CYP2D6) in order to exert its pharmacological effect (i.e., 
analgesia).  Genetic polymorphisms of CYP2D6 have been well described with some individuals 
completely lacking an active form of CYP2D6.  The frequency of the CYP2D6 poor-metabolizer 
(PM) phenotype varies from one ethnic group to another, but it is generally held that 5-7% of 
Caucasians, 2–4% of black Africans and African Americans, and 1–2% of Asians (Chinese and 
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Japanese) populations are CYP2D6 PMs, with higher rates in South Asians (1,20).  Thus, in PM 
patients, codeine is a much less effective analgesic than in patients with higher CYP2D6 activity 
(i.e., intermediate, extensive and ultrarapid metabolizers [IMs, EMs and UMs, respectively]).  
CYP2D6 also converts tamoxifen to endoxifen, which is 30- to 100-fold more potent than 
tamoxifen in suppressing estrogen-dependent cell proliferation, and thus prevents breast 
cancer.  Therefore, postmenopausal women who previously had estrogen receptor–positive 
breast cancer and are also CYP2D6 PMs treated with tamoxifen for > 5 years are at an 
increased risk for breast cancer recurrence (1,22).  The polymorphic enzyme CYP2C19 has 
also been strongly implicated for its role in the multi-step conversion of the antiplatelet drug 
clopidogrel to its pharmacologically active metabolite, a reactive thiol often referred to as H4 
(1,23).  The evidence for the involvement of CYP2C19 in the conversion of clopidogrel to H4 will 
be discussed in greater detail in later sections. 
Failure of therapy is also frequently the result of drug-drug interactions.  This is most 
commonly discussed in the setting of a pharmacokinetic interaction when the perpetrator drug 
induces an enzyme involved in the clearance of the victim drug (e.g., oral contraceptive failure 
upon coadministration of rifampin) (1).  Pharmacodynamic interactions can also lead to failure of 
therapy, such as when amphetamines are coadministered with antihypertensives, thus 
decreasing the antihypertensive effect because these drugs increase blood pressure (24).  
Finally, just as genetic polymorphisms are implicated in failure of therapy of prodrugs as 
discussed above, inhibition of the enzymes involved in the conversion such prodrugs through 
coadministration of a perpetrator drug can also lead to failure of therapy.  It is specifically for this 
reason that the 2013 FDA prescribing information for clopidogrel states that “concomitant use of 
certain drugs that inhibit the activity of [CYP2C19] results in reduced plasma concentrations of 
the active metabolite of clopidogrel and a reduction in platelet inhibition” (25).  Likewise, the 
2013 FDA prescribing information for codeine states that “drugs that are strong inhibitors of 
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codeine O-demethylation (cytochrome P-450 2D6) may decrease the plasma concentrations of 
codeine’s active metabolites, morphine and morphine-6-glucuronide” (26).  
The broad focus of this dissertation is on the pharmacokinetic interaction between 
omeprazole or esomeprazole (perpetrators) and victim drugs that are CYP2C19 substrates.  
Although this interaction has implications for any drug that is metabolized in large part by 
CYP2C19 such as moclobemide, diazepam, R-mephobarbital, proton-pump inhibitors (PPIs) 
(due to reaching supratherapeutic concentrations, i.e., Types A1 and A2 toxicities), the 
interaction with the CYP2C19 substrate and prodrug, clopidogrel, is of special importance as an 
example of failure of therapy caused by a drug-drug interaction (27).  Therefore, the main 
toxicological focus of this dissertation will be on Type F toxicity.   
1.2. Drugs as victims and perpetrators of pharmacokinetic drug-drug 
interactions 
From a drug-drug interaction perspective, drugs can be evaluated for their victim and 
perpetrator potential. Victims are those drugs whose clearance is predominantly determined by 
a single route of elimination, such as metabolism by a single cytochrome P450 (CYP) enzyme.  
Such drugs have a high victim potential because inhibition or complete loss of that elimination 
pathway, either due to a genetic deficiency in the relevant CYP enzyme or due to its inhibition 
by another, concomitantly administered drug, will result in a large decrease in clearance and a 
correspondingly large increase in exposure to the victim drug (e.g., area under the plasma 
concentration-time curve or AUC). Perpetrators are those drugs (or other environmental factors) 
that inhibit or induce the enzyme that is otherwise responsible for clearing a victim drug.  
Genetic polymorphisms that result in the partial or complete loss of enzyme activity (i.e., the 
intermediate and poor metabolizer genotypes) can also be viewed as perpetrators because they 
9 
 
have the same effect as an enzyme inhibitor: they cause a decrease in the clearance of – and 
an increase in exposure to – victim drugs. Likewise, genetic polymorphisms that result in the 
over-expression of enzyme activity (i.e., the UM genotype) can be viewed as perpetrators 
because they have the same effect as an enzyme inducer: they cause an increase in the 
clearance of – and a decrease in exposure to – victim drugs.  Several drugs whose elimination 
is largely determined by their CYP2C9- CYP2C19- or CYP2D6-mediated metabolism (three 
genetically polymorphic enzymes), are victim drugs because their clearance is diminished in 
PMs, i.e., individuals who are genetically deficient in one of these enzymes.  Drugs for which 
disposition is largely dependent on uptake or efflux by a transporter or on metabolism by a drug-
metabolizing enzyme other than cytochrome P450 can also be considered from the 
victim/perpetrator perspective.  From a drug interaction perspective, victim drugs are also 
known as objects, whereas perpetrators are also occasionally referred to as precipitants (16). 
Cerivastatin, terfenadine, cisapride, dofetilide and astemizole, are all victim drugs, to 
such an extent that they have all been withdrawn from the market or, in the case of cisapride 
and dofetilide, made available with severe restrictions (28).  These drugs are victim drugs 
because they are metabolized to a large extent by CYP3A4, the most abundant drug-
metabolizing CYP in the small intestine and the liver.  Inhibition of CYP3A4 by various 
antimycotic drugs such as ketoconazole, and antibiotic drugs such as erythromycin, decreases 
the clearance of terfenadine, cisapride, dofetilide and astemizole and increase their plasma 
concentrations to levels that, in some individuals, can cause fatal ventricular arrhythmias (i.e., 
QT prolongation and torsade de pointes) (16,28). 
The primary purpose of evaluating drugs as inhibitors of CYP enzymes in vitro is to 
determine their perpetrator or precipitant potential before advancing a candidate drug to a late 
stage of development.  However, identifying a drug as an in vitro inhibitor of a given CYP 
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enzyme does not imply that the drug will necessarily cause clinically relevant drug interactions.  
The clinical relevance of the inhibition must be considered in the following context: 
(1) The pharmacokinetics of the perpetrator (inhibitory) drug. 
(2) The potential of administering the perpetrator with a victim drug. 
(3) The extent to which the clearance of the victim drug is dependent on the inhibited CYP 
enzyme (i.e., fm(CYP)). 
(4) The potential for saturating or inactivating the enzyme that metabolizes the victim drug. 
(5) The clinical consequences of altering the pharmacokinetics of the victim drug (which 
may or may not be a cause for concern depending on the drug’s therapeutic index). 
(6) The therapeutic indication of the perpetrator and victim drug.  Drugs used to treat life-
threatening diseases (e.g., cancer, HIV) are permitted more regulatory leeway than life-
style enhancing drugs (such as drugs to treat baldness) or drugs that are not first-in-
class (as in the case of mibefradil, the withdrawal of which was facilitated by its being 
one of many calcium channel blockers on the market) (16). 
The in vitro studies detailed in this dissertation describe a set of tools for predicting the 
potential for inhibitory drug interactions.  Needless to say, a well-designed in vitro study can in 
most cases be a powerful predictor of clinical outcome.  Unfortunately, it is easy to design an in 
vitro experiment that is analytically sound but is so seriously flawed that it provides meaningless 
data.  For example, if amodiaquine (a high-turnover marker substrate for CYP2C8) is incubated 
under the same conditions (i.e., up to 1 mg/mL microsomal protein and 30 min incubation time) 
that are sometimes used for S-mephenytoin (a low turnover marker substrate for CYP2C19), 
then most of the amodiaquine would be converted to N-desethylamodiaquine.  Under such 
conditions, a drug candidate that partially inhibits CYP2C8 may go undetected because only 
marked inhibition of CYP2C8 will prevent complete metabolism of amodiaquine and decrease 
the amount of N-desethylamodiaquine formed.   
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1.3. Site of pharmacology versus site of toxicity 
In most cases when type A toxicity results from pharmacokinetic drug-drug interactions, 
it is simply because the victim drug accumulates in the systemic circulation upon repeated 
dosing, and the concentration of the drug is essentially the same at the site of pharmacology 
and the site of toxicity.  In some cases the drug is actively excluded from what would otherwise 
be the site of toxicity.  Such is the case with loperamide which slows gastric motility by 
interaction with opioid receptors in the gastrointestinal tract, but is actively excluded from the 
central nervous system in large part by the action of P-glycoprotein (MDR1), thus greatly 
minimizing the typical central toxicity observed with most opioid agonist analgesics (e.g., 
respiratory depression, lethargy) (29).  In other cases, the site of pharmacology for a drug is 
limited to a single organ, and low systemic bioavailability is desirable if the drug can be 
selectively delivered.  Such is the case with some of the statins, which generally have low 
systemic bioavailability (i.e., <5 to 20%, with only three, namely fluvastatin, cerivastatin and 
pitavastatin having more than 30%) (30), and are avidly taken up into hepatocytes, where they 
exert their desired pharmacological effect (i.e., inhibition of hepatic cholesterol synthesis).  
1.4. Overview of the in vitro evaluation of CYP inhibition 
Two major types of CYP inhibition are possible: direct inhibition and time-dependent 
inhibition (sometimes termed “reversible” and “irreversible”).  Direct inhibition occurs when a 
drug inhibits a CYP enzyme without a significant lag (i.e., as soon as it binds to the CYP 
enzyme) and without requiring biotransformation.  Examples of direct inhibition include inhibition 
of CYP2D6 and CYP3A4 by quinidine and ketoconazole, respectively.  Direct inhibition can 
occur with typical (Michaelis-Menten) or atypical kinetics, including partial inhibition, or two-site 
binding with heterotrophic cooperation.  Time-dependent inhibition occurs when the inhibitory 
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potency of the drug candidate increases with incubation time, which may simply reflect a slow 
on-rate or more commonly, biotransformation of the drug to a more potent inhibitor of the 
enzyme.  Time-dependent inhibition includes the quasi-irreversible or irreversible metabolism-
dependent inhibition caused by drugs such as troleandomycin, mibefradil, diltiazem, tienilic acid, 
halothane, and furafylline (1,16).  
Guidelines for detecting these types of CYP inhibition in vitro have been described in 
some detail by regulatory agencies such as the FDA and EMA, and in publications (31,32).  The 
hallmark of methods that meet or exceed the recommendations in these sources is the use of 
clinically used CYP-selective marker substrates in an appropriate in vitro test system (typically 
pooled human liver microsomes; for examples, see (33-35) and Chapters 3-6 in this 
dissertation.  Because the FDA and EMA prefer that these substrates are clinically used drugs 
whenever possible, none of these are amenable to rapid analytical methods that make use of 
optical plate readers.  Because of this, most definitive CYP inhibition studies must employ some 
type of separation technique such as HPLC, GC, capillary electrophoresis, etc.  These methods 
can be coupled with flow-through (or occasionally stop-flow) detection such as UV, 
fluorescence, radiometric, mass spectrometry, etc.  With the exception of LC-MS/MS methods, 
most of these methods require relatively long analytical run-times, which may limit throughput 
regardless of any automation applied to the incubation step. 
In the absence of analytical equipment that can detect extremely low (sub-nanomolar) 
concentrations of all typical CYP marker metabolites (e.g. << 0.3 ng/mL), certain compromises 
in the design of CYP inhibition studies are required.  The optimal design of an in vitro CYP 
inhibition study should therefore be based on a balance of microsomal protein concentrations, 
incubation times, marker substrates, positive control inhibitors, buffer components, automated 
liquid-handling systems, and analytical techniques all chosen specifically to minimize the 
limitations of each component.  For instance, protein concentrations can have a dramatic effect 
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on the results due to partitioning of the test compound into microsomal membranes (often 
referred to simply as “nonspecific binding”), such that lower protein concentrations generally 
provide results that are less likely to provide a false-negative result (i.e., a result of little or no 
inhibition in vitro, but clinically significant inhibition) (16,35,36).  Additionally, the substrate 
incubation time can also have a dramatic effect on the interpretation of metabolism-dependent 
inhibition, such that a shorter substrate incubation time provides a more accurate result (16,35).  
The methods described in this dissertation generally make use of very low protein 
concentrations (≤0.1 mg/mL) and uniform substrate incubation times (5 min).  Analytical 
methodology is central to achieving these conditions, and the methods have lower limits of 
quantitation as low as 0.3 ng/mL, as described previously (16,33-35,37,38).   
The starting point for these studies is a single experiment to determine three IC50 values 
from the same seven concentrations of drug: one for direct inhibition (zero-min pre-incubation 
with NADPH), one for time-dependent inhibition (30-min pre-incubation without NADPH), and 
one for NADPH- (and therefore metabolism-dependent) inhibition. If these IC50 determinations 
are designed with the substrate concentration approximately equal to Km for the marker 
reaction, the Ki value will be equal to one-half the IC50 value if the inhibition is competitive and 
equal to the Ki value if inhibition is noncompetitive (16,39).  This simple relationship provides 
more reason to begin an evaluation of CYP inhibition with IC50 rather than Ki determinations 
because a conservative estimate of the Ki value can be used to estimate the potential clinical 
significance of such in vitro inhibition (31). In follow up studies (e.g., determinations of Ki for 
direct inhibition, or KI and kinact for metabolism-dependent inhibition), most of the basic principles 
outlined above apply as well.  These studies can provide a quantitative measure of both direct 
and metabolism-dependent inhibition (i.e., inhibition by one or more CYP-dependent 
metabolites).  A potential limitation of this approach in human liver microsomes is the fact that 
potentially important non-CYP-dependent metabolites will not be formed if an added co-factor is 
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required (e.g. UDP-glucuronic acid).  For instance, glucuronidation converts gemfibrozil to a 
potent inactivator of CYP2C8 in vitro and causes clinically significant inhibition of CYP2C8 at 
even small multiple doses (i.e., 30 mg b.i.d. for 5 days, or 1/20 the normal dose) (33,40-43).   
1.5. Clopidogrel as a victim drug 
Clopidogrel is an antiplatelet thienopyridine prodrug indicated for prevention of 
cardiovascular death, myocardial infarction (MI), stroke or other major adverse cardiac events 
(MACE) in the setting of recent acute coronary syndrome, MI, stroke, or established peripheral 
arterial disease as well as prevention of stent thrombosis in patients undergoing percutaneous 
coronary intervention (PCI) (25).  Most of the absorbed clopidogrel (85-92% of circulating 
metabolites) is hydrolyzed by human carboxylesterase 1 (HCE1; gene symbol CES1) and other 
esterases to an inactive acid metabolite (1,44).  The remaining clopidogrel must undergo a 
multistep activation by multiple CYP enzymes, notably including CYP2C19, via the intermediacy 
of 2-oxo-clopidogrel, as shown in Figure 1.1 to the active 4b-cis-thiol metabolite, frequently 
called H4 (45-49).  The second CYP-mediated step converts 2-oxo-clopidogrel to a highly 
reactive S-oxide which readily reacts with water to produce sulfenic acid intermediates that are 
subsequently reduced to thiols (50) (for simplicity, the proposed intermediate steps are not 
shown in Figure 1.1).  The thiol “metabolite” of clopidogrel frequently referred to in literature 
actually exists as a mixture of four diastereomers, H1-H4, as well as a fifth “endo” thiol formed 
by PON1, but only H4 is responsible for clopidogrel’s antiplatelet activity (50-52). H4 exerts its 
pharmacological effect by irreversibly inactivating the platelet membrane G-protein coupled 
purinergic receptor known as P2Y12, which thereby decreases platelet activation by diminishing 
the ADP-dependent activation of the GpIIb-IIIa complex, the major receptor for fibrinogen on 
platelets (52).   
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Figure 1.1. Activation of clopidogrel by CYP enzymes 
The major CYP-dependent pathway is in red and other reactions are in blue.  Note that the 
second CYP-mediated step has been proposed to involve the intermediacy of an S-oxide which 
readily reacts with water to produce sulfenic acid intermediates that are subsequently reduced 
to thiols, including H4 (50).  For simplicity, the proposed intermediate steps are not shown. 
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The possibility of an interaction between proton pump inhibitors and clopidogrel is 
central to this dissertation because PPIs are coadministered with this anti-platelet drug in up to 
two-thirds of patients after discharge from the hospital for acute coronary syndromes (53).  PPIs 
are a well-characterized class of drugs, first introduced with the 1989 approval of omeprazole, 
that irreversibly inactivate the gastric parietal cell H+/K+ ATPase (gene symbol ATP4A).  All 
currently marketed PPIs are 2-pyridylmethylsulfinylbenzimidazole derivatives, with one 
imidazopyridine (i.e., tenatoprazole) in development (for a general structural scheme of PPIs, 
see Table 1.1).  The gastric proton pumps couple ATP hydrolysis with the exchange of 
extracellular K+ ions for cytoplasmic protons in the gastric parietal cell canaliculi in the final step 
of hydrochloric acid production.  PPIs are neutral lipophilic prodrugs that become protonated to 
form a sulfenic acid in the acidic parietal cell canaliculi.  The reactive sulfenic acid then 
hydrolyzes to the active cyclic sulfenamide form of the drug which covalently binds to cysteine 
residues of the gastric parietal cell H+/K+ ATPase as illustrated in Figure 1.2. 
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Figure 1.2. Acid catalyzed activation of proton pump inhibitors 
The activation of PPIs in the acidic environment of the gastric parietal cell canaliculi is shown.  
R-groups are as defined in Table 1.1.   
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Because this inactivation is irreversible, PPIs provide up to 48 h of acid suppression in 
spite of their short pharmacokinetic half-lives (typically <2 h; see Table 1.2) (54).  The major 
motivation for coadministration of PPIs and clopidogrel is to decrease the incidence of bleeding 
gastric ulcers because up to 12% of patients experience a bleeding ulcer within one year of 
starting clopidogrel, and PPI coadministration can decrease this risk of severe gastrointestinal 
bleeding (55).  Although clopidogrel does not cause gastrointestinal ulcers or erosions on its 
own, it is obvious that its mechanism of action can promote bleeding at lesions that are caused 
by the typically-coadministered aspirin (i.e., dual antiplatelet therapy – DAPT) or other drugs 
that can injure the gastric mucosa (e.g., NSAIDs).  H2 receptor antagonists (e.g., famotidine) 
have been found to confer only a modest benefit in preventing GI bleeding in clopidogrel-treated 
patients, whereas PPIs can reduce GI bleeding in this clinical setting by up to 50% (47).  
Because of these findings, the expert consensus report from the American College of 
Cardiology Foundation (ACCF), the American College of Gastroenterology (ACG), and the 
American Heart Association (AHA) recommend the coadministration of a PPI with 
thienopyridines in patients at high risk of gastrointestinal bleeding (47,56).  
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Table 1.1 General structural scheme of proton pump inhibitors 
 
Compound 
Substituents 
Stereochemistry 
X R1 R2 R3 R4 R5 
Omeprazole CH OCH3 H CH3 CH3 CH3 Racemate 
Esomeprazole CH OCH3 H CH3 CH3 CH3 S-Enantiomer of omeprazole 
Lansoprazole CH H H CH3 CH2CF3 H Racemate 
Dexlansoprazole CH H H CH3 CH2CF3 H R-Enantiomer of lansoprazole 
Pantoprazole CH OCHF2 H OCH3 CH3 H Racemate 
Rabeprazole CH H H CH3 (CH2)3OCH3 H Racemate 
Ilaprazole a CH Pyrrole H CH3 CH3 H Racemate 
Tenatoprazole b N OCH3 H CH3 CH3 CH3 Racemate 
AGN201904 c CH OCH3 §§ CH3 CH3 CH3 Prodrug of racemic omeprazole 
* Chiral center 
Sources: (57-63) 
a Ilaprazole is not currently FDA-approved. 
b Tenatoprazole, unlike the other PPIs is not a benzimidazole derivative, and consists of an 
imidazopyridine ring connected to a pyridine ring by a sulfinylmethyl chain.  It is not currently 
FDA-approved. 
c AGN201904 is not currently FDA-approved. 
§§ For AGN201904, R2 is sulfonylphenoxyacetate (-SO2-Ø-OCH2COOH).  Hydrolysis of this 
substituent releases omeprazole. 
X N
N
R1
S
O
R2
N
R5
OR4R3
1
2
34
5
6
7
*
1´
2´
3´
4´
5´
6´
Benzimidazole 
Sulfoxide 
Pyridine 
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Table 1.2 Pharmacokinetics of selected PPIs 
PPI 
Molecular 
weight 
(g/mol) 
Dose 
(mg) 
AUC 
(µg∙h/mL) 
Cmax 
(µg/mL) 
Cmax 
(µM) 
Tmax 
(h) 
t1/2 
(h) 
BA 
(%) 
Omeprazole 345.4 20 0.2-2.0 0.08-8.0 0.23-23 1-3 0.6-1.5 40–65 
Esomeprazole 345.4 40 7.3-13 3.5-5.1 10-15 1.6 1.1-1.6 >80 
Lansoprazole 369.4 30 1.7-5.2 0.6-1.2 1.6-3.2 1.7 0.9-1.6 >80 
Pantoprazole 383.4 40 2-16 1.1-3.3 2.9-8.6 2.5-4 0.9-1.9 77 
Rabeprazole 359.4 20 0.8-2.2 0.41-0.98 1.1-2.7 3.1 1-1.1 52 
Ilaprazole a 366.4 40 7.6 0.11 3.0 3.5 5.0 ND 
Tenatoprazole b 346.4 40 75-100 5.3-7.0 15-20 2-4 5.6-9.3 ND 
Sources: (59,61-63) 
BA: Oral bioavailability 
a Ilaprazole is not currently FDA-approved. 
b Tenatoprazole is not currently FDA-approved. 
ND: Not determined 
Note: Dexlansoprazole is not included in this table because the clinically used form of this drug 
consists of a mixture of two types of enteric-coated granules with different pH-dependent 
dissolution profiles, such that its pharmacokinetics are not comparable with other PPI 
formulations. 
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Published clinical evidence for the importance of CYP2C19 in the activation of 
clopidogrel 
As illustrated in Figure 1.1, CYP2C19 plays a prominent role in the conversion of 
clopidogrel to 2-oxo-clopidogrel and on to the active metabolite, H4.  The role of CYP2C19 in 
one or both of these steps has been a matter of considerable debate in the scientific literature 
since the first paper on the topic was published nine years after the FDA approved clopidogrel 
(64).  A search in PubMed for CYP2C19 and clopidogrel shows that over 600 papers cover 
these topics together to some extent.  The interest in the activation of clopidogrel by this 
enzyme in particular stems largely from the fact that CYP2C19 is polymorphically expressed 
with 34 alleles named through 2013 (65).  CYP2C19*1 homozygotes are considered the “wild-
type”, or extensive metabolizers (EMs).  The CYP2C19*2 and *3 alleles generate a CYP2C19 
enzyme with no activity and individuals who are homozygous or compound heterozygous for 
them account for the vast majority of CYP2C19 poor-metabolizers (PMs).  The *4, *5, *6, *7 and 
*8 alleles also confer no, or decreased activity, but their frequency is low compared with *2 and 
*3 (65).  The *17 allele confers increased CYP2C19 activity and is reportedly present in 10–27% 
of Europeans or Africans, with very low frequencies in Asians (i.e., <1%), and is considered by 
most authors to confer an ultra-rapid metabolizer phenotype (UMs) (65).  Heterozygotes 
carrying a normal or increased activity allele and a loss-of-function allele are generally 
considered intermediate metabolizers (IMs), or occasionally “reduced metabolizers” (66).  The 
frequency of the CYP2C19 PM phenotype varies markedly by ethnic group and is found in 
13-23% of Japanese, Chinese, Korean, Vietnamese and Indian populations, 3–5% in black 
African and African Americans, 1-7% in Caucasians (dependent on location), ~26% of 
Australian aboriginals, ~14% in South Pacific Islanders, and with a very high incidence (79%) on 
the island of Vanuatu (1).   
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Between 2007 and 2014 at least 30 clinical studies have examined the effects of the 
most common CYP2C19 loss-of-function alleles on the pharmacodynamics and/or 
pharmacokinetics of clopidogrel (27,67).  Several of these studies suggest that the presence of 
a CYP2C19 loss-of-function allele decreases the antiplatelet effect of clopidogrel, but there is 
considerable variability in the results, especially when pharmacodynamic endpoints alone are 
assessed (the vast majority of studies).  However, the reported association between decreased 
efficacy of clopidogrel and either CYP2C19 loss-of-function alleles or its inhibition by PPIs 
(discussed in greater detail below) prompted the FDA to take the unusual step of requiring the 
manufacturers of Plavix® (Sanofi-Aventis and Bristol-Myers Squibb) to conduct post-marketing 
studies to investigate the role of CYP enzymes in the bioactivation of clopidogrel (which had not 
been performed prior to its original approval in 1997), as well as to assess the impact of 
CYP2C19 loss-of-function alleles and interactions with PPIs (51).  The resulting clinical study 
sponsored by Sanofi-Aventis and Bristol-Myers Squibb in 40 healthy subjects (n=10 each from 
genetically determined CYP2C19 UMs, EMs, IMs and PMs) demonstrated that the mean 
exposure to H4 was 58–71% lower in PMs than in EMs (68).  The sponsor also conducted a 
pooled analysis of P2Y12 receptor, CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP3A5, CYP2D6, 
and P-gp polymorphisms in 396 healthy subjects and found that only CYP2C19 status had a 
significant impact on the antiplatelet effect of clopidogrel (68).   
The clinical study required by the FDA and sponsored by Sanofi-Aventis and Bristol-
Myers Squibb (68) would seem to have settled the question of the importance of CYP2C19 vs. 
CYP3A4 or other enzymes in the activation of clopidogrel.  In a previous study, coadministration 
of the strong CYP3A4 inhibitor, ketoconazole, with clopidogrel decreased exposure to H4 by 
only 22% (69).  In spite of these studies, there are several authors who maintain that CYP3A4, 
not CYP2C19, is the major CYP involved in the bioactivation of clopidogrel, and some further 
speculate that the “link of CYP2C19 genotype to platelet activity may be because an 
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endogenous substrate of CYP2C19, perhaps a polyunsaturated acid that yields a product that 
inhibits platelet aggregation” (70).  The latter hypothesis could only explain the link between 
CYP2C19 polymorphisms and pharmacodynamic endpoints such as platelet aggregation, or 
time to first MACE, not the link to decreased exposure to H4.  A later paper by one of these 
authors further states that clopidogrel “is primarily a CYP3A substrate. The TV commercials that 
tell one not to take clopidogrel with Nexium [esomeprazole] are not supported by the data” (71).  
It is notable that neither of the papers above cite the 2011 Simon paper sponsored by Sanofi-
Aventis and Bristol-Myers Squibb (68).  I very much disagree that the advice from the FDA to 
avoid clopidogrel coadministration with esomeprazole is “not supported by the data”, especially 
given that there are alternative PPIs that do not cause clinically significant interactions with 
CYP2C19 substrates (covered in more detail below).  I concede that as several authors have 
pointed out, many factors (e.g., diet, co-medications, compliance, exercise, genetic 
susceptibility to cardiovascular disease) undoubtedly come into play when considering the 
pharmacodynamic response or especially long-term outcomes with clopidogrel treatment across 
even a relatively large patient population.  However, I propose that if it is accepted that 
clopidogrel exerts its pharmacological effect through formation of H4 and that CYP2C19 plays 
even some role in two separate steps involved in its formation, then it logically follows that a 
significant decrease in CYP2C19 activity and therefore H4 formation in a particular patient 
(whether that patient is a CYP2C19 PM due to genetic polymorphisms {up to a 71% decrease in 
H4 AUC (68)} or inactivation of the enzyme by omeprazole {up to a 48% decrease in H4 AUC 
(72)}) will decrease the benefit of clopidogrel in that individual.  This sentiment is echoed by a 
quote from Leeder in the context of preemptive pharmacogenetic testing: 
For example, the proximal phenotype for CYP2C19 technically is the 
disappearance of the substrate (clopidogrel) and formation of the active platelet 
inhibiting metabolite; this genotype–phenotype association is several steps 
removed from the cardiovascular events to be reduced by preemptive 
genotyping. Is it necessary to demonstrate a robust association between 
CYP2C19 genotype and a reduction in intervention-related cardiovascular events 
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at a population level to establish sufficient clinical utility for widespread 
acceptance?  (73) 
In addition, although investigation of CYP3A4 inhibition by omeprazole or esomeprazole 
was not a specific aim of this dissertation, there are some data to suggest that omeprazole, 
esomeprazole or some of its metabolites may also act as clinically relevant inhibitors of 
CYP3A4, causing 25, 30 and 90% increases in exposure to the CYP3A4 substrates nifedipine, 
cisapride and carbamazepine (74-78).  Both CYP2C19 and CYP3A4 were found to be involved 
in the second CYP-dependent step in the activation of clopidogrel with a Simcyp-predicted 
21.1% and 33.5% contribution to the total CYP-dependent pathway, respectively (Figure 1.1) 
(44). Therefore, the combined impact of inhibition of two enzymes involved in H4 formation by 
omeprazole or esomeprazole and its metabolites, would be expected to have a super-
proportional impact on the decrease in H4 exposure, similarly to the observed impact of 
grapefruit juice (which affects both CYP2C19 and CYP3A4 in the small intestine and causes an 
unexpectedly large 80% decrease in H4 exposure, discussed below), but in contrast to inhibition 
of CYP3A4 alone by ketoconazole (i.e., only a 22% decrease in H4 exposure) (17,44,69,79).  
These findings bolster the argument that coadministration of omeprazole or esomeprazole with 
clopidogrel would be expected to decrease H4 exposure by inhibition of CYP2C19 in the 
conversion of clopidogrel to 2-oxo-clopidogrel, and inhibition of both CYP2C19 and CYP3A4 by 
their metabolites in the conversion of 2-oxo-clopidogrel to H4. 
Still other authors implicated polymorphisms in paraoxonase 1 (PON1) as the major 
factor accounting for the variable clinical response to clopidogrel (80).  This finding was 
essentially discredited by other authors (52,81,82), largely due to the apparent inability of the 
analytical method used by Bouman and colleagues to separate the endo metabolite from H1-H4 
(see further detail below).  It is possible that the PON1 polymorphisms described by Bouman et. 
al., can affect levels of the “inactive” metabolites which may have as yet poorly understood 
actions on platelet aggregation.   
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Adding to the apparent confusion regarding the role of CYP2C19 in the activation of 
clopidogrel is the fact that nine systematic reviews or meta-analyses were published from 2010 
to 2015 that reported differing conclusions on the association of CYP2C19 loss-of-function 
alleles and the risk of adverse cardiovascular events in patients treated with clopidogrel 
(reviewed by Sorich and colleagues (67)).  Each review evaluated between 7 and 26 primary 
studies (out of >30 primary clinical studies) representing between 8,043 to 26,251 patients.  
These reviews reported that carriage of reduced function CYP2C19 alleles conferred a relative 
risk for adverse cardiovascular events of 1.11 to 1.96 (67), with the lower value not reaching 
statistical significance.  Sorich and colleagues discussed the possible reasons for the 
differences in conclusions, including differences in event definitions, genotype grouping, and 
meta-analytic methods (67).  To this list, I would add that none of the reviewed studies 
attempted to correlate exposure to H4 with CYP2C19 phenotype, which would have been 
informative, at least for the studies that correctly grouped CYP2C19 phenotypes.  The main 
reason for the lack of H4 quantification was presumably the fact that an analytical method to 
quantify only H4, separately from the other inactive thiols, requires chiral chromatography along 
with a thorough understanding of the tandem mass spectral transitions of H1-H4 vs. the endo 
metabolite.  An analytical method that fully accounted for these aspects was not developed and 
fully validated until 2011, sponsored by Sanofi-Aventis and Bristol-Myers Squibb (83) in support 
of the clinical pharmacogenomic and PPI drug-drug interaction trials (68,84).  Studies that claim 
to have quantified H4 (e.g., (80)) without the use of a properly validated analytical method may 
have actually quantified either a mixture of diastereomers, or possibly only the inactive “endo” 
thiol isomer, which was later shown to be formed by PON1 (52,85).  Quantification of the endo 
thiol metabolite would lead to erroneous conclusions regarding the effects of polymorphisms in 
PON1 vs. CYP2C19.  Even if a validated chromatographic method succeeds in separating the 
diastereomers, one must also be familiar with the individual mass transitions in the MS/MS 
method because the 356→212 m/z transition is diagnostic of the “endo” thiol while the active cis 
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thiol (i.e., H4) eliminates H2S. The 356→322 m/z transition detects two trans and two cis thiol 
isomers (H1-H4) that also must be separated chromatographically (Dansette, personal 
communication and (52,85).  Indeed, in response to Dansette (86), Bouman and colleagues 
later acknowledged “we did not discriminate between the different putative thiol stereoisomers in 
our LC-MS-MS assay; instead we supposed a constant ratio of the formation of active and 
inactive thiol metabolites” (87).   
Nine clinical studies published from 2011 to 2014 have examined the pharmacokinetics 
of the clopidogrel active metabolite with regard to CYP2C19 (or other clopidogrel poor 
responder-associated genes) with validated analytical methods that appear to adequately 
separate H4 from the other inactive thiols (68,82,85,88-93).  Of these studies, only the study 
sponsored by Sanofi-Aventis and Bristol-Myers Squibb (68) was conducted as a randomized, 
double-blind placebo controlled study. The results of this study are described in the prescribing 
information for clopidogrel (25), which states in a black box to “consider alternative treatment or 
treatment strategies in patients identified as CYP2C19 poor metabolizers”.  In spite of possible 
limitations of the other eight studies, all concluded that CYP2C19 poor-metabolizers (e.g., *2/*2, 
*3/*3 homozygotes, or *2/*3 compound heterozygotes, etc.) had significantly less exposure to 
H4 than did extensive metabolizers.  Five of these studies also examined one or more 
intermediate metabolizer genotypes, and three (88,91,93) showed that CYP2C19 intermediate 
metabolizers also had significantly less H4 exposure than did extensive metabolizers.  
Importantly, of the studies listed above that examined individuals with decreased function 
variants of other clopidogrel poor responder-associated genes including PON1, ABCB1 (i.e., 
P-gp), and CYP2B6, none reported a significantly decreased H4 exposure relative to their “wild-
type” counterparts (82,85,91).  Finally, additional analyses of the Simon et al. and Angiolillo et 
al. clinical studies (i.e., (68,84), sponsored by Sanofi-Aventis and BMS in collaboration with 
Simcyp to model the two sequential steps in clopidogrel activation, provided estimates of the 
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overall fm(CYP2C19) for H4 formation of 0.64 (range 0.58 to 0.72, depending on population and 
simulation parameters) (94).  Although the foregoing publications do not conclude that 
CYP2C19 polymorphisms account for 100% of the variability in clinical response to clopidogrel, 
and furthermore cannot exclude the importance of other, as yet unknown, genetic 
polymorphisms or other factors in the variable response to clopidogrel, they do underscore the 
importance of CYP2C19 in the bioactivation of, and therefore clinical response to clopidogrel.  
Clinical studies implicating CYP2C19 inhibition as a cause for decreased 
clopidogrel efficacy 
All currently FDA-approved PPIs (i.e., omeprazole, esomeprazole, lansoprazole, 
dexlansoprazole, pantoprazole and rabeprazole) are metabolized in part by CYP2C19 (e.g., 
lansoprazole fmCYP2C19 = 0.82 and 0.87 for omeprazole (17)), and might be expected to inhibit 
this enzyme to some extent (27).  A search strategy in PubMed for any PPI and clopidogrel 
reveals that over 550 papers that cover these terms together have been published between 
2002 and 2014.  A search strategy limited to only omeprazole or esomeprazole and clopidogrel 
shows that nearly 200 of these papers cover these two PPIs with clopidogrel to some extent. 
In contrast to the >30 clinical studies examining the effect of loss-of-function alleles of 
CYP2C19 or other genes, 19 clinical drug-drug interactions studies conducted with clopidogrel 
as the victim drug have been published between 2004 and 2014, including two in new drug 
application (NDA) review documents for prasugrel and apixaban from 2009 and 2012, 
respectively;  (27)).  The majority of these studies examined the effects of one or more drugs 
(including aspirin, apixaban, atorvastatin, dabigatran, fluoxetine, ketoconazole, morphine, 
ranitidine, or rosuvastatin) or “life-style” environmental factors (including grapefruit juice intake, 
cigarette smoking or St. John’s wort intake) (69,79,82,95-103).  No interaction was reported for 
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aspirin, dabigatran or ranitidine, but at least a 20% induction or 20% inhibitory effect on either 
the pharmacokinetics of clopidogrel or its active metabolite, or on the pharmacodynamics of 
clopidogrel, was reported in at least one study for morphine, grapefruit juice, fluoxetine, 
rosuvastatin, St. John’s wort, atorvastatin, apixaban, ketoconazole and cigarette smoking.  A 
variety of mechanisms including delayed gastric emptying (i.e., morphine), transporter 
interactions (e.g., P-gp), induction or inhibition of minor enzymes involved in formation of H4 
such as CYP1A2 and 3A4 were implicated in these interactions, but with the exception of 
grapefruit juice (~80% decrease in active metabolite formation attributed to inhibition of both 
intestinal CYP2C19 and 3A4 (79)), most of the effects were relatively small (<30% change in 
active metabolite formation). Some of these studies provided contradictory results depending on 
the study design or end-points (e.g., atorvastatin and ketoconazole).  
Seven clinical DDI studies examined the effects of one or more PPIs on clopidogrel (i.e., 
omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole or rabeprazole – six 
with omeprazole and/or esomeprazole), six of which report the pharmacokinetics of the active 
metabolite of clopidogrel as well as the effects on clopidogrel pharmacodynamics (i.e., (72,104-
108) whereas the remaining study examined only the effects of PPIs on the pharmacodynamics 
of clopidogrel (66).  Of the studies reporting plasma concentrations of the active metabolite of 
clopidogrel, all concluded that coadministration of omeprazole and/or esomeprazole with 
clopidogrel caused a significantly decreased exposure to H4 (up to 50 % decrease in AUC or 
45% decrease in Cmax).  Of particular importance is that the study by Angiolillo found that 
separation of omeprazole and clopidogrel dosing by 12 hours did not mitigate the effects of 
omeprazole, which is consistent with irreversible inhibition of CYP2C19 given the short half-lives 
of omeprazole and its metabolites (<2 h) (84).  All but one study (104), demonstrated a 
significantly decreased pharmacodynamic effect of clopidogrel (e.g., ex vivo ADP-induced 
maximum platelet aggregation) upon coadministration of omeprazole and/or esomeprazole.  
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With one exception, studies that examined lansoprazole, dexlansoprazole or pantoprazole 
concluded that there was no significant effect on the pharmacokinetics of H4 or on the 
pharmacodynamics of clopidogrel (84,106,107).  Only Andersson and colleagues found that 
high-dose lansoprazole (60 mg q.d.) significantly decreased H4 formation by 30% (108).  
Finally, of the two clinical studies that examined the effects of rabeprazole on clopidogrel, the 
one that reported pharmacokinetic and pharmacodynamic data concluded there was no 
interaction (104), whereas Furuta and colleagues concluded that rabeprazole caused a 
significant decrease in clopidogrel pharmacodynamic action, but only in CYP2C19 “reduced 
metabolizers” (i.e., carriers of one or more reduced function CYP2C19 alleles, so IMs or PMs) 
(66).  
From the foregoing, it can also be concluded that the interaction between omeprazole or 
esomeprazole and clopidogrel is not caused by decreased absorption due to decreased gastric 
acid because there should be a class-effect if true, and ranitidine would also be expected to 
cause an interaction with clopidogrel, which it does not (103).  In addition, the FDA and EMA 
have issued various warnings against coadministration of omeprazole or esomeprazole at 
various times, with the FDA in 2010 noting specifically:  
With regard to the proton pump inhibitor (PPI) drug class, this 
recommendation applies only to omeprazole and not to all PPIs. Not all PPIs 
have the same inhibitory effect on the enzyme (CYP 2C19) that is crucial for 
conversion of Plavix into its active form.  Pantoprazole (Protonix) may be an 
alternative PPI for consideration. It is a weak inhibitor of CYP2C19 and has less 
effect on the pharmacological activity of Plavix than omeprazole.  (109) 
In addition, the FDA- approved prescribing information for clopidogrel updated in December, 
2013 states: 
Avoid concomitant use of Plavix with omeprazole or esomeprazole. In 
clinical studies, omeprazole was shown to reduce the antiplatelet activity of 
Plavix when given concomitantly or 12 hours apart. A higher dose regimen of 
clopidogrel concomitantly administered with omeprazole increases antiplatelet 
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response; an appropriate dose regimen has not been established. A similar 
reduction in antiplatelet activity was observed with esomeprazole when given 
concomitantly with Plavix. Consider using another acid-reducing agent with 
minimal or no CYP2C19 inhibitory effect on the formation of clopidogrel active 
metabolite. Dexlansoprazole, lansoprazole and pantoprazole had less effect on 
the antiplatelet activity of Plavix than did omeprazole or esomeprazole.  (25) 
The latter point made by the FDA, namely that dexlansoprazole, lansoprazole and 
pantoprazole had less of an impact on clopidogrel than did omeprazole or esomeprazole, is 
particularly interesting in light of the in vitro data regarding inhibition of CYP2C19 by PPIs, which 
will be covered in the next section.  In spite of the warnings and label changes by the FDA, data 
collected from a retail database of >200,000 patients receiving both clopidogrel and a PPI 
between January 1 and March 31, 2012, showed that approximately 60% were taking an 
omeprazole- or esomeprazole-containing product (110). 
1.6. In vitro and clinical studies demonstrating CYP2C19 inhibition by 
PPIs 
A total of 103 studies examining one or more PPIs as in vitro inhibitors of drug-
metabolizing enzymes were published between 1986 and 2014 (27).  Of these, 93 studies 
examined omeprazole or esomeprazole as in vitro inhibitors of drug-metabolizing enzymes.  
Through 2014, approximately 60 IC50 or Ki values for the direct inhibition of CYP2C19 by a PPI 
were published.  Only lansoprazole and omeprazole (and their S-enantiomers) directly inhibited 
CYP2C19 with IC50 or Ki values <1 µM, whereas the lowest reported IC50 or Ki values for 
rabeprazole and pantoprazole were 9.2 and 17 µM, respectively (27).  Both lansoprazole and 
omeprazole have similar half-lives, plasma protein binding and Cmax values and would be 
predicted to cause clinically relevant direct inhibition of CYP2C19 (see Table 1.2 for a summary 
of PPI pharmacokinetics) (111).  However, neither lansoprazole nor PPIs other than omeprazole 
and esomeprazole have been reported to cause clinically relevant interactions with any 
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CYP2C19 substrate (27).  In contrast, omeprazole does cause clinically significant inhibitory 
interactions with the CYP2C19 substrates, including moclobemide, escitalopram, proguanil, 
etravirine and voriconazole (27).  This apparent discrepancy would be explained if omeprazole 
and/or esomeprazole, but not lansoprazole or the other PPIs, were a metabolism-dependent 
inhibitor of CYP2C19.   
Clinical evidence for metabolism-dependent inhibition of CYP2C19 by omeprazole is in 
fact present in literature (with the benefit of hindsight).  For instance, in CYP2C19 extensive 
metabolizers (but not in poor metabolizers), the AUC of moclobemide (fmCYP2C19 ≈ 0.72 
calculated from a comparison of AUC values in PMs and EMs (17)) increased by ~31% after a 
single 40-mg dose of omeprazole, but increased by 121% after 8 days of dosing with 40 mg 
omeprazole (112).  Such an apparent increase in the exposure of a victim drug with repeated 
dosing of the perpetrator drug can be indicative of metabolism-dependent inhibition.  In addition, 
in vivo evidence for metabolism-dependent inhibition of CYP2C19 comes from the 
pharmacokinetic data for omeprazole itself (and its individual enantiomers), as summarized by 
Andersson and Weidolf (113).  In the studies presented, 15 mg of either omeprazole (i.e., the 
racemate), esomeprazole or R-omeprazole, were administered orally for seven days.  Exposure 
to esomeprazole (AUC) increased by 113% over 7 days, whereas exposure to omeprazole 
increased by only 52%, and exposure to R-omeprazole actually decreased by 9%.  Such time-
dependent changes in pharmacokinetics were initially attributed (in part) to decreased 
degradation of omeprazole in the stomach after multiple days of dosing because the gastric pH 
was increased by treatment, and omeprazole is acid labile (114).  However, if this hypothesis 
were to completely explain the observations, time-dependent changes would be observed for 
both omeprazole enantiomers, and likely for all PPIs.  Andersson et al., later concluded that 
“decreased hepatic metabolism of omeprazole might be responsible for the initial increase in 
AUC during repeated dosing” (115).  Indeed, neither lansoprazole, pantoprazole, nor 
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rabeprazole pharmacokinetics are altered by multiple dosing (116-118).  In contrast, the 
prescribing information for Nexium (esomeprazole) states “at repeated once-daily dosing with 
40 mg, the systemic bioavailability is approximately 90% compared to 64% after a single dose 
of 40 mg. The mean exposure (AUC) to esomeprazole increases from 4.32 μmol*hr/L on Day 1 
to 11.2 μmol*hr/L on Day 5 after 40 mg once daily dosing” (119).  Because esomeprazole is 
metabolized mainly by CYP2C19 (fmCYP2C19 ~ 0.87 – calculated from a comparison of AUC 
values in PMs and EMs (17)), this 2.6-fold increase in exposure with multiple dosing is strongly 
suggestive of metabolism-dependent autoinhibition, given the short half-life of esomeprazole (1 
– 1.6 h).  
Given omeprazole’s in vitro and clinical inhibitory effects on CYP2C19 in contrast to 
other PPIs, I set out to re-examine omeprazole and esomeprazole as metabolism-dependent 
inhibitors of CYP2C19.  It was particularly noteworthy that none of the approximately 40 in vitro 
studies published prior to 2011 identified any PPI as a metabolism-dependent inhibitor of 
CYP2C19 (34) (See Chapter 4).  After I identified omeprazole as an irreversible metabolism-
dependent inhibitor of CYP2C19 in vitro (Chapters 4-5 and (34,111,120), 25 additional studies 
reported one or more PPIs as in vitro inhibitors of one or more drug-metabolizing enzymes, with 
eight studies examining inhibition of CYP2C19 by omeprazole, esomeprazole or its metabolites 
as inhibitors of CYP2C19 (27).  Only four of these later studies specifically examined 
metabolism-dependent inhibition of CYP2C19 by omeprazole or esomeprazole or their 
metabolites (excluding my preliminary publications which will be covered in Chapters 5–6: 
(75,78,94,111,120,121).  
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Chapter 2. STATEMENT OF PURPOSE 
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2.1. Objectives and significance of the study 
In 1991, the US Food & Drug Administration (FDA) approved ticlopidine as the first 
thienopyridine platelet aggregation inhibitor (or P2Y12 inhibitor) indicated for secondary 
prevention of thrombotic strokes or primary prevention in patients at high risk of stroke.  
Because of its high risk for life-threatening blood dyscrasias such as agranulocytosis, aplastic 
anemia and thrombocytopenic purpura, this drug was reserved for use in high-risk patients who 
were intolerant of aspirin or had already failed aspirin or other anti-platelet therapy (e.g., 
cilostazol or dipyridamole).  Clopidogrel was approved in the US in 1997 as the second 
thienopyridine platelet aggregation inhibitor and was initially indicated for reduction of 
atherosclerotic events including stroke and myocardial infarction in patients with atherosclerosis 
and a recent myocardial infarction (MI) or stroke, or in those with established peripheral artery 
disease.  Clopidogrel therapy demonstrated much lower risk for the blood dyscrasias associated 
with ticlopidine therapy and it quickly supplanted ticlopidine as the primary therapeutic option for 
reducing atherothrombotic events.  Due to the continued safety record of clopidogrel and 
completion of additional clinical trials, its use was expanded in 2002 to include FDA-approved 
indications for non-ST-segment acute coronary syndrome (e.g., unstable angina or non-Q-wave 
MI) and patients undergoing percutaneous coronary intervention or PCI (with or without stent 
placement).  An indication for secondary prevention after ST-elevation MI was also added to US 
labeling in 2006.  The FDA approved several generic formulations of clopidogrel in 2012.  In 
spite of the FDA approval of new P2Y12 inhibitors including prasugrel in 2009 and ticagrelor in 
2011, clopidogrel remains the preferred treatment option for most indications, especially with 
regard to cost because it is now available in several generic formulations.  A 2015 review of 
P2Y12 inhibitors showed that the only cases when ticagrelor or prasugrel should be preferred 
over clopidogrel are in patients with carriage of known loss-of-function variants of CYP2C19 or 
in patients being treated concomitantly with proton pump inhibitors (PPIs) (see Chapter 1 for a 
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review of this topic) (122).  As mentioned in Chapter 1, PPIs are coadministered with clopidogrel 
in up to two-thirds of patients after discharge from the hospital for acute coronary syndromes to 
decrease the incidence and severity of gastrointestinal bleeding. 
In spite of the large number of publications discussing the interaction between PPIs and 
clopidogrel (reviewed in Chapter 1), the basis for the clinically relevant interaction between 
clopidogrel and omeprazole or esomeprazole but not other PPIs (in which the efficacy of 
clopidogrel is significantly reduced due to decreased formation of its active metabolite), has not 
yet been elucidated.  A determination of the basis for this interaction would allow for clinically 
actionable recommendations to be made by regulatory agencies and professional medical 
societies (e.g., The American College of Cardiology, The American College of 
Gastroenterology) regarding the co-administration of clopidogrel with currently used and 
potentially future PPIs.   
2.2. Specific aims 
Specific Aim 1 tests the hypothesis that the major proton pump inhibitors in clinical use differ in 
their ability to inhibit CYP2C19 in a metabolism-dependent manner. This hypothesis was tested 
in in vitro systems including pooled human liver microsomes, cryopreserved hepatocytes and 
recombinant human CYP2C19, as well as in a physiological-based pharmacokinetic model to 
assess the clinical significance of the in vitro findings with omeprazole.  The results of this 
specific aim are presented in Chapter 4.  
Specific Aim 2 tests the hypothesis that the metabolism-dependent inhibition of CYP2C19 by 
omeprazole is enantioselective and also occurs due to formation of one or more of its major 
metabolites. This hypothesis was tested in vitro in pooled human liver microsomes.  The results 
of this specific aim are presented in Chapters 4-5.  
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Specific Aim 3 tests the hypothesis that the metabolism-dependent inhibition of CYP2C19 by 
esomeprazole and its two inhibitory metabolites, omeprazole sulfone and 5-O-desmethyl 
omeprazole, is mechanism-based according to the following criteria: 1) inactivation of CYP2C19 
occurs in a concentration-, time- and metabolism-dependent manner, 2) the efficiency of 
inactivation is not diminished by glutathione, superoxide dismutase nor catalase (exogenous 
scavengers), 3) the inactivation is irreversible (by ultracentrifugation and washing), 4) the 
inactivation is saturable with respect to inactivator concentration, 5) an alternate CYP2C19 
substrate can protect the enzyme against inactivation, and 6) inactivation requires a catalytic 
event.  The criteria for this hypothesis were tested in vitro in pooled human liver microsomes in 
multiple studies and the results presented in Chapters 4-6.   
Specific aim 3A tests the hypothesis that the presence of a 5´-methyl substituent is necessary 
for metabolism-dependent inhibition of CYP2C19 by PPIs.  This hypothesis was tested in 
pooled human liver microsomes with two clinically used PPIs (i.e., ilaprazole and rabeprazole) 
that lack a 5´-methyl substituent and one investigational PPI, tenatoprazole which, like 
omeprazole and esomeprazole, does have a 5´-methyl substituent.  It was predicted that of the 
three, only tenatoprazole would cause metabolism-dependent inhibition of CYP2C19.  
Studies proposed in specific Aim 4 were designed to test the hypothesis that the inactivation of 
CYP2C19 by esomeprazole is the result of the formation of a reactive metabolite that binds 
covalently to the enzyme’s heme prosthetic group. The rationale for these studies was based, in 
part, on the demonstration that the mechanism of CYP2C19 inactivation by esomeprazole could 
not be ascribed to formation of a metabolite-inhibitory complex (MIC) (presented in Chapter 6). 
Towards this end, HLM were incubated with esomeprazole or known heme-alkylating agents 
(1-aminobenzotriazole and gemfibrozil glucuronide) and formation of heme adducts analyzed by 
ultra-high performance liquid chromatography (UHPLC) with UV/VIS detection and high 
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resolution mass spectrometry (HRMS) (UHPLC-UV/HRMS) followed by post-acquisition mass-
defect filtering.  The results of this specific aim are presented in Chapter 7.   
2.3. Innovation 
The research proposed in this dissertation is innovative, because it examined and 
successfully identified the basis for the unexpected clinical interaction between the anti-platelet 
drug clopidogrel and some but not all proton pump inhibitors, which have long been 
recommended as a comedication to reduce the severity of upper gastrointestinal bleeding 
caused by clopidogrel. The novel finding stemming from my dissertation research is that 
omeprazole and esomeprazole, but not pantoprazole or lansoprazole, are irreversible inhibitors 
of CYP2C19, the major enzyme responsible for converting clopidogrel to its pharmacologically 
active metabolite.  This discovery provides a mechanistic rationale for the FDA and EMA’s 
decision to recommend against the coadministration of clopidogrel with omeprazole or 
esomeprazole but not other PPIs. 
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MATERIALS AND METHODS 
Materials 
1-Aminobenzotriazole, catalase, fexofenadine, glutathione, 4′-hydroxymephenytoin, 
omeprazole, superoxide dismutase and Trizma® base (for Tris buffer) were purchased from 
Sigma-Aldrich (St. Louis, MO).  Esomeprazole, d3-4´-hydroxymephenytoin, 
5´-hydroxyomeprazole, 5-O-desmethylomeprazole, S-mephenytoin, lansoprazole, omeprazole 
sulfide and pantoprazole were purchased from Toronto Research Chemicals (North York, ON, 
Canada).  R-Omeprazole and omeprazole sulfone were purchased from SynFine Research 
(Richmond Hill, ON, Canada) or Toronto Research Chemicals (North York, ON, Canada).  
Ilaprazole was purchased from Clearsynth Labs (Mumbai, India).  Tenatoprazole was 
purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX). Human liver microsomes (pooled 
from 16 donors) and human hepatocytes were prepared from non-transplantable livers and 
characterized as described previously (35,123), and recombinant CYP2C19 (Bactosomes) was 
obtained from Cypex (Dundee, Scotland).  All other reagents were obtained from commercial 
sources, as detailed elsewhere (33-35,37,38).  
CYP2C19 Inhibition: IC50 determinations 
CYP2C19 activity in human liver microsomes (HLM) was determined according to 
previously published procedures (33-35,38,124).  Briefly, incubations were conducted in 200-μL 
incubation mixtures (pH 7.4) containing high purity water, potassium phosphate buffer (50 mM), 
MgCl2 (3 mM), EDTA (1 mM), NADP (1 mM), glucose-6-phosphate (5 mM), glucose-6-
phosphate dehydrogenase (1 Unit/mL), S-mephenytoin (approximately equal to Km, i.e., 40 µM, 
final) and HLM (0.1 mg protein/mL, except where otherwise noted).  All incubations were 
conducted in duplicate at 37°C for 5 min (except where otherwise noted) and were terminated 
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by the addition of 200 µL acetonitrile containing an internal standard 
(d3-4´-hydroxymephenytoin).  Aliquots of the stock and/or working solutions of the inhibitors (i.e., 
omeprazole, esomeprazole, R-omeprazole, lansoprazole, pantoprazole, 5´-hydroxyomeprazole, 
omeprazole sulfide, omeprazole sulfone, 5-O-desmethylomeprazole, rabeprazole, ilaprazole or 
tenatoprazole; final concentrations ranging from 0.1 to 100 µM (or 70 µM for 
5-O-desmethylomeprazole) in solvent were added to buffer mixtures containing the components 
described above, but prior to addition of the NADPH-generating system.  For experiments in 
which stock solutions of inhibitors were not kept, the solvent was methanol (for a final incubation 
concentration of 1% v/v) or a mixture of methanol/DMSO/Tris buffer (at pH 9.0) at 70/20/10% 
v/v/v (0.7/0.2/0.1% v/v/v final incubation concentrations) for 5-O-desmethylomeprazole.  For 
experiments in which stock solutions were to be saved for use in additional experiments (e.g., to 
decrease the amount of expensive PPIs or metabolites used), the solvent was a mixture of 
methanol and Tris buffer (pH 9.0 for greater stability) at 0.4/0.6% v/v final incubation 
concentration.  To evaluate the potential for MDI, the inhibitors (at the same concentrations 
used to evaluate direct inhibition) were pre-incubated in HLM (0.1 mg/mL final) at 37°C with and 
without NADPH for approximately 30 min (or 60 min for ilaprazole and tenatoprazole).  After the 
pre-incubation, S-mephenytoin (40 µM, final) was added, and the incubation was continued for 
5 min to measure residual CYP activity.  Precipitated protein was pelleted by centrifugation 
(920×g for 10 min at 10°C).  Calibration and quality control (QC) standards 
(4´-hydroxymephenytoin) were prepared in zero-time incubations.  IC50 determinations with 
recombinant human CYP2C19 (15 pmol/mL) were conducted in the same manner except that 
the incubation time was only 2 min to prevent over-metabolism of omeprazole.  Metabolite 
formation (4′-hydroxymephenytoin) was analyzed by LC-MS/MS as described previously (33-
35,37,38).  
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Incubations with cryopreserved human hepatocytes (pooled, n=3, 106 cells/mL) were 
conducted in 200-µL incubation mixtures at approximately 37°C in Krebs Henseleit Buffer 
(KHB), in triplicate.  In all cases, the solvent or omeprazole was allowed to equilibrate for 10 min 
with hepatocytes prior to incubations.  For samples with no pre-incubation with inhibitor, 
reactions were started by the addition of hepatocytes to pre-warmed KHB containing inhibitor 
and S-mephenytoin (40 µM, final concentration).  For reactions with a pre-incubation, 
hepatocytes and inhibitor were incubated at 37°C for 30 minutes and reactions were started by 
addition of S-mephenytoin (40 µM, final).  In all cases, marker substrate reactions were 
conducted for 60 min and terminated by the addition of an equal volume of acetonitrile and 
internal standard (d3-4´-hydroxymephenytoin).  Metabolite formation (4′-hydroxymephenytoin) 
was analyzed by LC-MS/MS as described previously (33-35,37,38). 
Metabolic stability of omeprazole 
The metabolic stability of omeprazole (10 µM), was determined at three concentrations 
of HLM (0.1, 1.0, and 2.5 mg/mL) under conditions similar to those described above for 
CYP2C19 inhibition experiments.  Omeprazole was incubated for zero, 5, 10, 20, 30, 45, and 60 
min, in triplicate.  Reactions were terminated by the addition of an equal volume of acetonitrile 
and internal standard (pantoprazole).  Precipitated protein was removed by centrifugation 
(920×g for 10 min at 10°C).  Omeprazole disappearance was monitored by LC-MS/MS as 
described below.  Calibration standards were prepared in zero-time incubations. 
Microsomal binding of omeprazole 
The binding of omeprazole to microsomal protein was determined by ultrafiltration with 
Millipore Amicon Centriplus centrifugal filter devices (15 mL, 30 kDa membrane) obtained from 
Fisher Scientific (Pittsburgh, PA). Omeprazole (2 and 10 µM), was incubated with pooled HLM 
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(zero, 0.1, 1.0, or 2.5 mg/mL), as described above, but in the absence of an NADPH-generating 
system at 37°C for 10 min.  Aliquots (1.1 mL) were then removed and added to the ultrafiltration 
devices, and centrifuged at 1900×g in a Sorvall RC 5C centrifuge with a Sorvall SS-34 rotor at 
room temperature for 5 min.  Aliquots of the ultrafiltrate (100 µL) were transferred to glass tubes 
and an equal volume of acetonitrile added and vortexed.  Precipitated protein was removed by 
centrifugation (920 × g for 10 min at 10°C).  Following centrifugation, an aliquot (100 µL) was 
transferred to an equal volume of acetonitrile (with pantoprazole as the internal standard) and 
analyzed for omeprazole concentration by LC-MS/MS. 
KI and kinact determinations 
To determine the KI and kinact values for the inactivation of CYP2C19, various 
concentrations of omeprazole (1 to 60 µM), esomeprazole (0.3 to 60), omeprazole sulfone 
(0.6-100 µM) or 5-O-desmethylomeprazole (0.6 – 70 µM) were pre-incubated at 37ºC for 
various times (i.e., 2.5 to 15 min for omeprazole; 3 – 30 min for esomeprazole, 3 – 30 min for 
omeprazole sulfone; and 3 – 30 min for 5-O-desmethylomeprazole) with pooled HLM (i.e., 0.1 
and 2.5 mg/mL for omeprazole; 0.1, 0.5 and 1 mg/mL for esomeprazole and omeprazole 
sulfone and 0.5 mg/mL for 5-O-desmethylomeprazole).  For the omeprazole experiments 
conducted at 0.1 mg/mL HLM (Chapter 4), after the pre-incubations, S-mephenytoin (40 or 
400 µM final concentration [1× and 10×Km]) was added and residual CYP2C19 activity 
determined as described above (i.e., no dilution).  For experiments conducted at 2.5 mg/mL, 
after the pre-incubation, an aliquot (8 µL) was transferred to another incubation tube (final 
volume 200 μL) containing S-mephenytoin (400 μM [10×Km]) and an NADPH-generating system 
in order to measure residual CYP2C19 activity as described above.  The latter procedure diluted 
the microsomes to 0.1 mg/mL and diluted omeprazole to 1/25th its original concentration.  For 
other KI and kinact determinations (i.e., esomeprazole, omeprazole sulfone and 
5-O-desmethylomeprazole presented in Chapters 5-6) a 10-fold dilution was always utilized, 
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with a saturating concentration of S-mephenytoin (400 μM).  Additional KI and kinact 
determinations for esomeprazole, omeprazole sulfone and 5-O-desmethylomeprazole 
presented in Chapters 6 were similarly carried out with the addition of glutathione (2 mM in pre-
incubation), superoxide dismutase (500 U/mL in pre-incubation), catalase (1000 U/mL in pre-
incubation) or pantoprazole (200 µM in pre-incubation).   Reactions were carried out in triplicate. 
CYP2C19 activity in cultured human hepatocytes 
Cultured human hepatocytes were prepared, treated, and microsomes (0.02 mg/mL) 
isolated as described previously (38).  Briefly, cultured human hepatocytes were treated for 72 h 
with 0.1% (v/v) DMSO (solvent control) or 100 µM omeprazole.  Isolated microsomes were 
washed and incubated for 30 min with marker substrate (40 µM S-mephenytoin) to determine 
CYP2C19 activity as described above.  
Assessment of MDI reversibility by ultracentrifugation 
Omeprazole (100 µM), R-omeprazole (100 µM), esomeprazole (100 µM), omeprazole 
sulfone (100 µM) or 5-O-desmethyl omeprazole (70 µM) were incubated in triplicate with 
NADPH-fortified pooled HLM (0.1 mg/mL) at 37°C for 30 min in potassium phosphate buffer 
(50 mM, pH 7.4), MgCl2 (3 mM), EDTA (1 mM, pH 7.4) and chemically reduced NADPH (1 mM), 
as described previously (34,35,111).  Incubations (n=3) with solvent alone (1% methanol v/v, 
final) served as controls.  Following the 30-min incubation, HLMs were (1) assayed directly for 
residual CYP2C19 activity, (2) re-isolated by ultracentrifugation and then assayed for residual 
CYP2C19 activity, or (3) treated with potassium ferricyanide, re-isolated by ultracentrifugation 
and then assayed for residual CYP2C19 activity. For samples in groups (2) and (3), microsomal 
protein was re-isolated by ultracentrifugation (100,000 × g for 30 min at 4ºC in a Beckman 
ultracentrifuge with a 70Ti rotor).  The supernatant fraction was discarded and the resultant 
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microsomal pellets were rinsed three times with wash buffer (150 mM potassium chloride and 
10 mM EDTA, pH 7.4) to remove residual omeprazole and/or any reversible inhibitory 
metabolites.  Microsomal pellets were re-suspended in 250 mM sucrose and the microsomal 
protein concentration was determined by the Pierce BCA Protein Assay (Pierce, Rockford, IL).  
For samples in group (3), HLMs were incubated with potassium ferricyanide (2 mM) for 10 min 
at 37°C prior to re-isolation of microsomal protein by ultracentrifugation to disrupt nitrogen-
based metabolite inhibitory complexes (MICs) (125).  Residual CYP2C19 activity was assessed 
at a final concentration of 0.1 mg/mL HLM (supplemented with an NADPH regenerating system) 
with S-mephenytoin (400 µM, i.e., 10 × Km) to reduce the inhibitory effects of any residual 
competitive inhibition.  
Spectrophotometric Assessment of MI Complex Formation 
Incubations were conducted in 1-mL incubation mixtures (pH 7.4) containing high purity 
water, potassium phosphate buffer (50 mM), MgCl2 (3 mM), EDTA (1 mM), NADPH (1 mM), and 
either rhCYP2C19 (for esomeprazole or S-fluoxetine) or rhCYP3A4 (for troleandomycin) at 50 
pmol/ml.  Reactions were initiated by the addition of inhibitor (esomeprazole [100 µM final]; 
S-fluoxetine [200 µM final] or troleandomycin [75 µM final]) to the sample cuvettes.  Solvent for 
each compound (methanol 1% v/v final for S-fluoxetine; acetonitrile 1% v/v final for 
troleandomycin or methanol/Tris (pH 9.0) at 0.4/0.6% v/v final) was added to the reference 
cuvettes.  A Varian Cary 100 BIO UV/visible spectrophotometer (Agilent Technology, Santa 
Clara, CA) equipped with a circulating water bath (37°C) was set to scan 400–500 nm 
approximately every 30 seconds for up to approximately 31 min (esomeprazole), 16 min 
(S-fluoxetine) or 15 min (troleandomycin).  
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Isolation of heme from human liver microsomes or recombinant CYPs 
Esomeprazole (100 µM), 1-aminobenzotriazole (2 mM – positive control for heme adduct 
formation that is undetectable at UV wavelengths), gemfibrozil glucuronide (100 µM – positive 
control for heme adduct formation that is detectable at UV wavelengths) were incubated in 3-mL 
incubation mixtures (pH 7.4) containing high purity water, potassium phosphate buffer (50 mM), 
MgCl2 (3 mM), EDTA (1 mM), NADP (1 mM), glucose-6-phosphate (5 mM), glucose-6-
phosphate dehydrogenase (1 Unit/mL), and HLM (1 mg protein/mL).  Reactions were 
terminated after 60 min (gemfibrozil glucuronide) or 120 min (esomeprazole or 1-ABT), by the 
addition of 0.75 mL 1 N HCl and extracted with two volumes of dichloromethane.  The organic 
fraction was evaporated to dryness and the residue reconstituted with acetonitrile prior to 
analysis of heme by UHPLC with UV and HRMS detection.   
HPLC-MS/MS Analytical methods 
LC-MS/MS methods for CYP marker metabolites were carried out as described 
previously (33-35,37,38).  Omeprazole analysis was performed with an Applied Biosystems/ 
Sciex API2000 HPLC-MS/MS system equipped with an electrospray (TurboIonSpray) ionization 
source (Applied Biosystems, Foster City, CA), two LC-10ADvp pumps with an SCL-10Advp 
controller, SIL-HTA autosampler, and DGU-14 solvent degasser (Shimadzu, Columbia, MD). 
The HPLC column used was an Atlantis dC18, 5 µm, 100 x 2.0 mm column (Waters), which was 
preceded by a direct connection guard column with a C8, 4.0 mm x 2.0 mm cartridge 
(Waters).  Masses were monitored in the multiple reaction monitoring mode (MRM): 
omeprazole, 345.9 →197.9 and internal standard, pantoprazole, 383.9 →199.9. Mobile phases 
were: A=0.2% formic acid in water, B=0.2% formic acid in methanol and omeprazole and 
pantoprazole were eluted with a linear gradient (25%B to 75%B) over 2.5 min. 
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UHPLC-UV/HRMS analytical methods 
Heme and potential adducts were monitored by UHPLC-UV/HRMS with a Waters 
Synapt G2 quadrupole time of flight mass spectrometer equipped with a Waters Acquity LC 
system as described previously (126-129).  Briefly, for chromatographic separation, 0.1% formic 
acid in water and acetonitrile were applied to an Agilent Zorbax 300 SB-C18 LC column (2.1 x 
150 mm; 5 µm) with a gradient ranging from 2-98% organic mobile phase over 11 min, following 
an initial 1 min 2% hold. The mobile phase composition was held at 98% organic for an 
additional 2 min.  The mass spectrometer was operated in positive, resolution MSE mode with 
fexofenadine as a real-time mass calibrant.  Data were acquired over the m/z range 50 – 1200 
using a capillary voltage of 3.5 kV, sampling cone voltage of 20 V, source temperature of 120°C 
and desolvation temperature of 350°C. For the high energy scan function, a collision energy 
ramp of 15 – 45 eV was applied at the trap traveling wave ion guide.  For product ion spectra 
acquisition (i.e., MS/MS), precursor ions were first selected with the quadrupole and a collision 
energy ramp of 15 – 45 eV was applied at the trap traveling wave ion guide.  In-line UV/visible 
detection with a photodiode array detector scanning from 200 – 500 nm was incorporated. 
Data Analyses and Simulations 
All IC50, half-life, KI and kinact, values were determined by nonlinear regression with 
GraFit (version 7.0.2; Erithracus Software Ltd., Horley, Surrey, UK), as detailed previously (33-
35,37,38).  Ninety percent confidence intervals for kinact / KI values were calculated about the 
arithmetic mean with Student’s t-distribution.   
Accurate mass data were acquired with MassLynx version 4.1 SCN 712 (Waters). Data 
were processed with the MetaboLynx XS subroutine of MassLynx for dynamic mass-defect 
filtering about the accurate mass defect of heme (±35 mDa). The structure-based C-heteroatom 
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dealkylation algorithm was employed to construct mass-defect filters for heme and possible 
heme-related components, similar to methods described previously (126-129). 
In vitro-to-in vivo extrapolation of CYP2C19 inactivation data was performed using both 
a mechanistic static model (MSM) to calculate the AUC ratio (i.e., AUCi
AUC
 or simply AUCR, as 
defined by FDA) (31,94,130) and a mechanistic dynamic model (MDM) (131) in Chapter 4. The 
MSM was based on the following equation: 
 
AUCi
AUC
 = 
1
⎝
⎜
⎛ 𝑓m,CYP
1 + � 𝑘inact  ∙  [𝐼]𝑘deg ∙ (𝐾I + [𝐼])
�
⎠
⎟
⎞
+ �1 −  𝑓m,CYP�
 
Equation 3.1 
where (fm,CYP) represents the fraction of a hypothetical concomitantly administered drug 
metabolized by a given P450 enzyme, [I] is the inactivator concentration, and kinact and KI are 
the in vitro inactivation parameters, and kdeg is the rate constant for enzyme degradation (which 
has not been determined experimentally in vivo for CYP2C19, but for which the average value 
was reported to be 0.000445 min-1 based on in vitro data (132,133).  The unbound plasma Cmax 
was previously found to be more predictive than total Cmax for MDIs (130,134).  Therefore, this 
value was used in the MSM (equation 1), and was based on the total omeprazole plasma Cmax 
of 3.87 µM after 5 days of dosing (40 mg q.d.) in CYP2C19 EMs (135), coupled with its plasma 
protein binding of 95%, for an unbound plasma Cmax of 0.19 µM.  For the MSM analyses 
presented in Chapter 5, (fm,CYP2C19) for H4 formation from clopidogrel was set equal to either 
0.64 or 0.72 based on those reported by Boulenc et al. (94). Because a decrease in H4 was 
expected, data were presented as the H4 ratio (using parameters defined by Boulenc et al. (94)) 
or 1/AUCR (using conservative default parameters defined by the FDA (31)).  Plasma 
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concentrations of omeprazole, esomeprazole, omeprazole sulfone or 5-ODM omeprazole were 
based on various sources for dosage regimens as discussed in Chapter 5. 
The MDM simulations were carried out using Simcyp Population-Based Simulator 
(V10.2; Simcyp Limited, UK). The differential equations which make the basis of these 
simulations are described in detail elsewhere (131).  Input parameters can be found in the 
supplemental data to the paper published in 2011 (34). 
The purpose of the MDM simulations was to assess the time varying effect of repeated 
omeprazole administration (40 mg every 12 h) on the level of active CYP2C19 in liver. This 
included the self-inhibition effect as the deactivation of CYP2C19 led to lower clearance and 
higher concentrations of omeprazole itself. The simulations were carried out twice using the 
lower (1.7 µM) and upper (9.1 µM) boundaries of observed KI values and taking into account an 
unbound fraction of 0.75 (i.e., the free fraction of omeprazole in HLM at 1-2.5 mg/mL). kinact was 
assumed to be 0.045 min-1 and turn-over of CYP2C19 was the same as that assumed for the 
MSM.  
Although the main purpose of the simulations was to assess the level of active enzyme, 
S-mephenytoin was simulated as a substrate on day 14 following simulated administration of 
omeprazole and the effect on AUC was simulated on day 7 following administration of 
omeprazole.  The simulated omeprazole dose was continued until day 14 and the AUC for 
S-mephenytoin was assessed from day 7 until the end of simulation (day 14) and compared 
with AUC in the absence of an inactivator. 
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Chapter 4. OMEPRAZOLE (AND SELECTED METABOLITES), 
LANSOPRAZOLE AND PANTOPRAZOLE AS METABOLISM-
DEPENDENT INHIBITORS (MDIs) OF CYP2C19 
 
 
 
This chapter is reprinted with permission of the American Society for Pharmacology and 
Experimental Therapeutics, with minor modifications. All rights reserved. Copyright © 2011 by 
The American Society for Pharmacology and Experimental Therapeutics DMD 39:2020–2033, 
2011. 
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Abstract 
As a direct-acting inhibitor of CYP2C19 in vitro, lansoprazole is more potent than 
omeprazole and other proton pump inhibitors (PPIs), and yet lansoprazole does not cause 
clinically significant inhibition of CYP2C19 whereas omeprazole does.  To investigate this 
apparent paradox, omeprazole, esomeprazole, R-omeprazole, lansoprazole and pantoprazole 
were evaluated for their ability to function as direct-acting and metabolism-dependent inhibitors 
(MDIs) of CYP2C19 in pooled human liver microsomes (HLM), as well as in cryopreserved 
hepatocytes and recombinant CYP2C19.  In HLM, all PPIs were found to be direct-acting 
inhibitors of CYP2C19 with IC50 values varying from 1.2 µM (lansoprazole; Cmax = 2.2 µM) to 
93 µM (pantoprazole; Cmax = 6.5 µM).  In addition, omeprazole, esomeprazole, R-omeprazole, 
and omeprazole sulfone were identified as MDIs of CYP2C19 (they caused IC50 shifts after a 
30-min pre-incubation with NADPH-fortified HLM of 4.2-, 10-, 2.5-, and 3.2-fold, respectively), 
whereas lansoprazole and pantoprazole were not MDIs (IC50 shifts <1.5-fold).  The MDI of 
CYP2C19 by omeprazole and esomeprazole was not reversed by ultracentrifugation, 
suggesting the inhibition was irreversible (or quasi-irreversible), whereas ultracentrifugation 
largely reversed such effects of R-omeprazole.  Under various conditions, omeprazole 
inactivated CYP2C19 with KI values of 1.7 – 9.1 μM and kinact values (maximal rate of 
inactivation) of 0.041 – 0.046 min-1.  This study identified omeprazole, and esomeprazole, but 
not R-omeprazole, lansoprazole or pantoprazole, as irreversible (or quasi-irreversible) MDIs of 
CYP2C19.  These results have important implications for the mechanism of the clinical 
interaction reported between omeprazole and clopidogrel, as well as other CYP2C19 
substrates. 
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Introduction 
Omeprazole and other proton pump inhibitors (PPIs, i.e., esomeprazole, lansoprazole, 
dexlansoprazole, rabeprazole, and pantoprazole) are well known for a relatively low incidence of 
adverse events and pharmacokinetic drug-drug interactions (DDIs).  Nevertheless, PPIs are the 
perpetrators of interactions with cyclosporine (omeprazole and rabeprazole), diazepam 
(esomeprazole and omeprazole) and warfarin (esomeprazole, lansoprazole, omeprazole, and 
rabeprazole) (136).  In addition, all drugs that increase gastric pH can affect the bioavailability of 
drugs such as ampicillin esters, iron salts and ketoconazole, among others (136).  Omeprazole, 
the first approved PPI, decreases the clearance of drugs such as diazepam, moclobemide, 
escitalopram, carbamazepine, saquinavir, sibutramine, proguanil, etravirine, disulfiram, 
phenytoin, voriconazole, and clopidogrel, and, by inducing CYP1A2, increases the clearance of 
several antipsychotic drugs, such as imipramine, theophylline, and tacrine (27,84,136).   
The inhibitory DDIs listed above have been attributed, at least in part, to inhibition of 
CYP2C19 by omeprazole.  However, clinically relevant DDIs with omeprazole are generally of 
low magnitude (≤120% [2.2-fold] increase in plasma AUC of CYP2C19 substrates) (27).  By way 
of comparison, there is up to a 14.6-fold increase in the AUC of omeprazole when CYP2C19 is 
completely absent as occurs in genetically determined CYP2C19 poor metabolizers (137).  Over 
60 in vitro studies examining PPIs as CYP inhibitors have been published (27).  Only 
omeprazole, lansoprazole, (and their S-enantiomers) have been shown to inhibit CYP2C19 with 
IC50 or Ki values ≤1.0 µM.  Of particular interest is that none of these in vitro studies published 
prior to 2012 examined the PPIs as MDIs (a.k.a. time-dependent inhibitors) of P450 enzymes.  
Based on the lowest reported Ki values for CYP2C19 inhibition in the MTDI database (i.e., 
0.45 µM for lansoprazole and 1 µM for omeprazole), and the reported plasma Cmax for 
lansoprazole (30 mg, day 7) and omeprazole (40 mg, day 5) in CYP2C19 extensive 
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metabolizers (2.2 and 3.9 µM, respectively; (135,138), the so-called R1 values (i.e., 1 + [I]total/ Ki) 
values for lansoprazole and omeprazole would be 5.9 and 4.9, respectively (calculated as 
recommended in the Draft FDA Guidance for Industry, 2012; (31)), which means that both drugs 
would be expected to cause clinically relevant direct inhibition of CYP2C19, but that 
lansoprazole would have a higher likelihood of doing so than would omeprazole.  However, 
lansoprazole has been reported to cause no interaction with the CYP2C19 substrates 
diazepam, and phenytoin (27,136).  The lack of clinically relevant direct inhibition of CYP2C19 
by lansoprazole is likely explained by its relatively short half-life (1.1 hr; (138) and high plasma 
protein binding (~97%; (116)).  However, omeprazole also has a short half-life (0.7 hr; (135) and 
high plasma protein binding (~95%; (139)), and yet, as described above, omeprazole does 
cause clinically significant inhibition of CYP2C19.  This apparent discrepancy could be 
explained if omeprazole, but not lansoprazole, were an irreversible inhibitor of CYP2C19.   
A large clinical study in 282 healthy subjects (84) demonstrated that omeprazole inhibited 
the CYP2C19-dependent activation of clopidogrel as evidenced by a 40-47% decrease in the 
formation of H4, the purported active antiplatelet metabolite of clopidogrel.  Inhibition of 
clopidogrel activation was observed even when the two drugs were administered 12 hours 
apart.  In the same subjects, no such interaction was observed between pantoprazole and 
clopidogrel.  Additional clinical studies are reviewed in Chapter 1. 
The interaction between clopidogrel and PPIs and the impact of the CYP2C19 poor 
metabolizer phenotype have prompted warnings from the FDA and EMA (109,140), although 
the FDA specifically warns against coadministration of clopidogrel and omeprazole and further 
specifically suggests that pantoprazole may be a safer alternative.   
The identity of the enzyme(s) responsible for the multi-step activation of clopidogrel is 
controversial (45-49) (see Chapter 1 for additional review of this topic).  Much of the 
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pharmacogenomic data strongly implicate CYP2C19 as the most important enzyme for 
clopidogrel activation, based on poor response to clopidogrel in carriers of reduced function 
CYP2C19 alleles (e.g., the *2 and *3 alleles), and also increased bleeding in carriers of the 
increased function CYP2C19*17 allele (141).  The DDI between PPIs and clopidogrel is of 
particular importance because PPIs are co-prescribed in up to ~2/3 of patients after discharge 
from hospital because PPIs lessen the severity of the gastrointestinal hemorrhage associated 
with clopidogrel treatment (53).   
In this study the in vitro inhibitory potential of omeprazole, its individual enantiomers and 
selected metabolites, as well as lansoprazole and pantoprazole (Figure 4.1) were examined in 
pooled HLM, pooled cryopreserved hepatocytes and rCYP2C19, with a special emphasis on the 
potential for these drugs to cause MDI of CYP2C19.  The implications of our results were 
explored by dynamic simulations assessing the level of active CYP2C19 under multiple doses of 
omeprazole.  This PBPK modeling and simulation provided additional insight into the ongoing 
debate surrounding the interaction between PPIs and clopidogrel. 
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Figure 4.1. Structures of the PPIs and omeprazole metabolites examined. 
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Results 
4.1. Inhibitory effect of omeprazole on S-mephenytoin 4´-hydroxylation in 
multiple test systems: IC50 determinations, metabolic stability and 
microsomal protein binding 
Omeprazole was evaluated as a direct-acting and MDI of CYP2C19 activity 
(S-mephenytoin 4´-hydroxylation) in pooled human liver microsomes (n=16), recombinant 
CYP2C19 (Bactosomes®), and pooled, cryopreserved human hepatocytes (n=3), at a substrate 
concentration approximately equal to Km (40 µM).  The results are summarized in Figure 4.2a-d 
and Table 4.1.  The results show that omeprazole caused MDI of CYP2C19 as evidenced by a 
left shift in IC50 curves following a 30-min pre-incubation with NADPH-fortified HLM, 
recombinant CYP2C19 and human hepatocytes (IC50 shifts of 4.1, 6.9 and 3.6-fold, 
respectively).  A left shift of ≥1.5 fold is considered indicative of MDI (35).  With no pre-
incubation, omeprazole inhibited CYP2C19 in all three systems with similar IC50 values ranging 
from 4.7 to 9.6 µM, which decreased to approximately 1.5 µM in all three test systems after pre-
incubation with NADPH.  The experiment presented in Figure 4.2a also included an IC50 
determination with a 30-min pre-incubation step without NADPH, to confirm that the IC50 shift 
was NADPH-dependent (Table 4.1 [for clarity, these data are not presented in Figure 4.2a]).  
Omeprazole was also examined as an inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2D6, 3A4 and 2J2 
and was found to be a weak direct inhibitor of these enzymes (IC50 values > approximately 
100 µM), with no NADPH-dependent IC50 shift > 1.5 fold (supplemental data shown in Table 
4.2).   
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Figure 4.2. Evaluation of omeprazole as a direct-acting and MDI of CYP2C19.  
Each symbol represents the average of duplicate determinations unless otherwise indicated.  
(a) Omeprazole inhibited CYP2C19 in pooled HLM with IC50 values as shown (S-mephenytoin 
4´-hydroxylation control rates = 97.3 and 95.0 pmol/mg/min with and without pre-incubation, 
respectively). (b) Omeprazole inhibited CYP2C19 in pooled HLM with IC50 values as shown 
(S-mephenytoin 4´-hydroxylation control rates = 97.3 and 74.3 pmol/mg/min with and without 
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pre-incubation, respectively).  (c) Omeprazole inhibited recombinant human CYP2C19 with IC50 
values as shown (S-mephenytoin 4´-hydroxylation control rates = 0.690 and 0.828 min-1 with 
and without pre-incubation, respectively). (d) Omeprazole inhibited CYP2C19 cryopreserved 
human hepatocytes with IC50 values as shown (S-mephenytoin 4´-hydroxylation control rates = 
24.7 and 24.8 pmol/million cells/min with and without pre-incubation, respectively).  Each 
symbol represents the average of triplicate determinations and error bars represent the 
standard deviations. (e) The metabolic stability of omeprazole (10 µM) was evaluated in HLM at 
the protein concentrations utilized in this study (0.1, 1.0, and 2.5 mg/mL), as described in 
Chapter 3.  Half-life values for the disappearance of omeprazole are as indicated.  Each symbol 
represents the average of triplicate determinations and error bars represent the standard 
deviations; (f) The microsomal binding of omeprazole (2 and 10 µM) was evaluated as 
described in Chapter 3.    
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Table 4.1. Inhibition of CYP2C19 in human liver microsomes by omeprazole, its 
enantiomers or its major metabolites and lansoprazole and pantoprazole 
Compound 
IC50 (μM)a 
IC50 shift 
(fold)b 
No pre-incubation 
30 min pre-
incubation 
(-NADPH) 
30 min pre-
incubation 
(+NADPH) 
Omeprazole 6.9 ± 0.7 8.7 ± 0.6 1.7 ± 0.0 4.2 
Esomeprazole 15 ± 1 16 ± 1 1.5 ± 0.1 10 
R-Omeprazole 8.1 ± 1.2 12 ± 1 3.3 ± 0.4 2.5 
Omeprazole sulfide 9.7 ± 0.5 8.4 ± 2.7 9.6 ± 1.0 1.0 
Omeprazole sulfone 18 ± 2 12 ± 3 5.6 ± 0.5 3.2 
5-Hydroxyomeprazole > 100 > 100 > 100 NA 
Lansoprazole 1.2 ± 0.1 1.2 ± 0.1 1.2 ± 0.0 1.0 
Pantoprazole 93 ± 7 >100 65 ± 4 1.4 
a Values are displayed to two significant figures, ± standard error of the measurement 
b Calculated from full precision values as (IC50 with no pre-incubation) ÷ (IC50 with 30 min pre-
incubation + NADPH) and rounded to two significant figures.  IC50 shifts > 1.5-fold appear in 
bold. 
NA: Not applicable (i.e., IC50 values greater than the highest concentration examined) 
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Table 4.2. Summary of P450 inhibition in human liver microsomes by omeprazole 
Enzyme 
(substrate) 
IC50 (μM)a 
No pre-incubation 30 min pre-incubation 
(+NADPH) 
IC50 shift 
(fold)b 
 
CYP1A2 
(phenacetin) 
> 100 > 100 NA  
CYP2B6 
(bupropion) 
> 100 > 100 NA  
CYP2C8 
(Amodiaquine) 
95 ± 5 78 ± 8 1.2  
CYP2C9 
(Diclofenac) 
> 100 > 100 NA  
CYP2D6 
(Dextromethorphan) 
> 100 > 100 NA  
CYP3A4 
(Midazolam) 
> 100 69 ± 5 NA  
CYP3A4 
(Testosterone) 
> 100 > 100 NA  
CYP2J2 
(Ebastine) 
> 100 > 100 NA  
a Values are displayed to two significant figures, ± standard error of the measurement 
b Calculated from full precision values as (IC50 with no pre-incubation) ÷ (IC50 with 30 min pre-
incubation + NADPH) and rounded to two significant figures.   
NA: Not applicable (i.e., IC50 values greater than the highest concentration examined). 
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The data presented in Figure 4.2a were obtained under “low microsomal protein−short 
incubation time” conditions (i.e., 0.1 mg/mL HLM for 5 minutes).  However, S-mephenytoin is a 
low turnover substrate in HLM, for which reason S-mephenytoin 4´-hydroxylation activity is 
frequently assessed by incubating S-mephenytoin with high concentrations of HLM (i.e., ≥ 0.2 
mg/mL) for 20 - 40 min (e.g., (142,143).  Because MDI of CYP2C19 by omeprazole had not 
been previously described, the ability of omeprazole to inhibit CYP2C19 under “high microsomal 
protein−long incubation time” conditions (i.e., 1 mg/mL HLM for 30 minutes) was also examined.  
Under such conditions no MDI of CYP2C19 by omeprazole (i.e., IC50 shift <1.5; Figure 4.2b) 
was detected.   
Because of the difference in results between “low microsomal protein−short incubation 
time” and “high microsomal protein−long incubation time” conditions, the metabolic stability and 
non-specific binding of omeprazole in HLM was examined.  In NADPH-fortified HLM at 0.1 
mg/mL, omeprazole was relatively stable with a half-life of 98 min (Figure 4.2e).  However, at 
1.0 mg/mL and 2.5 mg/mL HLM (i.e., the concentration utilized in one of the kinact 
determinations, see below) omeprazole rapidly disappeared from incubations, with half-life 
values of only 14 and 5.7 min, respectively.  Non-specific binding of omeprazole to HLM was 
also examined (by ultrafiltration) as a possible cause of the discrepancy in results between “low 
microsomal protein−short incubation time” and “high microsomal protein−long incubation time” 
conditions.  As shown in Figure 4.2f, however, >75% of omeprazole (2 and 10 µM) remained 
free in the incubation from 0.1 to 2.5 mg/mL. 
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4.2. Inhibitory effects of the major omeprazole metabolites and enantiomers 
on S-mephenytoin 4´-hydroxylation in human liver microsomes: IC50 
determinations 
Esomeprazole, R-omeprazole, omeprazole sulfide, omeprazole sulfone, and 
5´-hydroxyomeprazole were evaluated as direct-acting and MDIs of CYP2C19 activity 
(S-mephenytoin 4´-hydroxylation) in pooled human liver microsomes (n=16, 0.1 mg/mL) at a 
substrate concentration approximately equal to the Km (40 µM).  The results are summarized in 
Table 4.1 and Figure 4.3.  The results show that esomeprazole (Figure 4.3a), R-omeprazole 
(Figure 4.3b), and omeprazole sulfone (Figure 4.3d) caused MDI of CYP2C19 as evidenced by 
a left shift in IC50 curves (>1.5-fold) following a 30-min pre-incubation with NADPH-fortified HLM 
(10, 2.5 and 3.2-fold IC50 shifts, respectively), with similar “shifted” IC50 values ranging from 1.5 
to 5.6 µM.  The IC50 values following a 30-min pre-incubation in the absence of NADPH were 
higher than those in the presence of NADPH, suggesting that the time-dependent inhibition of 
CYP2C19 by these compounds was in fact metabolism-dependent (Table 4.1).  The IC50 values 
for omeprazole sulfide after 30 min pre-incubation with or without NADPH remained similar to 
the value without pre-incubation (IC50 shift <1.5-fold), suggesting that omeprazole sulfide is only 
a direct-acting inhibitor of CYP2C19 (Figure 4.3c, Table 4.1).  5´-Hydroxyomeprazole, one of the 
major metabolites formed by CYP2C19, was a weak inhibitor of CYP2C19 (IC50 values > 
100 µM) (Figure 4.3e).  The experiments presented in Figure 4.3 also included an IC50 
determination with a 30-min pre-incubation step without NADPH, to confirm that the IC50 shift 
was NADPH-dependent (Table 4.1 [for clarity, these data are not presented in Figure 4.3]). 
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Figure 4.3. Evaluation of esomeprazole, R-omeprazole, omeprazole sulfide, omeprazole 
sulfone, and 5´-hydroxyomeprazole as direct-acting and MDIs of CYP2C19.  
Each symbol represents the average of duplicate determinations unless otherwise indicated.  
(a) Esomeprazole inhibited CYP2C19 in pooled HLM with IC50 values as shown (S-mephenytoin 
4´-hydroxylation control rates = 80.9 pmol/mg/min and 88.1 pmol/mg/min with pre-incubation). 
(b) R-Omeprazole inhibited CYP2C19 in pooled HLM with IC50 values as shown (S-mephenytoin 
4´-hydroxylation control rates = 106 and 108 pmol/mg/min, with and without pre-incubation, 
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respectively). (c) Omeprazole sulfide inhibited CYP2C19 in pooled HLM with IC50 values as 
shown (S-mephenytoin 4´-hydroxylation control rates = 89.8 and 82.2 pmol/mg/min, with and 
without pre-incubation, respectively).  (d) Omeprazole sulfone inhibited CYP2C19 in pooled 
HLM with IC50 values as shown (S-mephenytoin 4´-hydroxylation control rates = 85.4 and 84.7 
pmol/mg/min, with and without pre-incubation, respectively).  (e) 5´-Hydroxyomeprazole weakly 
inhibited CYP2C19 in HLM (S-mephenytoin 4´-hydroxylation control rates = 108 and 97.0 
pmol/mg/min, with and without pre-incubation, respectively). 
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4.1.3.  Inhibitory effects of lansoprazole and pantoprazole on S-mephenytoin 
4´-hydroxylation in human liver microsomes and cryopreserved human 
hepatocytes: IC50 determinations 
Lansoprazole and pantoprazole were evaluated as direct-acting and MDIs of CYP2C19 
activity (S-mephenytoin 4´-hydroxylation) in pooled human liver microsomes (n=16) and pooled, 
cryopreserved human hepatocytes (n=3), at a substrate concentration approximately equal to 
the Km (40 µM).  The results are summarized in Table 4.1 and Figure 4.4.  Neither lansoprazole 
nor pantoprazole caused MDI of CYP2C19 in either HLM or cryopreserved human hepatocytes 
(i.e., IC50 shifts <1.5-fold).  Lansoprazole was a relatively potent (i.e., IC50 ≈1.0 µM), direct-acting 
inhibitor of CYP2C19 in both HLM and cryopreserved human hepatocytes (Figure 4.4a and b), 
whereas pantoprazole was a relatively weak inhibitor (Figure 4.4c and d).  The experiments 
presented in Figure 4.4a and c also included an IC50 determination with a 30-min pre-incubation 
step without NADPH, to confirm that the IC50 shift was NADPH-dependent (Table 4.1 [for clarity, 
these data are not presented in Figure 4.4]).  
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Figure 4.4. Evaluation of lansoprazole and pantoprazole as direct-acting and MDIs of 
CYP2C19 
Each symbol represents the average of duplicate determinations unless otherwise indicated.  
(a) Lansoprazole inhibited CYP2C19 in HLM with IC50 values as shown (S-mephenytoin 
4´-hydroxylation control rates = 83.8 and 79.6 pmol/mg/min, with and without pre-incubation, 
respectively).  (b) Lansoprazole inhibited CYP2C19 in cryopreserved human hepatocytes with 
IC50 values as shown (S-mephenytoin 4´-hydroxylation control rates = 30.4 and 26.6 
pmol/million cells/min, with and without pre-incubation, respectively).  Each symbol represents 
the average of triplicate determinations and error bars represent the standard deviations; 
(c) Pantoprazole inhibited CYP2C19 in pooled HLM with IC50 values as shown (S-mephenytoin 
4´-hydroxylation control rates = 61.7 and 71.0 pmol/mg/min, with and without pre-incubation, 
respectively).  (d) Pantoprazole inhibited CYP2C19 in cryopreserved human hepatocytes with 
IC50 values as shown (S-mephenytoin 4´-hydroxylation control rates = 24.5 and 14.2 
pmol/million cells/min, with and without pre-incubation, respectively).  Each symbol represents 
the average of triplicate determinations and error bars represent the standard deviation. 
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4.3  Inactivation of CYP2C19 by omeprazole: KI and kinact determinations 
The results in Figure 4.2 suggest that omeprazole is an MDI of CYP2C19.  Accordingly, 
experiments were performed to determine KI (the concentration of omeprazole supporting half 
maximal rate of CYP2C19 inactivation) and kinact (the first order rate constant for CYP2C19 
inactivation).  The results from three different experiments are summarized in Figure 4.5.  The 
three experimental conditions were (1) low HLM concentration with [S] = Km with no dilution step 
(Figure 4.5a-b), (2) low HLM concentration with [S] = 10 × Km (Figure 4.5c-d), and (3) high 
[HLM] with [S] = 10 × Km with a 25-fold dilution step (Figure 4.5e-f).  Under all three conditions, 
the inactivation of CYP2C19 was dependent on the concentration of omeprazole (over the full 
ranges examined) and the time course conformed to a first-order inactivation process (as 
indicated by the linearity of plots of the log of the residual enzyme activity against time; Figure 
4.5a, c, and e).  The KI values differed depending on whether omeprazole was pre-incubated 
with human liver microsomes at 2.5 mg/mL (and subsequently diluted 25 fold to determine 
residual CYP2C19 activity with substrate = 10Km; Figure 4.5e-f) or 0.1 mg/mL (and not diluted 
to determine residual CYP2C19 activity, with substrate = 10Km or Km; Figure 4.5a-d).  The KI 
value was approximately 9 µM in the former case, and approximately 2 µM in the latter cases.  
In all three cases, the kinact values were approximately 0.04 min-1, which means that, in the 
presence of saturating concentrations of omeprazole, 4% of CYP2C19 was inactivated every 
minute.  The efficiency of CYP2C19 inactivation (kinact/KI) decreased by a factor of approximately 
five when the concentration of HLM was increased and a dilution step was used.  Taken 
together, these data suggest that omeprazole is an irreversible inactivator of CYP2C19.  
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Figure 4.5. Determination of KI and kinact for the MDI of CYP2C19 by omeprazole  
Individual points represent the average of triplicate determinations ± standard deviation, unless 
otherwise noted.  For graphs in (a) and (c), omeprazole was pre-incubated (at concentrations 
indicated in the legend of panel c) and residual CYP2C19 activity determined as described in 
Chapter 3.  For the graph in (e), omeprazole was pre-incubated (at concentrations indicated) 
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and residual CYP2C19 activity determined as described in Chapter 3 (after a 25-fold dilution).  
The graphs in (b), (d), and (f) represent the direct plots of the initial rates of inactivation of 
CYP2C19.  Values are the slopes of the initial rates of inactivation (kobs) at each concentration 
of omeprazole, shown ± standard error. 
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4.4. Effects of omeprazole on CYP2C19 activity in microsomes prepared 
from hepatocytes after three days of treatment 
CYP2C19 activity (S-mephenytoin 4´-hydroxylation) was measured in microsomes 
isolated from fresh primary cultures of human hepatocytes treated with omeprazole (100 µM; 
three days).  It should be noted that this concentration is approximately 19-times greater than 
the Cmax in PMs (5.3 µM [(144)]; who can be neither induced nor inhibited with respect to 
CYP2C19), and 26-times greater than the Cmax in EMs (135) after a 40 mg oral dose of 
omeprazole.  Omeprazole treatment decreased microsomal CYP2C19 activity in hepatocytes 
that initially expressed high levels of CYP2C19, but increased microsomal CYP2C19 activity in 
hepatocytes that initially expressed low levels of CYP2C19 (Figure 4.6).  This dual effect likely 
reflects the overall effect of two opposing actions of omeprazole; in hepatocytes with high 
CYP2C19 activity, the predominant effect of omeprazole was irreversible inactivation, but in 
hepatocytes with low CYP2C19 activity the predominant effect was induction via PXR activation 
(145).  These data were obtained from many studies conducted to examine the potential for 
drug candidates to induce P450 enzymes, in which primary cultures of human hepatocytes were 
treated with 100 µM omeprazole, a well-known AhR activator and therefore positive control for 
CYP1A2 induction.  Because the microsomes are obtained from these studies in a way that 
washes out residual inhibitor, these data provided additional evidence that omeprazole is an 
irreversible inactivator of CYP2C19. 
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Figure 4.6. CYP2C19 activity (S-Mephenytoin 4'-hydroxylation) in microsomes isolated 
from fresh-plated hepatocytes treated with DMSO (control) or omeprazole 
Primary cultures of human hepatocytes were treated for three consecutive days with DMSO or 
omeprazole (100 µM) and microsomes prepared from the hepatocytes 24-h after the last 
treatment.  CYP2C19 activity was determined as described in Chapter 3.  Activities were sorted 
in rank order from highest to lowest control rates (a) and the corresponding omeprazole-treated 
samples are displayed in panel (b) in terms of percent of control activity. 
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4.5  Irreversible or quasi-irreversible inhibition of CYP2C19 by omeprazole 
and esomeprazole, but not R-omeprazole: ultracentrifugation 
Because esomeprazole was approximately 4-fold more effective as a MDI of CYP2C19 
than R-omeprazole (Table 4.1, Figure 4.3a-b) with a 10-fold shift in IC50 value for the former and 
a 2.5-fold shift for the latter, omeprazole and its individual enantiomers were further examined to 
determine whether the inactivation of CYP2C19 involved irreversible or quasi-irreversible 
inhibition based on an ultracentrifugation method described in Chapter 3 and previously (35).  A 
concentration of inhibitor that caused nearly complete (i.e., > ~95% inhibition) after 30-min pre-
incubation with NADPH, but incomplete (< ~85%) inhibition after 30-min pre-incubation in the 
absence of NADPH was chosen (i.e., 100 µM for all).  Pooled HLM were treated with inhibitor or 
solvent (methanol, 0.1% v/v) for 30 min in the presence of NADPH, and in the presence or 
absence of potassium ferricyanide (to reverse the formation of metabolite inhibitory complex 
associated with quasi-irreversible inactivation (125)) (Figure 4.7).  Following the 30-min 
incubation, pooled HLM samples were either (1) assayed directly for residual CYP activity (“Pre-
spin”), (2) re-isolated by ultracentrifugation and then assayed for residual CYP activity (“Post-
spin”), or (3) treated with potassium ferricyanide, re-isolated by ultracentrifugation and then 
assayed for residual CYP activity (“Post-spin + K3[Fe(CN)6]”).  As expected, substantial 
inhibition was observed after treatment with omeprazole, esomeprazole and R-omeprazole 
(Figure 4.7, “pre-spin”), in a rank-order consistent with the IC50 shifts: esomeprazole ≈ 
omeprazole > R-omeprazole.  Surprisingly, centrifugation and re-isolation of HLM after pre-
incubation largely reversed the inhibition caused by R-omeprazole (Figure 4.7, “Post-spin” and 
“Post spin + K3[Fe(CN)6]”).  In contrast, centrifugation did not fully restore CYP2C19 activity 
after treatment with omeprazole or esomeprazole, which suggests that esomeprazole is the 
major contributor to the inactivation of CYP2C19 by omeprazole.  Potassium ferricyanide 
treatment of the samples caused some additional restoration of activity after treatment with 
omeprazole and esomeprazole, but did not fully restore CYP2C19 activity.  Taken together, 
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these results suggest that the MDI of CYP2C19 observed with racemic omeprazole is largely 
irreversible (due to covalent binding to the apoprotein, heme moiety or both).  However, given 
the partial restoration of CYP2C19 activity with potassium ferricyanide, contribution of a quasi-
irreversible mechanism (due to metabolite inhibitory complex [MIC] formation) cannot be 
completely ruled out.  However, the results presented in Figure 4.7 show that the MDI of 
CYP2C19 caused by R-omeprazole is largely reversible after re-isolation of HLM, suggesting 
that one or more metabolites of this enantiomer is simply a more potent inhibitor of CYP2C19 
than the parent, whereas metabolism of esomeprazole largely leads to irreversible inactivation 
of CYP2C19.   
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Figure 4.7. Reversibility assessment of the MDI of CYP2C19 by omeprazole and its 
enantiomers with the ultracentrifugation method   
The potential reversibility of the MDI of CYP2C19 NADPH-fortified HLM (0.1 mg/mL) by 
omeprazole and its individual enantiomers (100 µM) was evaluated with the ultracentrifugation 
method, as described in Chapter 3.  Incubations labeled “Pre-spin” were conducted similarly to 
analogous samples in the IC50 determinations (conduced in triplicate and displayed as the 
average rates of S-mephenytoin 4´-hydroxylation ± standard deviation).  For incubations labeled 
“Post-spin” (conducted in triplicate and analyzed in triplicate), microsomal protein was isolated 
by ultracentrifugation after 30 min incubations with the inhibitor and NADPH, and analyzed in 
triplicate for residual CYP2C19 activity (S-mephenytoin 4´-hydroxylation) displayed as the 
average rates ± standard error, as described in Chapter 3.  Half of the incubations from the 
“Post-spin” samples included potassium ferricyanide (2 mM, final concentration) as indicated.  
Samples treated with methanol (1% v/v, final) served as controls.  All rates were normalized to 
final microsomal protein concentrations, as described in Chapter 3.  
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4.6  Simulation of time-dependent changes in active CYP2C19 
Active levels of hepatic CYP2C19 in the presence of omeprazole (40 mg b.i.d. for 14 
days) were simulated with Simcyp V10.2, as described in Chapter 3.  Figure 4.8 shows the 
active CYP2C19 levels with time.  Depending on the assumption regarding KI (1.7 or 9.1 µM) 
the level of active enzyme could decrease to approximately 10 to 60% of the baseline which 
would be associated with a 1.4 to 10-fold increase in AUC of compounds mainly metabolized by 
CYP2C19.  However, the simulated effect of omeprazole on S-mephenytoin AUC showed only a 
1.45-fold increase when the KI value was 9.1 µM, and a 5.46-fold increase when the KI value 
was 1.7 µM, rather than a 10-fold increase, likely due to the contribution of other enzymes in its 
metabolism (e.g. CYP2B6 and CYP2C9 (146,147)).    
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Figure 4.8. Simulation of time-dependent changes in active CYP2C19 
Active levels of hepatic CYP2C19 in the presence of omeprazole (40 mg b.i.d. for 14 days) were 
simulated with the Simcyp Simulator V10.2, as described in Chapter 3.  Panel (a) is based on a 
KI value of 1.7 µM; panel (b) is based on a KI value of 9.1 µM. 
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Discussion 
Given the relatively few drugs that are metabolized extensively by CYP2C19, it is not 
surprising that few DDIs have been attributed to clinically relevant inhibition of CYP2C19.  As 
noted in the Introduction to this chapter and in Chapter 1, there is evidence of clinically relevant 
inhibition of CYP2C19 by omeprazole, but direct competitive inhibition of CYP2C19 is an 
unlikely cause; if it were, lansoprazole would be expected to inhibit CYP2C19 more than 
omeprazole whereas the converse is observed clinically.  It should be noted that the dose of 
lansoprazole versus omeprazole (which depends on indication) could partly explain this 
difference.  For the lowest dose indications (i.e., GERD or maintenance of healing of erosive 
esophagitis), it is 20 mg q.d. for omeprazole ((139), and 15 mg q.d. for lansoprazole (116).  For 
the highest dose indication (i.e., Zollinger–Ellison or other hypersecretory syndromes), the 
doses are equal (60 mg q.d. or up to 120 mg per day in divided doses).  Based on this 
comparison alone, it seems unlikely that the slight difference in the low dose explains the 
differences in clinical DDIs.  This supposition is borne out by clinical data in the MTDI: negative 
interactions were reported between lansoprazole (60 mg q.d., 10 days) and the CYP2C19 
substrates diazepam and phenytoin (lansoprazole dose 60 mg q.d., 9 days with the latter drug) 
(27).  No positive DDIs with CYP2C19 substrates have been reported in the MTDI with 
lansoprazole with the exception of a case report regarding a possible interaction with 
voriconazole in a CYP2C19 IM (27).  On the other hand, with a low dose of omeprazole (20 mg 
q.d.) in various studies (8 to 23 days), the exposure (AUC) of the CYP2C19 substrates 
diazepam and escitalopram increased from 26 to 91% (27). 
With the exception of the preliminary findings (148), in vitro evidence for MDI of 
CYP2C19 had not been described for any PPI prior to the publication of the data in this chapter 
in 2011 (34).  In the current study, omeprazole, esomeprazole, R-omeprazole, and omeprazole 
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sulfone were identified as MDIs of CYP2C19 (IC50 shifts after a 30-min pre-incubation with 
NADPH of 4.2, 10, 2.5, and 3.2, respectively), whereas lansoprazole and pantoprazole were not 
MDIs (IC50 shifts <1.5).  Furthermore, the MDI of CYP2C19 by omeprazole and esomeprazole 
was not reversed by ultracentrifugation, suggesting the inhibition was irreversible, whereas 
ultracentrifugation largely reversed such effects of R-omeprazole.  Under various conditions, 
omeprazole inactivated CYP2C19 with KI values of 1.7 – 9.1 μM and kinact values (maximal rate 
of inactivation) of 0.041 – 0.046 min-1 (corresponding to kinact/KI values ranging from 5.1 to 24 
min-1 · mM-1 depending on the experimental conditions used (Figure 4.5).  The variation in KI 
values, but not kinact values, is generally consistent with previous reports investigating the impact 
of dilution (35,149).  The quasi-irreversible or irreversible MDI of CYP2C19 by omeprazole 
(rather than reversible inhibition) likely explains, at least in part, the observed clinical 
interactions between omeprazole (and esomeprazole) and CYP2C19 substrates, including 
clopidogrel, notwithstanding the considerable debate surrounding the role of CYP2C19 in the 
activation of the latter drug (80,81) (see Chapter 1 for additional review of this topic).   
Why did previous in vitro studies miss the MDI of CYP2C19 by omeprazole?   
The IC50 or Ki values for inhibition of CYP2C19 in HLM by omeprazole reported in the 
literature range from 150 µM to 1 µM in >40 studies (27).  The lowest values (1 and ~4 µM) 
were reported with some of the longest substrate incubation periods (60 – 120 min; presumably 
used due to the low turnover of S-mephenytoin), and few (if any) studies specifically included a 
pre-incubation with NADPH-fortified HLM to examine the possibility of MDI of CYP2C19.  Based 
on Fig. 4.5, 60 – 120 min would provide ample time for inactivation of CYP2C19 by omeprazole 
during the substrate incubation, therefore leading to “unintentional” MDI and artificially low IC50 
or Ki values, as reviewed previously (35).  The data also show that the IC50 shift diminishes as 
higher protein concentrations and longer substrate incubation times are utilized (Figure 4.2b), 
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likely due to the combination of inhibitor depletion (Figure 4.2e) and the “unintentional” MDI 
during the long substrate incubation (35).   
Would clinically relevant CYP2C19 inhibition by omeprazole be predicted on the basis of 
direct inhibition alone?   
As noted in the introduction to this chapter, and in Chapter 1, clinically significant 
inhibition of CYP2C19 by omeprazole would not be predicted based on competitive inhibition 
alone.  A thorough prediction of the impact of omeprazole on CYP2C19 substrates based on the 
experimentally determined KI and kinact values necessitated the use of physiologically based 
pharmacokinetic (PBPK) modeling to allow dynamic simulation of changes to both omeprazole 
(including self-inhibition), substrate concentrations as well as enzyme turnover (i.e., a so-called 
mechanistic dynamic model [MDM]), with the mechanistic static model (MSM, Equation 3.1) 
used as a comparator.   
In the MDM under conditions where in vitro inhibitor depletion and microsomal protein 
binding of omeprazole were minimal (Figure 4.1e-f; i.e., KI = 1.7 µM, Figure 4.5d) the level of 
active CYP2C19 is predicted to decrease to ~ 10% of baseline, after approximately 7 days of 
simulated omeprazole administration (Figure 4.8a) which could cause up to a 10-fold increase in 
the AUC of compounds predominantly metabolized by CYP2C19.  When the higher estimate of 
KI  is used in the MDM (obtained with a 25-fold dilution, under conditions in which significant 
inhibitor depletion occurs, Figure 4.2e), the level of active CYP2C19 is predicted to decrease to 
~60% of baseline, after approximately 12 days of simulated omeprazole administration (Figure 
4.8b).  Although S-mephenytoin is a model CYP2C19 probe substrate, only a 1.45 - 5.46-fold 
increase in its AUC (depending on KI) is predicted by the MDM after 14 days of simulated  
omeprazole administration (40 mg b.i.d.), partly because of the contribution of other enzymes to 
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its metabolism (e.g. CYP2B6 and CYP2C9 (146,147)), and possibly due to less than complete 
inactivation of CYP2C19. 
In the MSM, when the lowest value of KI is used, omeprazole is predicted to cause a 
2.85-fold increase in the AUC of a drug such as moclobemide which has an fmCYP2C19 of 0.72 
(112).  The predicted AUC increase with moclobemide falls to 1.96-fold with the KI value of 9.1 
µM.  If the fmCYP2C19 were equal to 1.0, and the lowest KI value used, omeprazole is predicted to 
cause up to a 10.4-fold increase in the AUC of such a hypothetical “perfect” CYP2C19 
substrate.  However, because there is up to a 14.6-fold increase in the AUC of omeprazole in 
CYP2C19 PMs relative to EMs, (137), this prediction suggests that omeprazole does not 
completely inactivate CYP2C19, which is consistent with either scenario in the MDM after 
several days of administration of omeprazole (Figure 4.8). 
The clinical example of moclobemide (fmCYP2C19 = 0.72) is generally in agreement with 
these predictions, with AUC∞ increases averaging 2.21-fold (1.03 to 3.39-fold) in CYP2C19 EMs 
with omeprazole coadministration (112).  The AUC increases predicted with the lowest KI in the 
MSM value fall within this observed range.  In addition, in order to achieve the reported 1.39-fold 
increase in AUC of clopidogrel with concomitant dosing of omeprazole (84), the fmCYP2C19 for 
clopidogrel would need only to be approximately 0.31 according to the MSM. 
Given the large difference in predicted active CYP2C19 after several days of simulated 
omeprazole administration in the MDM depending on which KI value is used (Figure 4.8), the 
importance of determining the KI value under conditions where microsomal protein binding and 
inhibitor depletion are minimized is underscored, similar to the case with IC50 values (35).   
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Is there clinical evidence of CYP2C19 inhibition by omeprazole?   
In vivo evidence for MDI of CYP2C19 by omeprazole has already been reported (also 
reviewed in Chapter 1).  For instance, Klotz reported that healing rates of GERD after 4 weeks’ 
therapy with esomeprazole were not dependent on CYP2C19 status, as they are for 
lansoprazole (150).  Based on the metabolite ratios of 5´-hydroxyomeprazole (formed by 
CYP2C19) to omeprazole sulfone (formed by CYP3A4), it was concluded that CYP3A4 plays 
the major role in the metabolism of esomeprazole after multiple dosing, consistent with 
autoinhibition of CYP2C19 and conversion of CYP2C19 EMs to IMs or PMs after repeat dosing 
(150).  The changes in metabolite ratio suggests that the impact of multiple dosing on 
omeprazole reflects autoinhibition of CYP2C19, rather than increased stability due to higher 
gastric pH as originally suspected, especially because such time-dependent changes do not 
occur with other PPIs. On the other hand, the prescribing information for Nexium states “at 
repeated once-daily dosing with 40 mg, the systemic bioavailability is approximately 90% 
compared to 64% after a single dose of 40 mg” (119).  In addition, Andersson and Weidolf (113) 
reported that when 15 mg of either omeprazole (i.e., the racemate), esomeprazole or 
R-omeprazole was administered orally for seven days, exposure to esomeprazole (plasma 
AUC) increased by approximately twofold over 7 days, whereas exposure to omeprazole 
increased by only 52%, and exposure to R-omeprazole actually decreased by 9%.  These 
results are consistent with the in vitro results presented in this chapter showing that the 
inhibition of CYP2C19 by R-omeprazole appears to be largely reversible, whereas that of the 
racemate and esomeprazole are largely irreversible (Figure 4.7). 
In vivo evidence for MDI of CYP2C19 by omeprazole also comes from clinical DDI 
studies with omeprazole as the perpetrator.  For instance, in CYP2C19 extensive metabolizers 
(but not in poor metabolizers), the AUC of moclobemide increased by ~31% after a single 40 
mg dose of omeprazole, but increased by 121% after 8 days of dosing with 40 mg omeprazole 
81 
 
(112).  Such an apparent increase in the exposure of a victim drug with repeated dosing of the 
perpetrator drug is often apparent with MDIs.  In addition, omeprazole (but not lansoprazole or 
pantoprazole) has long been known to inhibit the metabolism of diazepam in vivo, and this 
inhibition occurs in CYP2C19 EMs but not PMs, further suggesting the mechanism involves 
CY2C19 inhibition by omeprazole (151-153). 
Does MDI of CYP2C19 by omeprazole explain the PPI-clopidogrel interaction?   
The data and the predictions detailed above may explain, at least in part, the interaction 
between omeprazole (or esomeprazole) and clopidogrel.  As noted in the introduction to this 
chapter, the FDA specifically warns against coadministration of clopidogrel and omeprazole 
(109).  Given that the in vivo half-life of omeprazole (and other PPIs) is short, and plasma 
protein binding is high, it is remarkable that many publications attributed the 
clopidogrel-omeprazole interaction to competitive (reversible) inhibition of CYP2C19 by 
omeprazole, with some suggestion that separation of dosing can prevent the interaction 
(47,154,155).  However, it should be noted that for clopidogrel, genetic differences in both the 
metabolism or transport of the drug and in the therapeutic target (the P2Y12 receptor on 
platelets), as well as environmental factors (e.g., diet, disease, coadministered drugs) have 
been implicated in the variation in its clinical effect (47,154-156).  As noted in Chapter 1, 
however, later pooled analysis of P2Y12 receptor, CYP1A2, CYP2B6, CYP2C9, CYP2C19, 
CYP3A5, CYP2D6, and P-gp polymorphisms in nearly 400 subjects found that only CYP2C19 
status had a significant impact on the antiplatelet effect of clopidogrel (68). 
In addition, the interaction between omeprazole (or esomeprazole) and clopidogrel is 
particularly complex, as noted by Zhang et al. (157).  These authors note that clopidogrel itself 
is an MDI of CYP2C19, increasing the ratio of 5´-hydroxyomeprazole to omeprazole by ~75% in 
CYP2C19 EMs (144,157) and that both clopidogrel and its 2-oxo metabolite (the precursor to 
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the active metabolite) also directly inhibit CYP2C19 with IC50 values ≤1 µM.  The authors 
suggested that the “stronger” effect of omeprazole on CYP2C19 may be due to the “time-
dependent” inhibition reported in the preliminary work (157).  The finding of irreversible or quasi-
irreversible inactivation of CYP2C19 by omeprazole, with up to a predicted 90% decrement in 
active CYP2C19 after approximately 7 days of simulated dosing (Figure 4.8a) is consistent with 
this hypothesis.  The fact that the FDA warning applies only to omeprazole or esomeprazole 
(109) and not the other PPIs is consistent with a lack of MDI by the other PPIs examined in this 
study.   
Given only minor inhibitory effects of omeprazole on other P450 enzymes (Table 4.2), 
the MDI of CYP2C19 by omeprazole and the reports of clinical interactions are consistent with a 
significant role for CYP2C19 in the metabolism of clopidogrel.  In addition, as described in the 
introduction to this chapter, direct inhibition of CYP2C19 by other PPIs is not likely to be the 
cause of a clinically significant interaction with clopidogrel, which is consistent with the lack of in 
vitro MDI of CYP2C19 by lansoprazole and pantoprazole reported in this chapter, and a lack of 
clinically significant pharmacokinetic interactions between either lansoprazole or pantoprazole 
and clopidogrel (27). 
Potential mechanisms of inactivation of CYP2C19 by omeprazole 
Follow up studies to further elucidate the mechanism of inactivation of CYP2C19 by 
esomeprazole are covered in Chapters 5 – 7 of this dissertation.  However, a few possibilities 
for the mechanism of CYP2C19 inactivation by omeprazole (or esomeprazole) were 
hypothesized at the time the work this was conducted based on the reported metabolism of the 
individual enantiomers of omeprazole (Figure 4.9, adapted from (113,158).    
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Figure 4.9. Metabolic scheme for omeprazole enantiomers 
The conversion of each enantiomer of omeprazole to the major metabolites and enzymes 
responsible for each is shown.  The scheme is adapted from that published by Andersson and 
Weidolf (113), which is in turn based on in vitro data published by Abelö et al. (158), which is the 
source of the CLint values. 
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At the time the work presented in this chapter was published, it was hypothesized that 
methylhydroxylation of omeprazole to form 5´-hydroxyomeprazole could involve the 
intermediacy of a benzylic radical and heme alkylation, analogous to the inactivation of CYP2C8 
by gemfibrozil glucuronide (33,159).  The formation of 5-O-desmethylomeprazole (a para-
aminophenol) could also lead to a reactive quinoneimine that could inactivate CYP2C19 if 
formed in its active site.  The latter possibility may be unlikely given that the 5-hydroxylation of 
lansoprazole also leads to para-aminophenol formation (Figure 4.10; admittedly a tautomer of 
the analogous 5-O-desmethylomeprazole para-aminophenol), and yet lansoprazole is not an 
MDI of CYP2C19 (Figure 4.4a).  Because the presence of glutathione could mitigate inhibition 
caused by such a mechanism, this possibility was followed up and will be presented in the 
following chapters.   
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Figure 4.10. Possible para-aminophenol formation from metabolites of omeprazole and 
lansoprazole 
Major metabolites of omeprazole (O-desmethylomeprazole) and lansoprazole 
(5-hydroxylansoprazole) are shown.  The highlighted area indicates the part of the molecules 
that are potentially reactive para-aminophenols. 
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However, the data presented in Figure 4.7 suggest that esomeprazole has a greater MDI 
effect on CYP2C19 than does R-omeprazole.  These data are in fact consistent with clinical 
observations in which the plasma Cmax of esomeprazole (40 mg q.d., oral solution) increases 
from 3.07 to 4.86 µM from day 1 to day 5, and that of omeprazole (40 mg q.d., oral solution) 
increases from 2.32 to 3.87 µM, while that of R-omeprazole (40 mg q.d., oral solution) only 
increases from 1.62 to 1.98 µM (135).  In addition, published in vitro results in HLM suggest that 
the CLint for esomeprazole sulfoxidation (catalyzed by CYP3A4) is 4.6-fold greater than that for 
R-omeprazole (158), even though the total CLint for R-omeprazole is approximately threefold 
higher than for esomeprazole.  This finding is even more apparent in the clinical data, which 
show an approximately 14-fold higher AUC for the sulfone when esomeprazole is administered 
for one day (20 or 40 mg) than for R-omeprazole; this ratio increases to nearly 40-fold after 5 
days’ dosing (158) because CYP3A4 plays a more important role in esomeprazole metabolism 
after multiple dosing (150).  Because of the finding that omeprazole sulfone is also an MDI of 
CYP2C19, it seemed possible at the time these data were generated that the combination of 
effects from esomeprazole and its sulfone explain the much greater inactivation of CYP2C19 by 
esomeprazole than R-omeprazole, and this possibility is followed up on in Chapters 5-6.   
At the same time, the CLint for the 5´-hydroxylation of R-omeprazole is approximately 10-
fold higher than for esomeprazole, which, along with the results presented in this chapter 
(Figure 4.7) suggest that, unless there is also a difference in the ultimate fate of R- vs. 
S-5´-hydroxyomeprazole (e.g., benzylic radical formation and oxygen rebound or other 
inactivating pathways), this pathway may not explain the formation of a reactive metabolite that 
inactivates CYP2C19.  Enantiomer-enantiomer interactions at the active site of CYP2C19 when 
the racemate is used (as in some experiments in this study) could also complicate the 
interpretation of results with the single enantiomers as previously described (160), especially 
considering that the presence of R-omeprazole acts as an alternative substrate and offers 
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substrate-protection for the irreversible inactivation by esomeprazole or its sulfone.  It is for this 
reason that primarily esomeprazole is investigated in later chapters. 
In conclusion, in this study it was shown that omeprazole (but not pantoprazole or 
lansoprazole) is an MDI of CYP2C19 in HLM, cryopreserved human hepatocytes and 
recombinant human CYP2C19.  Based on the KI and kinact values for the MDI of CYP2C19 by 
omeprazole in HLM, it was predicted that this inactivation is clinically significant.  Furthermore, 
evidence was provided that esomeprazole is more likely to irreversibly inactivate CYP2C19 than 
is R-omeprazole.  These findings have implications for the ongoing debate surrounding the 
interaction between clopidogrel (as well as other CYP2C19 substrates) and omeprazole and, in 
particular, esomeprazole, which is followed up on in the following chapters. 
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Chapter 5. ESOMEPRAZOLE AND TWO METABOLITES AS 
METABOLISM-DEPENDENT INHIBITORS (MDIs) OF 
CYP2C19  
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Abstract 
As shown in the previous chapter, simulations of the effect of omeprazole on CYP2C19 
did not predict complete inactivation of this enzyme.  I hypothesized that the overall irreversible 
inhibitory effect of omeprazole (and esomeprazole in particular) on CYP2C19 may be due to a 
combination of effects of the parent drug and its sulfone (already established as a metabolism-
dependent inhibitor of CYP2C19) as well as the 5-O-desmethyl metabolite.  In an effort to 
characterize the potency with which esomeprazole and its major metabolites inactivate 
CYP2C19, experiments were undertaken in NADPH-fortified pooled human liver microsomes 
(HLM) under various conditions. 5-O-desmethyl omeprazole was first established as a 
metabolism-dependent inhibitor of CYP2C19 with an IC50 shift of 5.6-fold.  Ultracentrifugation 
experiments subsequently established that, like esomeprazole, the MDI of CYP2C19 by 
omeprazole sulfone and 5-O-desmethyl omeprazole was largely irreversible.  Depending on the 
experimental conditions used, KI and kinact values ranged from 3.23 – 13.9 µM and 0.048 – 
0.068 min-1, respectively for esomeprazole; 0.8 – 5.5 µM and 0.017 – 0.025 min-1, respectively 
for omeprazole sulfone, and 10.3 – 11.9 µM and 0.025 – 0.028 min-1, respectively for 5-O-
desmethyl omeprazole.  A mechanistic static drug-drug interaction model incorporating these 
values along with those for omeprazole or esomeprazole, was also employed in an attempt to 
rationalize the clinical interaction between omeprazole or esomeprazole and clopidogrel in 
terms of CYP2C19 inactivation.  The model overpredicted (by a factor of ~2) the ability of 
omeprazole to block the conversion of clopidogrel to H4, but established that inactivation of 
CYP2C19 is the likely mechanism for the clinical interaction between omeprazole/esomeprazole 
and clopidogrel.  The results of this study suggest that esomeprazole inactivates CYP2C19 at a 
rate similar to racemic omeprazole, and that omeprazole sulfone as well as 5-O-desmethyl 
omeprazole can also contribute to the overall in vivo inactivation of CYP2C19 by omeprazole 
and esomeprazole.        
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Introduction 
In Chapter 4, I presented data showing that omeprazole (but not pantoprazole or 
lansoprazole) is an MDI of CYP2C19 in human liver microsomes (HLM), cryopreserved human 
hepatocytes and recombinant human CYP2C19 (34).  I also presented evidence that 
esomeprazole is more likely to irreversibly inactivate CYP2C19 than is R-omeprazole.  The 
major omeprazole metabolites, namely omeprazole sulfone, omeprazole sulfide and 
5´-hydroxyomeprazole were also investigated as MDIs of CYP2C19 in pooled HLM, and only 
omeprazole sulfone was found to be an MDI (Chapter 4).  Another major omeprazole 
metabolite, 5-O-desmethyl omeprazole, was not investigated in Chapter 4, and was therefore 
characterized as part of the studies presented in this chapter (for structure, see Figure 4.9).  
The studies presented in this chapter were undertaken as a further step toward characterizing 
the effect of esomeprazole and its metabolites on CYP2C19 pooled HLM with the ultimate goal 
of providing a basis for the clinically relevant interaction between esomeprazole and clopidogrel 
or other CYP2C19 substrates.    
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Results 
5.1. Inhibitory effects of 5-O-desmethyl omeprazole on S-mephenytoin 
4´-hydroxylation in human liver microsomes: IC50 shifts 
5-O-Desmethyl omeprazole was not initially examined in the studies presented in 
Chapter 4, but as noted, is a major metabolite of esomeprazole and its formation (as a para-
aminophenol) could lead to a reactive quinoneimine that could inactivate CYP2C19 if formed in 
its active site.  Based on this possibility, IC50 determinations toward CYP2C19 activity as 
detailed in Chapter 3 were made.  Once a commercial source of 5-O-Desmethyl omeprazole 
was found, qualitative solubility testing was undertaken, and this metabolite was found to have 
low solubility in the solvent used for the other compounds.  Various combinations of solvents 
were attempted with the most successful being a mixture of methanol/DMSO/Tris buffer (at pH 
9.0 to allow greater stability of the stock for longer storage) at 70/20/10% v/v/v, respectively, 
with an approximate stock concentration of 7 mM achieved.  This combination of solvents was 
then used for additional experiments with this metabolite. 
5-O-Desmethyl omeprazole was evaluated as a direct-acting and MDI of CYP2C19 
activity (S-mephenytoin 4´-hydroxylation) in pooled human liver microsomes (n = 16, 0.1 
mg/mL) at a substrate concentration approximately equal to the Km for the marker reaction 
(40 µM).  The results are summarized in Figure 5.1.  The results show that 5-O-desmethyl 
omeprazole caused MDI of CYP2C19 as evidenced by a left shift in IC50 curves (44 → 8.2 µM or 
~5.4-fold shift) following a 30-min pre-incubation with NADPH-fortified HLM.  The IC50 value 
following a 30-min pre-incubation in the absence of NADPH (i.e., 93 µM) was higher than that in 
the presence of NADPH, suggesting that the time-dependent inhibition of CYP2C19 by these 
compounds was in fact also metabolism-dependent.    
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Figure 5.1. Evaluation of 5-O-desmethylomeprazole as a direct-acting and MDI of 
CYP2C19  
Each symbol represents the average of duplicate determinations.  5-O-desmethyl omeprazole 
inhibited CYP2C19 in pooled HLM with IC50 values as shown (S-mephenytoin 4´-hydroxylation 
solvent control rates = 53.5, 58.8, and 45.8 pmol/mg/min for zero-min, 30-min –NADPH, and 
30-min + NADPH pre-incubations, respectively).  
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5.2. Determination of irreversibility of MDI for omeprazole sulfone and 
5-ODM omeprazole 
Having established that omeprazole sulfone and 5-ODM omeprazole were metabolism-
dependent inhibitors of CYP2C19 (Table 4.1 and Figure 5.1, respectively), these metabolites 
were further examined to determine whether the inactivation of CYP2C19 involved irreversible 
or quasi-irreversible inhibition based on the ultracentrifugation method described in Chapters 3 
and 4 and previously (34,35).  A concentration of omeprazole sulfone that caused nearly 
complete (i.e., >~90% inhibition) after 30-min pre-incubation with NADPH, but incomplete 
(<~85%) inhibition after 30-min pre-incubation in the absence of NADPH was chosen (i.e., 
100 µM).  Because the solubility of 5-ODM omeprazole was limiting, 70 µM was chosen as the 
concentration to be investigated, which caused ~40% inhibition after 30-min pre-incubation in 
the absence of NADPH but ~85% inhibition after 30-min pre-incubation in the absence of 
NADPH.  Pooled HLM were treated with inhibitor or solvent for 30 min in the presence of 
NADPH, and in the presence or absence of potassium ferricyanide (to potentially reverse the 
formation of a metabolite inhibitory complex associated with quasi-irreversible inactivation) 
(Figure 5.2).  Following the 30-min incubation, pooled HLM samples were either (1) assayed 
directly for residual CYP activity (“pre-spin”), (2) re-isolated by ultracentrifugation and then 
assayed for residual CYP activity (“post-spin”), or (3) treated with potassium ferricyanide, re-
isolated by ultracentrifugation and then assayed for residual CYP activity (“post-spin + 
K3[Fe(CN)6]”). Substantial direct inhibition was observed after treatment with omeprazole 
sulfone and 5-ODM omeprazole (Figure 5.2, “pre-spin”), consistent with the results of the IC50 
determinations.  Centrifugation alone or with potassium ferricyanide did not restore CYP2C19 
activity after treatment with omeprazole sulfone or 5-ODM omeprazole.  Taken together, these 
results suggest that the MDI of CYP2C19 observed by omeprazole sulfone and 5-ODM 
omeprazole is largely irreversible (possibly due to covalent binding to the apoprotein, heme 
moiety or both).    
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Figure 5.2. Reversibility assessment of the MDI of CYP2C19 by omeprazole sulfone and 
5-ODM omeprazole with the ultracentrifugation method  
The potential reversibility of the MDI of CYP2C19 NADPH-fortified HLM (0.1 mg/mL) by 
omeprazole sulfone and 5-ODM omeprazole (at concentrations shown) was evaluated with the 
ultracentrifugation method, as described in Chapter 3.  Incubations labeled “Pre-spin” were 
conducted similarly to analogous samples in the IC50 determinations (conduced in triplicate and 
displayed as the average rates of S-mephenytoin 4´-hydroxylation ± standard deviation).  For 
incubations labeled “Post-spin” (conducted in triplicate), microsomal protein was isolated by 
ultracentrifugation after 30 min incubations with the inhibitor and NADPH, and analyzed in 
triplicate for residual CYP2C19 activity (S-mephenytoin 4´-hydroxylation) displayed as the 
average rates ± standard error, as described in Chapter 3.  Half of the incubations from the 
“Post-spin” samples included potassium ferricyanide (2 mM, final concentration) as indicated.  
Samples treated with methanol (1% v/v, final) served as controls.  All rates were normalized to 
final microsomal protein concentrations, as described in Chapter 3. 
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5.3. Inactivation of CYP2C19 by esomeprazole: KI and kinact determinations 
Because I had previously established that the MDI of CYP2C19 by esomeprazole was 
largely irreversible (Figure 4.7), I performed experiments to determine KI (the concentration of 
esomeprazole supporting half maximal rate of CYP2C19 inactivation) and kinact (the first order 
rate constant of enzyme inactivation).  The results from three different experiments are 
summarized in Figure 5.3 and Table 5.1.  The three experimental conditions were (1) “high” 
[HLM] (i.e., 1 mg/mL in pre-incubation) (Figure 5.3a - b), (2) “low” [HLM] (i.e., 0.1 mg/mL in pre-
incubation) (Figure 5.3c-d), and (3) “medium” [HLM] (i.e., 0.5 mg/mL in pre-incubation) (Figure 
5.3e-f).  In all experiments, a 10-fold dilution step was utilized prior to the substrate incubation, 
which included S-mephenytoin (the marker substrate) at 10 × Km.  Under all three conditions, 
the inactivation of CYP2C19 was dependent on the concentration of esomeprazole (over the 
ranges examined) and the time course conformed to a first-order inactivation process (as 
indicated by the linearity of plots of the log of the residual enzyme activity against time; (Figure 
5.3a, c, and e).  However, because near-saturation of inactivation was not achieved in the first 
two experiments at esomeprazole concentrations up to 30 µM in pre-incubation, the final 
experiment used concentrations that were twice those used in the first two experiments.  As with 
omeprazole (Chapter 4), the KI values for esomeprazole generally decreased with microsomal 
protein concentration (Figure 5.3b and d).  However, because of poor analytical sensitivity and a 
lack of saturation of inactivation under low protein conditions (Figure 5.3c-d), the KI value 
actually decreased from this value at medium protein conditions (Figure 5.3e-f).  Because of the 
acceptable analytical sensitivity at 0.05 mg/mL microsomal protein (final), the third experiment 
was considered definitive.  However, in all three cases, the kinact values ranged from 
approximately 0.048 – 0.068 min-1, which means that, in the presence of saturating 
concentrations of esomeprazole, approximately 5 - 7% of CYP2C19 was inactivated every 
minute.  The efficiency of CYP2C19 inactivation (kinact/KI) also increased by a factor of 
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approximately three when the concentration of HLM was decreased from 0.1 mg/mL (Figure 
5.3b) to 0.05 mg/mL (Figure 5.3f) and saturating concentrations of esomeprazole were used.  
Taken together, these data further suggest that esomeprazole is an irreversible inactivator of 
CYP2C19. 
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Figure 5.3. Determination of KI and kinact for the MDI of CYP2C19 by esomeprazole at 
various final protein concentrations 
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Individual points represent the average of triplicate determinations ± standard deviation, unless 
otherwise noted.  For graphs in (a), (c), and (e) esomeprazole was pre-incubated (at 
concentrations indicated) and residual CYP2C19 activity determined (at final protein 
concentrations indicated) as described in Chapter 3.  The graphs in (b), (d), and (f) represent 
the direct plots of the initial rates of inactivation of CYP2C19.  Values are the slopes of the initial 
rates of inactivation (kobs) at each concentration of esomeprazole, shown ± standard error. 
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5.4. Inactivation of CYP2C19 by omeprazole sulfone: KI and kinact 
determinations 
Having shown that, like esomeprazole, the metabolism-dependent inhibition of 
CYP2C19 by omeprazole sulfone was largely irreversible (Figure 5.2), I also determined its KI 
and kinact, under the same three conditions used for esomeprazole (section 5.3).  The results 
from these three experiments are summarized in Figure 5.4 and Table 5.1.  As for 
esomeprazole, the three experimental conditions were (1) “high” [HLM] (i.e., 1 mg/mL in pre-
incubation) (Figure 5.4a - b), (2) “low” [HLM] (i.e., 0.1 mg/mL in pre-incubation) (Figure 5.4c-d), 
and (3) “medium” [HLM] (i.e., 0.5 mg/mL in pre-incubation) (Figure 5.4e-f).  In each experiment, 
a 10-fold dilution step was utilized prior to the substrate incubation.  Under all three conditions, 
the inactivation of CYP2C19 was dependent on the concentration of omeprazole sulfone (over 
the ranges examined) and the time course conformed to a first-order inactivation process (as 
indicated by the linearity of plots of the log of the residual enzyme activity against time (Figure 
5.4a, c, and e).  However, because saturation of inactivation was achieved in the first two 
experiments (i.e., KI values ≈ 1 – 4 µM) at omeprazole sulfone concentrations up to 100 µM in 
pre-incubation, the final experiment used lower concentrations and longer pre-incubations in an 
attempt to more accurately determine the KI value.  The apparent KI values for the inactivation 
of CYP2C19 by omeprazole sulfone did not vary substantially between 0.1 and 0.05 mg/mL final 
microsomal protein concentration (Figure 5.4b and f).  However, because of poor analytical 
sensitivity under low protein conditions (Figure 5.4c-d), the KI value decreased by a factor of 5.5 
from that at high protein conditions (Figure 5.4a-b).  Because of the acceptable analytical 
sensitivity at 0.05 mg/mL microsomal protein (final), the third experiment was considered 
definitive, and further experiments were conducted under similar conditions.  In spite of the 
variability in KI values, the kinact values spanned a relatively tight range from approximately 0.017 
– 0.025 min-1, which means that, in the presence of saturating concentrations of omeprazole 
sulfone, approximately 1.7 – 2.5% of CYP2C19 was inactivated every minute.  The efficiency of 
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CYP2C19 inactivation (kinact/KI) remained within a factor of 1.5 when the final concentration of 
HLM was decreased from 0.1 mg/mL (Figure 5.4b) to 0.05 mg/mL (Figure 5.4f).  These data 
provide additional evidence that omeprazole sulfone is an irreversible inactivator of CYP2C19. 
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Figure 5.4. Determination of KI and kinact for the MDI of CYP2C19 by omeprazole sulfone at 
various final protein concentrations 
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Individual points represent the average of triplicate determinations ± standard deviation, unless 
otherwise noted.  For graphs in (a), (c), and (e) omeprazole sulfone was pre-incubated (at 
concentrations indicated) and residual CYP2C19 activity determined (at final protein 
concentrations indicated) as described in Chapter 3.  The graphs in (b), (d), and (f) represent 
the direct plots of the initial rates of inactivation of CYP2C19.  Values are the slopes of the initial 
rates of inactivation (kobs) at each concentration of omeprazole sulfone, shown ± standard error. 
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5.5. Inactivation of CYP2C19 by 5-O-desmethyl omeprazole: KI and kinact 
determinations 
The experience gained in the experiments detailed in Figure 5.3 and Figure 5.4 allowed 
me to move forward with additional experiments under a single set of experimental conditions, 
namely 0.5 mg/mL pooled human liver microsomes in the pre-incubation with a 10-fold dilution, 
and marker substrate assay at 10 × Km.  Reproducibility under these conditions was explored in 
additional “quality control” assays which will be detailed in Chapter 6.     
Having also shown that the metabolism-dependent inhibition of CYP2C19 by 5-ODM 
omeprazole was largely irreversible (Figure 5.2), I determined the KI and kinact values for this 
major metabolite of esomeprazole, but only under the “definitive” conditions (i.e., 0.5 mg/mL 
pooled human liver microsomes in pre-incubation with a 10-fold dilution and substrate at 
10 × Km).  However, as noted previously, this metabolite was found to have poor solubility in 
standard solvents and a mixture of methanol/DMSO/Tris buffer (at pH 9.0 for greater stability of 
the stock) at 70/20/10%v/v, respectively, was used.  However, the stock solution (7 mM) 
appeared to precipitate during the course of the first experiment, and I was concerned about the 
accuracy of any KI value obtained with this preparation (Figure 5.5a-b).  Because of this, I 
prepared a new stock solution with a top concentration of 6 mM and conducted a second 
experiment (Figure 5.5c-d).   
The results from the two different experiments are summarized in Figure 5.5 and Table 
5.1.  In both experiments, the inactivation of CYP2C19 was dependent on the concentration of 
5-ODM omeprazole (over the ranges examined) and the time course conformed to a first-order 
inactivation process (as indicated by the linearity of plots of the log of the residual enzyme 
activity against time (Figure 5.5a and c).  In spite of solubility concerns in the first experiment, 
the KI value in the first experiment (11.9 µM) was within approximately 15% of the second 
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(10.3 µM).  Similarly, kinact values were within approximately 10% of one another (0.0251 and 
0.0278 min1), which means that, in the presence of saturating concentrations of 5-ODM 
omeprazole, approximately 2.5 – 2.8% of CYP2C19 was inactivated every minute.  These data 
provide additional evidence that 5-ODM omeprazole is an irreversible inactivator of CYP2C19. 
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Figure 5.5. Determination of KI and kinact for the MDI of CYP2C19 by 5-ODM omeprazole on 
two different days 
Individual points represent the average of triplicate determinations ± standard deviation, unless 
otherwise noted.  For graphs in (a) and (c), 5-ODM omeprazole was pre-incubated (at 
concentrations indicated) and residual CYP2C19 activity determined as described in Chapter 3.  
The graphs in (b) and (d) represent the direct plots of the initial rates of inactivation of 
CYP2C19.  Values are the slopes of the initial rates of inactivation (kobs) at each concentration 
of 5-ODM omeprazole, shown ± standard error.  
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Table 5.1. Summary of KI and kinact determinations for esomeprazole, omeprazole sulfone 
and 5-O-desmethyl omeprazole 
Compound Final [Microsomal protein] (mg/mL) 
KI 
(µM) a 
kinact 
(min-1) a 
kinact / KI 
(min-1 · mM-1) b 
Esomeprazole 
0.1 13.9 ± 3.4 0.0677 ± 0.0072 4.86 ± 1.29 
0.01 5.73 ± 0.59 0.0582 ± 0.0018 10.2 ± 1.1 
0.05 3.23 ± 0.35 0.0481 ± 0.0018 14.9 ± 1.7 
Omeprazole 
sulfone 
0.1 4.43 ± 0.62 0.0254 ± 0.0015 5.73 ± 0.87 
0.01 0.803 ± 0.302 0.0172 ± 0.0009 21.4 ± 8.1 
0.05 5.50 ± 1.94 0.0211 ± 0.0016 3.85 ± 1.39 
5-O-Desmethyl 
omeprazole 
0.05 (Day 1) 11.9 ± 3.3 0.0251 ± 0.0027 2.12 ± 0.63 
0.05 (Day 2) 10.3 ± 3.4 0.0278 ± 0.0033 2.70 ± 0.94 
a Values are displayed to three significant figures, ± standard error of the measurement. 
b Calculated from full precision values and rounded to three significant figures.   
Values in bold are considered the definitive values. 
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5.6. Estimation of the clinical impact of esomeprazole and its major 
metabolites on the decrease in H4 formation from clopidogrel 
Based on the definitive KI and kinact values in Table 5.1, along with direct inhibition 
parameters presented in Figure 5.1 and Table 4.1 an attempt was made to estimate the in vivo 
impact that esomeprazole, omeprazole sulfone or 5-ODM omeprazole would have on the 
exposure to H4 upon coadministration of esomeprazole with clopidogrel under a number of 
scenarios as shown in Table 5.2 with two mechanistic static models, one with parameters as 
defined by Boulenc et al., (i.e., H4 ratio) and the other (i.e., 1/AUCR) with conservative default 
parameters defined by the FDA (31).  Two fm(CYP2C19) values for the CYP2C19-dependent 
activation of clopidogrel to H4, reported by Boulenc et al. were used (94).  The worst-case (i.e., 
most inhibitory) scenario for omeprazole (Figure 4.5e) was included as a comparator.  The 
results in Table 5.2 are presented as reciprocal AUCR values (31) (because I was interested in 
a decrease in exposure to a metabolite, not an increase in AUC of the parent drug) and H4 AUC 
ratios following the method outlined by Boulenc and colleagues (94).  Observed H4 ratios were 
included from two studies under similar omeprazole or esomeprazole dosing regimens (84,108) 
for comparison.  The parameters used in the AUCR calculations, such as plasma protein 
binding, Cmax, etc. for the metabolites were obtained from (75).  The results of these simulations 
predict that omeprazole and esomeprazole would be expected to cause a significant decrease 
in exposure to H4.  It should be noted that the effects of omeprazole metabolites were not 
added to the effects of omeprazole (because it worsened the over-prediction), but are modeled 
on their own for comparison.  
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Table 5.2. Predicted and observed impact on H4 formation after coadministration of 
either omeprazole or esomeprazole with clopidogrel 
Perpetrator 
(dose and regimen) 
Perpetrator 
Cmax 
(µM)a 
Predicted H4 ratio 
fm(CYP2C19) = 0.64b 
Predicted H4 ratio 
fm(CYP2C19) = 0.72b Observed 
H4 ratio 
1/AUCRi H4 ratioj 1/AUCRi H4 ratioj 
Omeprazole 
(20 mg single dose)c 
0.660 
(0.033) 0.46 0.59 0.40 0.54 NA 
Omeprazole 
(20 mg 5 days)d 
1.13 
(0.057) 0.45 0.52 0.38 0.46 NA 
Omeprazole 
(40 mg 5 days)e 
3.87 
(0.19) 0.40 0.42 0.32 0.35 NA 
Omeprazole 
(80 mg 10 days)f 
8.92 
(0.45) 0.38 0.39 0.31 0.31 0.58
k 
Esomeprazole 
(20 mg single dose)g 
1.32 
(0.040) 0.44 0.63 0.37 0.59 NA 
Esomeprazole 
(20 mg 5 days)h 
2.1 
(0.063) 0.43 0.57 0.36 0.51 0.62
l 
Esomeprazole 
(40 mg 5 days)h 
4.7 
(0.14) 0.40 0.47 0.32 0.41 0.63
l 
Omeprazole sulfone 
(20 mg omeprazole 
single dose)c 
0.14 
(0.0028) NC 0.98 NC 0.98 NA 
5-O-Desmethyl 
omeprazole 
(20 mg omeprazole 
single dose)c 
0.030 
(0.029) NC 0.92 NC 0.91 NA 
a Plasma Cmax of drug or metabolite.  Values in parentheses are the unbound plasma 
concentrations. 
b From (94) where the two fm(CYP2C19) values for H4 were obtained from two clinical studies to 
determine the impact of CYP2C19 polymorphisms (68) or the effects of omeprazole or 
pantoprazole on H4 formation from clopidogrel (84).  
c From (75).  Value in parentheses is the unbound plasma concentration. 
d From (161) 
e From (135), used in Simcyp simulations presented in Chapter 4 
f From (94) 
g From (162) 
h From Nexium (esomeprazole) prescribing information (119) 
i 1/AUCR calculated based on (31) 
j H4 ratio calculated based on (94) 
k From (84)  
l From (108) 
NA: No studies found that match the perpetrator dose and regimen 
NC: Not calculated for metabolites because the AUCR equations uses dose in mg.  
109 
 
Discussion 
In my previous studies (Chapter 4) I presented evidence that omeprazole sulfone 
(formed by CYP3A4) was an MDI of CYP2C19 (Figure 4.3), and that esomeprazole was an 
irreversible MDI of CYP2C19 whereas R-omeprazole was not (Figure 4.7).  Furthermore, 
because 5-O-desmethyl omeprazole is the major metabolite formed from esomeprazole based 
on in vitro intrinsic clearance (Figure 4.9), I speculated that that this metabolite also contributes 
to CYP2C19 inactivation (Figure 4.10), but it was not commercially available to examine at the 
time (34).  These findings were followed up in this chapter, and I showed that 5-O-desmethyl 
omeprazole is in fact a metabolism-dependent inhibitor of CYP2C19 (Figure 5.1), and 
furthermore that both it and omeprazole sulfone irreversibly inactivate CYP2C19 (Figure 5.2).   
The major metabolite formed from R-omeprazole based on in vitro intrinsic clearance  is 
5´-hydroxyomeprazole (Figure 4.9, (113)), which I previously showed was a weak direct inhibitor 
of CYP2C19 (i.e., IC50 > 100 µM) and not a metabolism-dependent inhibitor (Figure 4.3e).  This 
finding is consistent with the nearly complete reversal of CYP2C19 inhibition by R-omeprazole 
upon centrifugation (Figure 4.7).  The initial findings that both 5-O-desmethyl omeprazole and 
omeprazole sulfone were MDIs of CYP2C19 suggested the possibility that the clinically relevant 
CYP2C19 inhibition caused by omeprazole (reviewed in Chapter 1) is predominantly due to the 
combination of the presence of the S-enantiomer in the racemic drug, as well as formation of its 
major metabolites, 5-O-desmethyl omeprazole, mainly through CYP2C19, and omeprazole 
sulfone, mainly by CYP3A4.  In an attempt to confirm or refute this hypothesis, I quantified the 
inactivation of CYP2C19 by each of these compounds. 
KI and kinact values for esomeprazole, 5-O-desmethyl omeprazole and omeprazole 
sulfone were determined in order to attempt to predict the in vivo impact of esomeprazole and 
its inhibitory metabolites on CYP2C19, and clopidogrel in particular.  Ideally, a PBPK model 
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would be used for this assessment as presented for omeprazole in Chapter 4. However, for a 
quantitative PBPK model to accurately predict the clinical impact of esomeprazole and its 
metabolites on clopidogrel, the kinetics of esomeprazole at steady-state, the formation-rate 
limited kinetics of 5-ODM omeprazole and the elimination rate-limited kinetics of omeprazole 
sulfone from both omeprazole and esomeprazole would be required (75,163).  Most of these 
parameters are not currently available in the literature, although preliminary findings from my 
studies, including the KI and kinact values for esomeprazole, 5-O-desmethyl omeprazole and 
omeprazole sulfone, were previously presented (111,120).  In spite of the lack of some 
experimentally determined parameters, the FDA collaborated with Simcyp to validate a PBPK 
model for the nonlinear pharmacokinetics of omeprazole enantiomers and the racemate (164), 
based in part on my previously published data (Chapter 4; (34).  In addition, Sanofi-Aventis 
collaborated with Simcyp to validate a PBPK model for the sequential metabolism of clopidogrel 
(44).  These latter two models combined with my KI and kinact values presented in this chapter 
may allow for an adequate PBPK model of the effect of omeprazole or esomeprazole on 
clopidogrel to be developed at some point in the future. 
Because 5-ODM omeprazole and omeprazole sulfone are both direct-acting and MDIs of 
the enzymes that form them (i.e., CYP2C19 – above, and CYP3A4 – (75)), these inhibitor-
inhibitor interactions would need to be accounted for over time in such a quantitative PBPK 
model of the impact of omeprazole or esomeprazole on clopidogrel (34,75,78,94,111,120,121).  
An additional complication in any PBPK modeling of the effect of esomeprazole or omeprazole 
and its metabolites on the two-step clopidogrel activation is the fact that clopidogrel and/ or its 
2-oxo-metabolite are also MDIs of CYP2B6, 2C19 and 3A4 (three CYPs that are involved in 
activation of clopidogrel, two of which are involved in omeprazole and esomeprazole 
metabolism) (143,157,165-167).  Therefore, as first hypothesized by Zhang et al. (157) 
clopidogrel coadministration with omeprazole or esomeprazole could potentially amplify the 
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impact that omeprazole or esomeprazole have on clopidogrel because they are metabolized by 
CYP2C19 and 3A4. For reasons listed above, the use of a PBPK model in this instance is much 
more complicated than that presented in Chapter 4, and is beyond the scope of this dissertation.  
Therefore, a modified mechanistic static model based on that described by Boulenc and 
colleagues was utilized (94).  
The mechanistic static model I used in this chapter utilized the lowest and highest 
fm(CYP2C19) values for the conversion of clopidogrel to H4 as determined by Boulenc and 
colleagues in CYP2C19 EMs, namely 0.64 and 0.72 (94).  The lower value is similar to the 
overall fm(CYP2C19)  determined in vitro by Kazui and colleagues (0.45 for the conversion of 
clopidogrel to 2-oxo-clopidogrel and 0.21 for the subsequent conversion to H4, i.e., 0.66) (48).  
In addition, in a full PBPK model of the two-step activation of clopidogrel, CYP2C19 was 
predicted to contribute 49% to the first step and 21% to the second, for a total fm(CYP2C19)  of 0.7 
(44), again within the ranges I incorporated in my MSM.  In spite of the agreement with the 
published fm(CYP2C19) values for clopidogrel activation to H4, I found that the MSM over-predicted 
the decrease in H4 formation by omeprazole (80 mg dose for 10 days) by approximately 1.5 - 
1.9-fold (Table 5.2).  For esomeprazole (20 mg for 5 days) the MSM was in closer agreement to 
observed values, with an over-prediction in the decrease in H4 formation of approximately 1.1 – 
1.7-fold.  For esomeprazole (40 mg for 5 days) the MSM over-predicted the decrease in H4 
formation by approximately 1.3 – 1.9-fold.  Because of the over-predictions with the parent 
drugs, the effects of the metabolites were not added to the MSM for either omeprazole or 
esomeprazole (which would only worsen the over-prediction), but are modeled on their own for 
comparison.  Consistent with this over-prediction without consideration of the metabolites, 
Shirasaka and colleagues also found that the drug-drug interaction risk of omeprazole toward 
CYP2C19 was correctly identified (i.e., true positive) from their clinical and in vitro data on 
omeprazole without accounting for the contribution of metabolites (75). The modified MSM used 
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in this chapter also agrees relatively well with that proposed in Chapter 4 for the interaction 
between omeprazole (40 mg q.d. for for 5 days) and moclobemide (i.e. a predicted 2.85-fold 
increase in moclobemide AUC, fmCYP2C19 of 0.72), with a predicted 2.73-fold increase in 
moclobemide caused by esomeprazole (40 mg q.i.d. for for 5 days).  Although a clinical study 
has not been performed with esomeprazole and moclobemide, the observed moclobemide 
AUC∞ increases averaged 2.21-fold (1.03 to 3.39-fold) in CYP2C19 EMs with omeprazole (112).  
On the basis of this comparison, the MSM appears to provide only a 1.3-fold over-prediction of 
the effect of esomeprazole on moclobemide, which has the same apparent fmCYP2C19 as H4 
formation from clopidogrel.   
The over-predictions of the impact that omeprazole and esomeprazole have on H4 
formation are likely due in part to the fact that I made use of a static model, and omeprazole and 
esomeprazole have short half-lives.  The MSM is also relatively sensitive to small changes in KI 
and kinact values, which, as demonstrated in Chapter 4, can vary significantly with experimental 
conditions (34,35).  Additionally, the activation of clopidogrel requires two sequential CYP-
mediated steps and the MSM does not consider these, which is likely another source of error.  
In addition, Zvyaga and colleagues raised the possibility that KI and kinact values for the 
inactivation of CYP2C19 by omeprazole or esomeprazole may be substrate-dependent (78).  
Substrate-dependence for in vitro inhibition of CYP2C19 has previously been documented 
(168), and it is possible that a determination of KI and kinact with a different CYP2C19 marker 
substrate would yield better predictions.  A seemingly obvious experimental design would utilize 
clopidogrel and 2-oxo-clopidogrel as the substrates and determine the KI and kinact values with 
omeprazole and esomeprazole as the inhibitors.  However, as reviewed in Chapter 1, the 
analytical method to quantify H4 is particularly challenging and can lead to erroneous 
conclusions if metabolites other than H4 are inadvertently monitored.  Ohbuchi and colleagues 
showed that omeprazole produces a 2-fold shift in IC50 upon pre-incubation in recombinant 
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human CYP2C19 (121) toward the formation of a putative clopidogrel active metabolite.  
However, the authors conceded that their analytical method detected three 3´-methoxyphenacyl 
bromide-derivatized metabolites, and the IC50 values for each were then averaged to determine 
the shift after pre-incubation.   
In spite of the over-prediction (by a factor of ~2), the mechanistic static model does 
accurately predict that esomeprazole would be expected to decrease formation of H4 from 
clopidogrel.  With recent advances in the PBPK modelling of omeprazole enantiomer 
pharmacokinetics (164) and the sequential metabolism of clopidogrel (44), more accurate PBPK 
models of the drug-drug interaction between these drugs should be possible in the future by 
incorporating the KI and kinact values for the inactivation of CYP2C19 by esomeprazole and its 
major metabolites that I presented in this chapter.   
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Chapter 6. MECHANISTIC STUDIES ON THE INACTIVATION OF 
CYP2C19 BY ESOMEPRAZOLE, 5-O-DESMETHYL 
OMEPRAZOLE, OMEPRAZOLE SULFONE AND 
INVESTIGATION OF ILAPRAZOLE, RABEPRAZOLE AND 
TENATOPRAZOLE AS METABOLISM-DEPENDENT 
INHIBITORS OF CYP2C19 
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Abstract 
In Chapters 4 and 5, I presented evidence that esomeprazole, omeprazole sulfone and 
5-O-desmethyl omeprazole, but not R-omeprazole, are irreversible metabolism-dependent 
inhibitors of CYP2C19.  For esomeprazole, omeprazole sulfone and 5-O-desmethyl 
omeprazole, these studies established the following criteria for mechanism-based inhibition: 
1) inactivation of CYP2C19 occurs in a concentration-, time- and metabolism-dependent 
manner, 2) the inactivation is largely irreversible (by ultracentrifugation and washing), and 3) the 
inactivation is saturable.  Further studies were conducted to provide additional evidence that the 
irreversible MDI of CYP2C19 by esomeprazole and its inhibitory metabolites is in fact 
mechanism-based inactivation.  Accordingly, near-complete substrate protection was achieved 
wtih the CYP2C19 substrate, pantoprazole (200 µM), for esomeprazole, omeprazole sulfone 
and 5-O-desmethyl omeprazole.  Neither of the “protectants” glutathione (2 mM), superoxide 
dismutase (500 U/mL) nor catalase (1000 U/mL) significantly altered the efficiency of 
inactivation of CYP2C19 in pooled human liver microsomes by esomeprazole, omeprazole 
sulfone or 5-O-desmethyl omeprazole.  In addition, quality control assays were performed to 
assess the robustness of the determination of efficiency of inactivation (i.e., kinact/KI) by each of 
these compounds from assay to assay in order to demonstrate that these protectants did not 
significantly affect inactivation of CYP2C19 by the three compounds.  In addition, and as 
expected, esomeprazole did not form a metabolite inhibitory complex (MIC) under conditions in 
which the selective CYP2C19 inhibitor, S-fluoxetine, did, either in recombinant human 
CYP2C19 or in pooled human liver microsomes. Finally, to examine the hypothesis that the 
presence of a 5´-methyl substituent in PPIs is necessary for metabolism-dependent inhibition of 
CYP2C19, ilaprazole, rabeprazole and tenatoprazole were evaluated as direct-acting and MDIs 
of CYP2C19 activity.  This study showed that tenatoprazole, the only PPI other than omeprazole 
and esomeprazole with a 5´-methyl substituent, is also an MDI of CYP2C19, whereas ilaprazole 
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and rabeprazole are not.  The results of this study provide further evidence that esomeprazole, 
omeprazole sulfone and 5-O-desmethyl omeprazole inactivate CYP2C19 in a mechanism-
based manner and suggest that the presence of a 5´-methyl substituent is necessary for 
metabolism-dependent inhibition of CYP2C19 by PPIs.   
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Introduction 
The phrase “mechanism-based inhibition” is frequently used to refer to any irreversible 
or quasi-irreversible metabolism-dependent inhibition of CYP enzymes.  However, by definition, 
the phrase “mechanism-based inhibition” excludes the formation of metabolites that are simply 
more potent direct-acting inhibitors than the parent, whereas the term “metabolism-dependent 
inhibition” includes this type of time-dependent inhibition.  Simply put, mechanism-based 
inactivators are substrates for a CYP enzyme that, during catalysis by the enzyme, are 
converted to one or more products that immediately and irreversibly inactivate the enzyme and 
do not leave the active site (169).  Strictly speaking, irreversible inhibitors that are affinity 
labeling agents, transition state analogs and slow, tight-binding inhibitors are not mechanism-
based inhibitors because they do not require a metabolic event to exert their inhibitory effect 
(169).  For a metabolism-dependent inhibitor of a CYP enzyme to be categorized as a 
mechanism-based inactivator, however, it must meet certain criteria that can be determined 
experimentally, according to Silverman, and as put in the context of CYP enzymes in later 
reviews (170-172), and further reviewed in my book chapter (16):  
1. The CYP inhibition must be concentration-, NADPH-, and time-dependent. This was 
demonstrated for esomeprazole, omeprazole sulfone and 5-ODM omeprazole in 
Chapters 4 and 5. 
2. Inactivation must occur prior to the release of the inhibitory metabolite.  Any metabolite 
that is released from the active site cannot be the metabolite that inactivates the 
enzyme.  (This criterion distinguishes mechanism-based inactivators from metabolism-
dependent inhibitors that generate and release electrophilic metabolites.  In such a case, 
inactivation may occur by binding to a site other than the active site, or by 
rearrangement of the metabolite prior to its return to the active site.)  Furthermore, the 
addition of glutathione (GSH), radical scavengers, or other exogenous nucleophiles 
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cannot prevent inactivation in the case of true mechanism-based inhibition, but they 
often abrogate the inhibition observed with other types of metabolism-dependent 
inhibition.  GSH, superoxide dismutase and catalase were examined in this chapter to 
meet this criterion for esomeprazole, omeprazole sulfone and 5-ODM omeprazole. 
3. Mechanism-based inhibition should be irreversible.  Dialysis, ultrafiltration, or 
ultracentrifugation and washing the protein (e.g., by isolating microsomes by 
centrifugation and resuspending them in drug-free buffer) will not restore enzyme 
activity.  Evidence for this criterion was provided in Chapters 4 and 5 for esomeprazole, 
omeprazole sulfone and 5-ODM omeprazole with the use of ultracentrifugation.  It should 
be noted, however, that some exceptions to irreversibility in spite of meeting most other 
criteria for MBI have been reported.  For instance, the MBI of CYP2B4 by by tert-butyl 
acetylene is partially reversible upon overnight dialysis and the heme N-alkylation of 
chloroperoxidase by allylbenzene and 1-hexyne is transient (173,174). 
4. Mechanism-based inhibition should be saturable.  The rate of inactivation is proportional 
to the concentration of the inactivator until all enzyme molecules are saturated, in 
accordance with Michaelis-Menten kinetics.  Additionally, the decrease in enzymatic 
activity over time should follow pseudo-first order kinetics.  Again, evidence for this 
criterion was provided in Chapters 4 and 5 for esomeprazole, omeprazole sulfone and 
5-ODM omeprazole.   
5. Alternate substrates should protect against mechanism-based inhibition.  The addition of 
an alternative substrate or competitive inhibitor with good affinity for the enzyme will 
prevent or at least decrease the rate of inactivation.  The CYP2C19 substrate 
pantoprazole, which has an fm(CYP2C19) of 0.80, based on the change in AUC from 
genetically determined EMs to PMs (175) was utilized for this purpose in this chapter. 
6. There should be stoichiometric (ideally one-to-one) binding of inactivator to enzyme.  
This was not attempted in this chapter, in part because of the complicating fact that two 
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inhibitory metabolites are also formed, namely 5-ODM omeprazole by CYP2C19 and 
omeprazole sulfone by CYP3A4. 
7. CYP content is usually reduced by mechanism-based inhibitors.  This criterion was not 
examined in this chapter, but evidence for a decrease in ~400 nm-detectable heme in 
the presence of esomeprazole will be presented in Chapter 7. 
8. Enzyme inactivation should be preceded by a catalytic event that converts the 
mechanism-based inhibitor to the inactivating metabolite.  Evidence was provided for 
this criterion in Chapters 4 and 5 in that enzyme inactivation required NADPH, the 
cofactor for CYP-dependent metabolism.   
In the typical drug-development process for the evaluation of drug candidates that are 
irreversible MDIs of CYPs, only criteria 1, 3, 4 and 8 are established because the purpose of 
these evaluations is to decide if a drug candidate should be further investigated in a clinical DDI 
study.  Establishment of criterion 4 is usually conducted as part of a KI and kinact determination 
such that mechanistic static models or PBPK models can be used to predict whether or not a 
drug candidate is likely to cause clinically relevant enzyme inactivation.  Evidence that criteria 1, 
3, 4 and 8 were met for esomeprazole, omeprazole sulfone and 5-ODM omeprazole were 
previously provided.  Experiments conducted as part of this chapter were undertaken in an 
attempt to meet criteria 2 and 5 as well as to assess the robustness of the determination of 
efficiency of inactivation (i.e., kinact/KI) under the same set of experimental conditions.  Additional 
experiments were conducted to provide further evidence that quasi-irreversible inhibition of 
CYP2C19 involving metabolite inhibitory complex formation by esomeprazole does not occur.  
Finally, to further probe the mechanism by which esomeprazole causes MDI of CYP2C19, it 
was hypothesized that the presence of a 5´-methyl substituent in PPIs is necessary for MDI of 
CYP2C19.  To this end, two clinically used PPIs (i.e., ilaprazole and rabeprazole) that lack a 
5´-methyl substituent and one investigational PPI, tenatoprazole which, like omeprazole and 
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esomeprazole, does have a 5´-methyl substituent, were examined as MDIs of CYP2C19 in 
HLM.   
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Results 
As noted in Chapter 5, once “definitive” conditions were settled on, all additional 
experiments, including those detailed in this chapter were conducted under a single set of 
experimental conditions, namely (1) 0.5 mg/mL NADPH-fortified HLM in the pre-incubations, (2)  
a 10-fold dilution, and (3) 5-min incubation with the CYP marker substrate at 10 × Km, in order to 
minimize membrane partitioning and direct-acting competitive inhibition, and to allow for 
comparisons when changing only a single variable, such as the addition of a “protectant” (i.e., 
glutathione, superoxide dismutase, catalase, or the alternate CYP2C19 substrate, 
pantoprazole).  These methods are described in Chapter 3. 
6.1. Effects of glutathione, superoxide dismutase, catalase, and the 
alternate CYP2C19 substrate, pantoprazole, on the inactivation of 
CYP2C19 by esomeprazole 
Building on the evidence suggesting that esomeprazole is a metabolism-dependent 
inhibitor of CYP2C19 as described in Chapters 4 and 5, and to further test the hypothesis that 
esomeprazole is a mechanism-based inhibitor, I next performed experiments to determine KI 
and kinact values in the presence of the commonly used CYP enzyme “protectants”, namely 
glutathione (GSH), superoxide dismutase, and catalase, as well as the alternative CYP2C19 
substrate, pantoprazole.  The results from four different experiments are summarized in Figure 
6.1, Figure 6.5a and Table 6.1.  As expected for a mechanism-based inhibitor, the inactivation 
of CYP2C19 by esomeprazole appeared to be largely unaffected by the presence of GSH, 
superoxide dismutase, or catalase and was dependent on the concentration of esomeprazole 
(over the concentration range examined) and the time course conformed to a first-order 
inactivation process (as indicated by the linearity of plots of the log of the residual enzyme 
activity against time) (Figure 6.1a, c, and e), and was saturable (Figure 6.1b, d, and f).  The kinact 
values ranged from 0.042 – 0.050 min-1 and KI values ranged from 3.6 – 5.3 µM.  The efficiency 
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of CYP2C19 inactivation (kinact/KI) ranged from 9.4 – 13.4 min-1 ∙ mM-1.  A more thorough 
comparison between treatment and control values will be described Section 6.5.  In contrast, 
and as expected for a mechanism-based inactivator, the alternate CYP2C19 substrate, 
pantoprazole (200 µM), largely attenuated the ability of esomeprazole to inactivate CYP2C19, 
as summarized in Figure 6.1g-h and Table 6.1, with a loss of saturation, and inactivation only 
occurring to a small extent at 20 and 60 µM esomeprazole.   
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Figure 6.1. Determination of KI and kinact for the MDI of CYP2C19 in HLM by esomeprazole 
in the presence of glutathione, superoxide dismutase, catalase, and an 
alternate CYP2C19 substrate (pantoprazole) 
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Individual points represent the average of triplicate determinations ± standard deviation, unless 
otherwise noted.  For graphs in (a), (c), (e), and (g) esomeprazole was pre-incubated (at 
concentrations indicated and at final protein concentrations indicated) and residual CYP2C19 
activity determined as described in Chapter 3, in the presence of the additional component, as 
indicated.  The graphs in (b), (d), (f), and (h) represent the direct plots of the initial rates of 
inactivation of CYP2C19.  Values are the slopes of the initial rates of inactivation (kobs) at each 
concentration of esomeprazole, shown ± standard error.  
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6.2. Effects of glutathione, superoxide dismutase, catalase, and the 
alternate CYP2C19 substrate, pantoprazole, on the inactivation of 
CYP2C19 by omeprazole sulfone 
To further test the hypothesis that omeprazole sulfone is also a mechanism-based 
inhibitor of CYP2C19, I performed experiments to determine KI and kinact values in the presence 
of glutathione (GSH), superoxide dismutase, and catalase, as well as the alternative CYP2C19 
substrate, pantoprazole.  The results from four different experiments are summarized in Figure 
6.2, Figure 6.5b and Table 6.1.  As expected for a mechanism-based inhibitor, the inactivation 
of CYP2C19 by omeprazole sulfone appeared to be largely unaffected by the presence of GSH, 
superoxide dismutase, or catalase and was dependent on the concentration of omeprazole 
sulfone (over the concentration range examined) and the time course conformed to a first-order 
inactivation process (as indicated by the linearity of plots of the log of the residual enzyme 
activity against time) (Figure 6.2a, c, and e), and was saturable (Figure 6.2b, d, and f).  The kinact 
values ranged from 0.024 – 0.027 min-1 and KI values ranged from 4.8 – 9.2 µM.  The efficiency 
of CYP2C19 inactivation (kinact/KI) ranged from 2.9 – 5.0 min-1 ∙ mM-1.  A more thorough 
comparison between treatment and control values will be described Section 6.5.  In contrast, 
and as expected for a mechanism-based inactivator, the alternate CYP2C19 substrate, 
pantoprazole (200 µM), largely attenuated the ability of omeprazole sulfone to inactivate 
CYP2C19, as summarized in Figure 6.2g-h and Table 6.1, with a loss of saturation, and 
inactivation only occurring to a small extent at 20 and 60 µM omeprazole sulfone. 
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Figure 6.2. Determination of KI and kinact for the MDI of CYP2C19 in HLM by omeprazole 
sulfone in the presence of glutathione, superoxide dismutase, catalase, and an alternate 
CYP2C19 substrate (pantoprazole) 
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Individual points represent the average of triplicate determinations ± standard deviation.  For 
graphs in (a), (c), (e), and (g) omeprazole sulfone was pre-incubated (at concentrations 
indicated) and residual CYP2C19 activity determined (at final protein concentrations indicated) 
as described in Chapter 3, in the presence of the additional component, as indicated.  The 
graphs in (b), (d), (f), and (h) represent the direct plots of the initial rates of inactivation of 
CYP2C19.  Values are the slopes of the initial rates of inactivation (kobs) at each concentration 
of omeprazole sulfone, shown ± standard error.  
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6.3. Effects of glutathione, superoxide dismutase, catalase, and the 
alternate CYP2C19 substrate, pantoprazole, on the inactivation of 
CYP2C19 by 5-ODM omeprazole 
To further test the hypothesis that 5-ODM omeprazole is also a mechanism-based 
inhibitor of CYP2C19 in HLM, I performed experiments to determine KI and kinact values in the 
presence of glutathione (GSH), superoxide dismutase, and catalase, as well as the alternative 
CYP2C19 substrate, pantoprazole.  The results from four different experiments are summarized 
in Figure 6.3, Figure 6.5c and Table 6.1.  As expected for a mechanism-based inhibitor, the 
inactivation of CYP2C19 by 5-ODM omeprazole appeared to be largely unaffected by the 
presence of GSH, superoxide dismutase, or catalase and was dependent on the concentration 
of 5-ODM omeprazole (over the concentration range examined) and the time course conformed 
to a first-order inactivation process (as indicated by the linearity of plots of the log of the residual 
enzyme activity against time) (Figure 6.3a, c, and e), and was saturable (Figure 6.3b, d, and f).  
The kinact values ranged from 0.025 – 0.028 min-1 and KI values ranged from 7.8 – 14 µM.  The 
efficiency of CYP2C19 inactivation (kinact/KI) ranged from 2.1 – 3.7 min-1 ∙ mM-1.  A more 
thorough comparison between treatment and control values will be described Section 6.5.  In 
contrast, but as expected for a mechanism-based inactivator, the alternate CYP2C19 substrate, 
pantoprazole (200 µM), completely attenuated the ability of 5-ODM omeprazole to inactivate 
CYP2C19, as summarized in Figure 6.3g-h and Table 6.1. 
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Figure 6.3. Determination of KI and kinact for the MDI of CYP2C19 in HLM by 5-ODM 
omeprazole in the presence of glutathione, superoxide dismutase, catalase, and an 
alternate CYP2C19 substrate (pantoprazole) 
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Individual points represent the average of triplicate determinations ± standard deviation, unless 
otherwise noted.  For graphs in (a), (c), (e), and (g) 5-ODM omeprazole was pre-incubated (at 
concentrations indicated and at final protein concentrations indicated) and residual CYP2C19 
activity determined as described in Chapter 3, in the presence of the protectants, as indicated.  
The graphs in (b), (d), (f), and (h) represent the direct plots of the initial rates of inactivation of 
CYP2C19.  Values are the slopes of the initial rates of inactivation (kobs) at each concentration 
of 5-ODM omeprazole, shown ± standard error.   
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Table 6.1. Summary of KI and kinact determinations for esomeprazole, omeprazole sulfone 
and 5-O-desmethyl omeprazole in the presence of glutathione, superoxide 
dismutase, catalase, or pantoprazole 
Compound Additive KI (µM) 
kinact 
(min-1) 
kinact / KI 
(min-1 · mM-1) 
Esomeprazole 
GSH (2mM) 5.29 ± 0.42 0.0501 ± 0.0012 9.47 ± 0.79 
Superoxide dismutase 
(500 U/mL) 4.49 ± 0.42 0.0423 ± 0.0014 9.40 ± 0.94 
Catalase (1000 U/mL) 3.55 ± 055 0.0477 ± 0.0027 13.4 ± 2.2 
Pantoprazole (200 µM) > 60 < 0.02 < 0.33 
Omeprazole 
sulfone 
GSH (2mM) 8.30 ± 3.02 0.0237 ± 0.0028 2.86 ± 1.09 
Superoxide dismutase 
(500 U/mL) 4.75 ± 0.18 0.0238 ± 0.0002 5.01 ± 0.20 
Catalase (1000 U/mL) 9.19 ± 1.96 0.0269 ± 0.0019 2.92 ± 0.66 
Pantoprazole (200 µM) > 60 < 0.02 < 0.33 
5-O-Desmethyl 
omeprazole 
GSH (2mM) 7.77 ± 3.15 0.0284 ± 0.0049 3.66 ± 1.61 
Superoxide dismutase 
(500 U/mL) 13.6 ± 4.0 0.0280 ± 0.0027 2.06 ± 0.64 
Catalase (1000 U/mL) 11.6 ± 5.3 0.0248 ± 0.0036 2.14 ± 1.02 
Pantoprazole (200 µM) > 60 < 0.02 < 0.33 
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6.4. Quality control assays 
In Chapter 5, three microsomal protein concentrations were used to determine KI and 
kinact values for esomeprazole and omeprazole sulfone.  The “medium concentration” of 0.5 
mg/mL microsomal protein (pre-incubation concentration) appeared to be a good compromise 
with respect to the poor analytical sensitivity at 0.1 mg/mL and the higher membrane partitioning 
at 1 mg/mL (i.e., decreased free fraction of inhibitor).  Therefore, additional experiments were 
conducted under these “standard conditions”, namely 0.5 mg/mL NADPH-fortified HLM in the 
pre-incubation with a 10-fold dilution, and marker substrate assay at 10 × Km.  Some of the data 
in Chapter 5 also suggested the possibility that KI values varied more than would be expected 
with changes in microsomal protein concentration.  The efficiency of inactivation (i.e., kinact/KI), 
rather than the use of individual KI or kinact values, is a well-established parameter used to 
compare CYP inactivators with one another (35,134,176).  In order to investigate the 
reproducibility of the efficiency of CYP2C19 inactivation under “standard conditions”, 
abbreviated KI and kinact determinations in the absence of a “protectant” were conducted within 
at least three of the four assays for each compound (i.e., esomeprazole, omeprazole sulfone 
and 5-ODM omeprazole) presented in this chapter.  These additional assays included five 
concentrations of each compound for four pre-incubation time points.  
As in previous assays, the time course of CYP2C19 inactivation conformed to a first-
order inactivation process, and was dependent on the concentration of inactivator (Figure 6.4).  
For convenience of comparison in Figure 6.4, the definitive direct plots for inactivation of 
CYP2C19 by esomeprazole, omeprazole sulfone and 5-ODM omeprazole are reproduced from 
Figure 5.3f, Figure 5.4f, and Figure 5.5d, respectively, and kinact / KI values are also summarized 
in Figure 6.4 and Table 6.2.  The kinact / KI values for inactivation of CYP2C19 by esomeprazole 
in the absence of any protectants ranged from 10.5 to 14.9 min-1·mM-1 (average = 11.8 ± 2.1 
min-1·mM-1); 3.85 to 5.20 min-1·mM-1 (average = 4.45 ± 0.57 min-1·mM-1) for omeprazole sulfone, 
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and 1.84 – 2.70 min-1·mM-1 (average = 2.30 ± 0.35 min-1·mM-1) for 5-ODM omeprazole.  In all 
cases, individual values fell within the 90% confidence interval about the arithmetic mean of the 
four values for each compound.   
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Figure 6.4. Summary of quality control KI and kinact determinations for the MDI of 
CYP2C19 by esomeprazole, omeprazole sulfone and 5-ODM omeprazole in the absence 
of glutathione, superoxide dismutase, catalase, or pantoprazole 
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The graphs in (a), (b), and (c) represent the direct plots of the initial rates of inactivation of 
CYP2C19 with each inhibitor in the absence of glutathione, superoxide dismutase, catalase, or 
pantoprazole, in an abbreviated quality control assay.  Values are the slopes of the initial rates 
of inactivation (kobs) at each concentration, shown ± standard error. 
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Table 6.2 Summary of KI and kinact quality control assays for esomeprazole, omeprazole 
sulfone and 5-O-desmethyl omeprazole in the absence of glutathione, superoxide 
dismutase, catalase, or pantoprazole 
Compound QC Assay (in the absence of:) 
KI 
(µM) 
kinact 
(min-1) 
kinact / KI 
(min-1 · mM-1) 
Esomeprazole 
GSH ND ND ND 
Superoxide dismutase 4.65 ± 0.22 0.0509 ± 0.0007 11.0 ± 0.5 
Catalase 4.62 ± 0.4 0.0499 ± 0.0018 10.8 ± 1.0 
Pantoprazole 4.27 ± 0.49 0.0448 ± 0.0021 10.5 ± 1.3 
Omeprazole 
sulfone 
GSH ND ND ND 
Superoxide dismutase 5.27 ± 0.43 0.0274 ± 0.0007 5.20 ± 0.45 
Catalase 5.68 ± 1.98 0.0240 ± 0.0024 4.23 ± 1.54 
Pantoprazole 6.10 ± 0.84 0.0276 ± 0.0011 4.53 ± 0.65 
5-O-Desmethyl 
omeprazole 
GSH 17.5 ± 7.7 0.0407 ± 0.0086 2.32 ± 1.13 
Superoxide dismutase 17.4 ± 6.3 0.0319 ± 0.0054 1.84 ± 0.73 
Catalase 13.3 ± 6.9 0.0314 ± 0.0095 2.36 ± 0.32 
Pantoprazole ND ND ND 
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6.5. Comparison of kinact/KI values for the MDI of CYP2C19 by 
esomeprazole, omeprazole sulfone and 5-ODM omeprazole in the 
presence and absence of glutathione, superoxide dismutase or 
catalase 
For visual comparison, kinact/KI values are displayed in Figure 6.5.  The “control assays” 
represent the definitive values reported in Table 5.1 as well as the quality control values in 
Table 6.2  As noted previously, the four control kinact/KI values fell within the 90% confidence 
interval about the arithmetic mean for each compound.  As such, a comparison was then made 
for kinact/KI values in the presence of each protectant (i.e., GSH, SOD or catalase) with each 
compound.  The hypothesis being tested was that none of the protectants would significantly 
decrease the kinact/KI value compared with controls, consistent with mechanism-based inhibition.  
All of the kinact/KI values in the presence of the protectants fell within the 90% confidence interval 
about the arithmetic mean of the controls for each compound, with the exception of the GSH 
treatment with 5-ODM omeprazole (Figure 6.5c).  However, in this case, the kinact/KI value in the 
presence of GSH fell within the lower bound of the 90% confidence interval, but exceeded the 
upper limit of the 90% confidence interval by approximately 9%.   
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Figure 6.5. Graphical comparison of kinact/KI values for the MDI of CYP2C19 by 
esomeprazole, omeprazole sulfone and 5-ODM omeprazole in the presence and absence 
of glutathione, superoxide dismutase or catalase 
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Bars represent the efficiency of inactivation of CYP2C19 (kinact/KI values) ± standard error by (a) 
esomeprazole, (b) omeprazole sulfone, and (c) 5-ODM omeprazole.  Data were compiled from 
Table 5.1, Table 6.1 and Table 6.2. 
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6.6. An investigation into the possibility that esomeprazole forms a 
metabolite-inhibitory complex with CYP2C19 
As a further study into the investigation of the mechanism of inactivation of CYP2C19 by 
esomeprazole, spectral scans (400–500 nm) were measured over time to ascertain whether 
recombinant human CYP2C19 forms a metabolite-inhibitory complex (MIC) with esomeprazole 
(as described in Chapter 3).  Treatment with potassium ferricyanide (which is well known to 
oxidize the ferrous iron to the ferric state and reverse the interaction between ferrous iron and 
the coordinately bound metabolite in the complex) previously had only a minor effect on the 
inhibition of CYP2C19 by esomeprazole as shown in Figure 4.7 (34).  MICs typically absorb 
strongly around 455 nm, but some types (e.g., those formed by methylenedioxyphenyl-
containing compounds) have maxima around 427 nm, and the latter MICs are not disrupted by 
potassium ferricyanide (125). Therefore, the studies presented in this section were undertaken 
in an attempt to more thoroughly rule out MIC formation as the mechanism of inactivation of 
CYP2C19 by esomeprazole.    
Figure 6.6 shows a lack of formation of a peak near 427 or 455 when esomeprazole 
(100 µM) was incubated with recombinant human CYP2C19 (50 pmol/mL) for up to ~31 min.  
To further analyze these data, the change in absorbance between 427 or 455, and 490 nm (i.e., 
the isosbestic point) was also plotted vs. time as shown in Figure 6.7a-b.  The lack of a time-
dependent change the absorbance at these wavelengths provides further evidence that 
esomeprazole does not inactivate CYP2C19 through MIC formation. 
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Figure 6.6. Difference spectra of the potential formation of a metabolite inhibitory 
complex by esomeprazole (100 µM) in rhCYP2C19 (50 pmol/mL) 
The scan times are indicated after each line in the legend.  The sample cuvette contained 
recombinant human CYP2C19 (50 pmol/mL), esomeprazole (100 µM), NADPH (1 mM) and 
other buffer components as indicated in Chapter 3.  The reference cuvette contained the same 
components and the solvent used to dissolve esomeprazole as defined in Chapter 3.  
Absorbance was scanned from 400 – 500 nm approximately every 30 seconds up to 
approximately 31 min.  The lines represent the absorbance recorded at each wavelength for 
each incubation time.  
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Figure 6.7. Lack of metabolite inhibitory complex formation by esomeprazole (100 µM) in 
rhCYP2C19 (50 pmol/mL) 
Data are extracted from those presented in Figure 6.6, with points representing measurements 
of any absorbance increase at 455 (a) or 427 (b) nm relative to 490 nm (isosbestic point) over 
time.     
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6.7. Positive control assays 
To provide additional evidence that the results in Figure 6.6 and Figure 6.7 were not 
false negatives, and that the test system could adequately detect an MIC with rhCYP2C19, the 
ability of S-fluoxetine to form an MIC under the same conditions was also examined (Figure 
6.8).  S-Fluoxetine was chosen because it has been shown previously to form an MIC in human 
liver microsomes (177,178).  The concentration of S-fluoxetine chosen corresponds to 
approximately four-fold the total KI value we previously determined in human liver microsomes 
(35).  As shown in Figure 6.8 and Figure 6.9, a peak at approximately 455 nm formed 
immediately upon closing the spectrophotometer cover (i.e., 0 min), and continued to increase 
with time up to approximately 16 min of incubation.  These experiments demonstrate that MICs 
formed by the CYP2C19 and 3A4 quasi-irreversible inhibitor, S-fluoxetine, can be detected in 
recombinant human CYP2C19.   
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Figure 6.8. Difference spectra showing the formation of a metabolite inhibitory complex 
by S-fluoxetine (200 µM) in rhCYP2C19 (50 pmol/mL) 
The scan times are indicated after each line in the legend.  The sample cuvette contained 
recombinant human CYP2C19 (50 pmol/mL), S-fluoxetine (200 µM), NADPH (1 mM) and other 
buffer components as indicated in Chapter 3.  The reference cuvette contained the same 
components and the solvent used to dissolve S-fluoxetine as defined in Chapter 3.  Absorbance 
was scanned from 400 – 500 nm approximately every 30 seconds up to approximately 16 min.  
The lines represent the absorbance recorded at each wavelength. 
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Figure 6.9. Metabolite inhibitory complex formation by S-fluoxetine (200 µM) with 
rhCYP2C19 (50 pmol/mL) 
Data are extracted from those presented in Figure 6.8, with points representing measurements 
of the absorbance increase at 455 nm relative to 490 nm (isosbestic point) over time.    
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Finally, as an additional positive control, the ability of the well-known quasi-irreversible 
inhibitor of CYP3A4, troleandomycin, to form an MIC in recombinant human CYP3A4 was also 
demonstrated, as shown in Figure 6.10 and Figure 6.11.  The time course of MIC formation in 
recombinant human CYP3A4 was similar to previous results in a human liver microsomal 
sample with high CYP3A4 content (16), with a rapid increase in MIC formation over the first few 
minutes followed by a slower increase to approximately 15 min.   
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Figure 6.10. Difference spectra showing the formation of a metabolite inhibitory complex 
by troleandomycin (75 µM) in rhCYP3A4 (50 pmol/mL) 
The scan times are indicated after each line in the legend.  The sample cuvette contained 
recombinant human CYP3A4 (50 pmol/mL), troleandomycin (75 µM), NADPH (1 mM) and other 
buffer components as indicated in Chapter 3.  The reference cuvette contained the same 
components and the solvent used to dissolve troleandomycin as defined in Chapter 3.  
Absorbance was scanned from 400 – 500 nm approximately every 30 seconds up to 
approximately 15 min.  The lines represent the absorbance recorded at each wavelength. 
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Figure 6.11. Metabolite inhibitory complex formation by troleandomycin (75 µM) in 
rhCYP3A4 (50 pmol/mL) 
Data are extracted from those presented in Figure 6.10, with points representing measurements 
of the absorbance increase between 455 nm and 490 nm over time.    
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6.8. An investigation of additional proton pump inhibitors as metabolism-
dependent inhibitors of CYP2C19 
In Chapter 4 evidence that neither lansoprazole nor pantoprazole can cause 
metabolism-dependent inhibition of CYP2C19 (Table 4.1) was presented.  It was also 
hypothesized that 5´-methylhydroxylation of omeprazole or esomeprazole (to form 
5´-hydroxyomeprazole) could involve the intermediacy of a benzylic radical and heme alkylation, 
analogous to the inactivation of CYP2C8 by gemfibrozil glucuronide (33,148,159).  Interestingly, 
of the PPIs, only omeprazole, esomeprazole and tenatoprazole have a 5´-methyl substituent 
(Table 1.1).  In addition, conversion of omeprazole or esomeprazole to omeprazole sulfone or 
5-ODM omeprazole leaves this substituent intact, and these metabolites are also MBIs of 
CYP2C19 (Table 6.1).  In contrast, 5´-methylhydroxylation of esomeprazole or omeprazole 
leads to a metabolite that is not even a direct inhibitor of CYP2C19 (Table 4.1).  It is also known 
that omeprazole sulfone can be further metabolized by CYP2C19 to 5´-hydroxyomeprazole 
sulfone (179) as shown in Figure 6.12.  If hydroxylation at the 5´-position of omeprazole or 
esomeprazole and its inhibitory metabolites partitions between the formation of a non-inhibitory 
5´-hydroxy metabolite by oxygen rebound and formation of an inhibitory benzylic radical, then 
this pathway would be common to esomeprazole and its inhibitory metabolites.  This possibility 
is shown in Figure 6.13.   
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Figure 6.12. Metabolic scheme for omeprazole 
The metabolism of omeprazole with CYP2C19-mediated reactions in red and CYP3A4-
mediated reactions in blue.  Adapted from (57,179). 
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Figure 6.13. Omeprazole metabolites that can and cannot inactivate CYP2C19 and 
proposed mechanism  
Omeprazole
5-O-Desmethylomeprazole
5′-Hydroxyomeprazole
Omeprazole sulfone 5′-Hydroxyomeprazole
sulfone
5′-Hydroxy-5-O-desmethyl-
omeprazole
5′-Hydroxyomeprazole
5′-Hydroxylation via 
oxygen rebound from a
benzylic radical intermediate
MDI of CYP2C19
5′-Hydroxylation via 
oxygen rebound from a
benzylic radical intermediate
MDI of CYP2C19
5′-Hydroxylation via 
oxygen rebound from a
benzylic radical intermediate
MDI of CYP2C19
Formation of 5′-benzylic radical not possible
No MDI of CYP2C19
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Three PPIs were not evaluated as CYP2C19 inhibitors in previous chapters, namely 
tenatoprazole, ilaprazole and rabeprazole (see Figure 6.14 for their structures; note that 
AGN201904 [Table 1.1] is excluded from this list because it is simply a prodrug of omeprazole).  
Tenatoprazole is unlike the other PPIs in that it is not a benzimidazole derivative, but an 
imidazopyridine derivative.  However, like esomeprazole and its inhibitory metabolites, it does 
have a 5´-methyl substituent and was therefore predicted to cause metabolism-dependent 
inhibition of CYP2C19.  The two remaining PPIs that had not been examined, namely ilaprazole 
and rabeprazole, like lansoprazole and pantoprazole, do not have a 5´-methyl substituent, and 
therefore were predicted not to cause MDI of CYP2C19.  
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Ilaprazole Rabeprazole 
 
 
Tenatoprazole 
 
Figure 6.14. Structures of ilaprazole, rabeprazole and tenatoprazole 
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To test the hypothesis that the presence of a 5´-methyl substituent in PPIs is necessary 
for MDI of CYP2C19, ilaprazole, rabeprazole and tenatoprazole were evaluated as direct-acting 
and MDIs of CYP2C19 activity (S-mephenytoin 4´-hydroxylation) in pooled human liver 
microsomes as described in Chapter 3.  Because no in vitro CYP inhibition results have been 
reported for ilaprazole or tenatoprazole (27), 60-min, rather than the previously used 30-min 
pre-incubations, were used to increase the chance of observing a shift in IC50 values.  
Rabeprazole has already been reported to directly inhibit CYP2C19 with Ki values ranging from 
10 – 20 µM (27).  Rabeprazole is also non-enzymatically converted to its sulfide (or thioether) 
which directly inhibits CYP2C19 with a potency approximately 9-fold greater than the parent 
(138) (and is therefore and example of a reversible MDI).  As shown in Figure 6.15, 
CYP-mediated metabolism of rabeprazole plays a relatively minor role in its metabolism (57), 
and the standard pre-incubation time of 30 min was used.  The results are summarized in 
Figure 6.16 and Table 6.3.  
As in previous chapters, a zero-min pre-incubation IC50 determination was also included 
in these experiments.  For lansoprazole, pantoprazole, omeprazole, R-omeprazole and 
esomeprazole, all IC50 values with a pre-incubation in the absence of NADPH were greater than 
or equal to those with a zero-min pre-incubation (Table 4.1).  In contrast, for ilaprazole, 
rabeprazole and tenatoprazole the IC50 values with a pre-incubation in the absence of NADPH 
were less than those determined with a zero-min pre-incubation (for clarity, these data are not 
presented in Figure 6.16).  These results suggest that, as described for rabeprazole, and unlike 
the other PPIs and metabolites, ilaprzole and tenatoprazole may be more prone to non-
enzymatic reduction to their sulfides or conversion to other inhibitory degradation products.  
Because of this observation, IC50 shifts were based on a comparison of the IC50 values for the 
samples pre-incubated with and without NADPH as presented in Table 6.3.  This approach 
allowed any increase in inhibition upon pre-incubation with to be attributed to the presence of 
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NADPH (i.e., MDI).  The results show that, as predicted, only tenatoprazole caused MDI of 
CYP2C19 as evidenced by a 4.2-fold shift in IC50 value of following a 60-min pre-incubation with 
NADPH-fortified HLM.    
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Figure 6.15. Metabolic scheme for rabeprazole 
The metabolism of rabeprazole with CYP2C19-mediated reactions in red, CYP3A4-mediated 
reactions in blue and non-enymatic degradation in black.  Adapted from (57). 
 
 
  
Rabeprazole
Desmethylrabeprazole
O-Demethylation
CYP2C19 Minor
Rabeprazole thioether
Non-enzymatic Major
Rabeprazole sulfone
Sulfoxidation
CYP3A4 Minor Rabeprazole thioether
carboxylic acid
Desmethylrabeprazole
thioether
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(a) Ilaprazole (b) Rabeprazole 
  
(c) Tenatoprazole 
 
 
Figure 6.16. Evaluation of ilaprazole, rabeprazole and tenatoprazole as direct-acting and 
MDIs of CYP2C19  
Each symbol represents the average of duplicate determinations.  (a) Ilaprazole inhibited 
CYP2C19 in pooled HLM with IC50 values as shown (S-mephenytoin 4´-hydroxylation solvent 
control rates = 44.4 and 67.5 pmol/mg/min for 60-min –NADPH, and 60-min + NADPH pre-
incubations, respectively).  (b) Rabeprazole inhibited CYP2C19 in pooled HLM with IC50 values 
as shown (S-mephenytoin 4´-hydroxylation solvent control rates = 70.1 and 87.3 pmol/mg/min 
for 30-min –NADPH, and 30-min + NADPH pre-incubations, respectively).  (c) Tenatoprazole 
inhibited CYP2C19 in pooled HLM with IC50 values as shown (S-mephenytoin 4´-hydroxylation 
solvent control rates = 44.9 and 64.9 pmol/mg/min for 60-min –NADPH, and 60-min + NADPH 
pre-incubations, respectively). 
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Table 6.3. Inhibition of CYP2C19 in human liver microsomes by ilaprazole, rabeprazole 
and tenatoprazole 
Proton pump inhibitor 
IC50 (μM)a 
IC50 shift 
(fold)b 5´-methyl 
substituent 
Pre-incubation 
without NADPHc 
Pre-incubation 
with NADPHc 
Ilaprazole No 21 ± 2 33 ± 2 0.66 
Rabeprazole No 26 ± 2 22 ± 2 1.2 
Tenatoprazole Yes 58 ± 13 14 ± 1 4.2 
a Values are displayed to two significant figures, ± standard error of the measurement 
b Calculated from full precision values as (IC50 from pre-incubation without NADPH) ÷ (IC50 from 
pre-incubation with NADPH) and rounded to two significant figures.  IC50 shifts > 1.5-fold appear 
in bold. 
c Pre-incubation time is 60 min for ilaprazole and tenatoprazole and 30 min for rabeprazole. 
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Discussion 
As described in the introduction to this chapter, mechanism-based inhibition (MBI) is a subset of 
time- or metabolism-dependent inhibition, but experiments to provide evidence that meet all of 
the criteria for MBI as described by Silverman (169) are rarely performed in the typical course of 
drug development.  Taken together, the data presented in Chapter 5 and in this chapter (Table 
6.1, Figure 6.5) are consistent with several of the criteria for mechanism-based inhibition of 
CYP2C19 by esomeprazole, 5-ODM omeprazole and omeprazole sulfone (i.e., criteria 1, 2, 3. 4. 
5, and 8 as outlined in the introduction to this chapter and (16).  Neither glutathione, superoxide 
dismutase, nor catalase, had a significant impact on the inactivation of CYP2C19 by 
esomeprazole, 5-ODM omeprazole or omeprazole sulfone (criterion 2).  In addition, data 
presented in this chapter showed that the efficiency of inactivation of CYP2C19 by 
esomeprazole, 5-ODM omeprazole and omeprazole could be robustly determined in various 
experiments, providing more certainty that the effects of these “protectants” did not have a 
significant impact on CYP2C19 inactivation.  Particularly strong evidence for MBI was shown by 
the alternate CYP2C19 substrate, pantoprazole, which provided significant enzyme protection 
against the inactivation of CYP2C19 by these compounds (criterion 5 – a hallmark of MBI).  
Evidence for criterion 7 (i.e., reduction of CYP content) will be presented in Chapter 7 for 
esomeprazole.   
Are there structural features within omeprazole, esomeprazole or their metabolites that 
suggest possible mechanisms of inactivation of CYP2C19?   
As for gemfibrozil glucuronide (33,159), there are no particularly obvious structural 
moieties within esomeprazole associated with MBI of CYPs (170,171).  As hypothesized in 
Chapter 4, however, methylhydroxylation of esomeprazole to form 5´-hydroxyomeprazole could 
involve the intermediacy of a benzylic radical and heme alkylation, analogous to the inactivation 
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of CYP2C8 by gemfibrozil glucuronide as illustrated in Figure 6.17 (33,148,159).  In this case, 
gemfibrozil glucuronide appears to partition between the formation (and non-inhibitory release) 
of 4´-hydroxygemfibrozil glucuronide and the formation of the reactive benzylic radical that 
adducts to heme (159).   
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Figure 6.17. Benzylic radical formation as the mechanism of the irreversible metabolism-
dependent inhibition of CYP2C8 by gemfibrozil 
The metabolism-dependent inhibition of CYP2C8 by gemfibrozil involves the conversion of 
gemfibrozil to an acyl glucuronide which is then metabolized by CYP2C8 to a benzylic radical 
that covalently binds to the heme moiety and irreversibly inhibits the enzyme (33,148,159). 
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adduct in the active site of CYP2C8
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In such a case, benzylic radical formation as a potential cause of CYP2C19 inactivation 
by esomeprazole would also be a precursor to the formation of 5´-hydroxyomeprazole.  This 
benzylic radical would form prior to formation and release of 5´-hydroxyomeprazole, not after, 
explaining why 5´-hydroxyomeprazole does not inhibit CYP2C19 (Figure 4.3).  In this scenario, 
as in the case of CYP2C8 inactivation by gemfibrozil glucuronide, esomeprazole would be 
converted to a benzylic radical that has one of two fates: 1) it could alkylate the heme moiety 
and inactivate CYP2C19 or 2) undergo oxygen rebound to form 5´-hydroxyomeprazole.  
However, 5-ODM omeprazole is also an MBI of CYP2C19.  The second possibility for 
inactivation of CYP2C19 raised in Chapter 4 was that formation of 5-O-desmethylomeprazole (a 
para-aminophenol) could lead to a reactive quinoneimine that could inactivate CYP2C19 if 
formed in its active site, but the data presented in this chapter showing that inactivation of 
CYP2C19 by 5-ODM omeprazole is not decreased by the addition of GSH argues against this 
possibility.  Another remote possibility based on the presence of secondary and tertiary amines 
was that esomeprazole formed a MIC with CYP2C19.  Evidence against this mechanism was 
provided by the lack of reversal of inactivation in the presence of potassium ferricyanide (Figure 
4.7).  In the studies presented in this chapter there was no evidence that esomeprazole formed 
an MIC with rhCYP2C19 based on the spectrophotometric studies depicted in Figure 6.6 under 
conditions where S-fluoxetine did form an MIC with rhCYP2C19 and troleandomycin formed an 
MIC with rhCYP3A4 (Figure 6.8 and Figure 6.10). 
Do the metabolic pathways of omeprazole suggest that benzylic radical formation is a 
possible mechanism of CYP inactivation? 
In spite of the lack of any obvious structural moiety known to be associated with MBI of 
CYPs, the results implicating esomeprazole as an MBI of CYP2C19 are not surprising on their 
own given that it is a well-known substrate of CYP2C19, and could therefore be activated to a 
reactive species that inactivates the enzyme prior to leaving the active site.  Likewise, 
163 
 
5-ODM omeprazole is formed by CYP2C19, and additional oxidation of this metabolite once 
formed in the active site of CYP2C19 could conceivably give rise to a reactive intermediate that 
inactivates CYP2C19.  For omeprazole sulfone, the situation is more complex, because 
CYP3A4 is the main enzyme involved in the formation of this metabolite from esomeprazole 
(113).  For omeprazole sulfone to also be a MBI of CYP2C19, omeprazole sulfone would need 
to leave the active site of CYP3A4, and then be further oxidized by CYP2C19 to a reactive 
intermediate that inactivates this enzyme.   
There is in fact evidence that omeprazole sulfone is further metabolized to 
5´-hydroxyomeprazole sulfone by CYP2C19 and CYP3A4, with CYP2C19 acting as the high 
affinity enzyme (Km = 7.6 µM) and contributing approximately 70% to this conversion (179).  The 
known metabolic pathways for omeprazole and its metabolites are shown in Figure 6.12.  
Andersson et al., also showed that omeprazole sulfone inhibits the CYP2C19-dependent 
formation of 5´-hydroxyomeprazole and 5-ODM omeprazole from omeprazole with an apparent 
Ki value of approximately 10 µM (179).  These in vitro experiments were conducted at 1 mg/mL 
HLM for 30 min and, as discussed in Chapter 4, these conditions would have allowed ample 
time for MDI to occur, leading to the reasonable conclusion that the inhibition was competitive, 
without a specific examination of time-dependence.  It is also of interest that the estimated Km 
for formation of 5´-hydroxyomeprazole sulfone by CYP2C19 (i.e., 7.6 µM (179)) is similar to the 
KI value of 5.5 µM in the definitive KI and kinact determination for omeprazole sulfone toward 
CYP2C19 (Figure 5.4f).  A similar value for the inactivation of CYP2C19 by omeprazole sulfone 
was reported by Shirasaka et al., with a KI value of 5.7 µM (75).  The concordance in these 
values is notable because the KI value (i.e., the concentration that provides half-maximal 
inactivation) is analogous to Km (i.e., the concentration that provides half-maximal catalysis).  
The secondary metabolism of 5-ODM omeprazole has not been examined, but if, like 
omeprazole sulfone, it could also be hydroxylated at the 5´-position by CYP2C19, then the 
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possibility remains that oxidation at this position within the active site prior to release of a further 
metabolite could be a common pathway for the inactivation of CYP2C19 by esomeprazole, 
omeprazole and 5´-ODM omeprazole, as proposed in Figure 6.13.   
Why wouldn’t other PPIs potentially form benzylic radicals and inactivate CYP2C19? 
As shown in Table 1.1, of the PPIs, only omeprazole, esomeprazole and tenatoprazole 
have a 5´-methyl substituent.  In addition, omeprazole sulfone and 5-ODM omeprazole can 
inactivate CYP2C19, and conversion of either esomeprazole or omeprazole to these 
metabolites leaves the 5´-methyl substituent intact.  As described in Chapter 4, neither 
lansoprazole nor pantoprazole, which lack a 5´-methyl substituent can cause MDI of CYP2C19, 
and, based on their metabolic schemes (Figure 6.18), their metabolites are also not amenable 
to methylhydroxylation at the 5´-position. 
  
165 
 
 
 
Figure 6.18.  Metabolic schemes for lansoprazole and pantoprazole 
Lansoprazole
Lansoprazole Sulfide
Non-enzymatic
sulfide reduction
5-Hydroxylansoprazole
Aromatic hydroxylation
CYP2C19 Major
Lansoprazole sulfone
Sulfoxidation
CYP3A4 Minor
Lansoprazole
hydroxysulfone
CYP3A4
CYP2C19
Pantoprazole
Pantoprazole sulfide
Non-enzymatic
sulfide reduction
4’-O-Desmethylpantoprazole
4’-O-Demethylation
CYP2C19 Major
Pantoprazole sulfone
Sulfoxidation
CYP3A4 Minor
Desmethylpantoprazole
sulfone
CYP3A4
CYP2C19
3’-O-Demethylation
also occurs
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The metabolism of lansoprazole and pantoprazole with CYP2C19-mediated reactions in red, 
CYP3A4-mediated reactions in blue and non-enymatic degradation in black.  Adapted from (57). 
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The data presented in this chapter for rabeprazole and ilaprazole, which also lack a 
5´-methyl substituent, show that these PPIs do not cause MDI of CYP2C19 (Figure 6.16, Table 
6.3).  In contrast, tenatoprazole caused a 4.2-fold shift in IC50 value when pre-incubated with 
NADPH-fortified HLM, which is the same as that observed for omeprazole (Table 4.1).  
However, as for esomeprazole (113), the clinical pharmacokinetics of tenatoprazole are 
consistent with MDI of CYP2C19 (the enzyme largely responsible for its metabolism). The 
accumulation ratios of tenatoprazole AUC from day 1 to day 20 range from 1.4 – 2.2 over the 
dose range 10 – 120 mg (61).  Taken together with the data presented in Chapter 4 for 
lansoprazole and pantoprazole, all of these findings appear to be consistent with the hypothesis 
that the presence of a 5´-methyl substituent in a PPI is necessary for MDI of CYP2C19.  It 
should also be remembered that, as discussed in Chapter 4, R-omeprazole does not appear to 
be an irreversible MDI of CYP2C19 (Figure 4.7).  This suggests that the particular 
stereochemistry of the PPIs may also play a role in the ability of a PPI with a 5´-methyl 
substituent to inactivate CYP2C19.  The fact that conversion of R-omeprazole to the non-
inhibitory 5´-hydroxyomeprazole by CYP2C19 comprises more than 94% of the intrinsic 
clearance of this enantiomer (Figure 4.9) seems counter-intuitive to the hypothesis that this 
metabolite is produced by oxygen rebound after benzylic radical formation.  However, the 
results taken as a whole would suggest that if the “benzylic radical hypothesis” is true, then the 
partition ratio (i.e., the number of productive catalytic events per inactivation event) for 
R-omeprazole must be very high compared to esomeprazole (because a lower partition ratio 
means that more inactivation events occur than productive catalytic events).  This in turn 
suggests that the stereochemistry of esomeprazole may allow for a more favorable positioning 
of the theoretical 5´-hydroxy benzyl radical near the heme moiety than R-omeprazole.  This 
difference is reminiscent of the reportedly more favorable positioning of the ortho benzylic 
methyl group of gemfobrozil glucuronide within 3.0 – 4.0 Å of the γ-meso position of CYP2C8 
heme than the meta benzylic methyl group (159,180). The stereoselectivity of the inactivation of 
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CYP2C19 by esomeprazole and its metabolites needs to be investigated further, and will be 
discussed in Chapter 8.  Finally, the fact tenatoprazole, esomeprazole, and the esomeprazole 
and omeprazole metabolites, namely omeprazole sulfone and 5-ODM omeprazole, can 
inactivate CYP2C19, whereas 5´-hydroxyomeprazole cannot (Figure 6.13), suggests the 
possibility that, analogous to the proposed mechanism of inactivation of CYP2C8 by gemfibrozil 
glucuronide, formation of a reactive benzylic radical within the active site of CYP2C19 may be 
the common mechanism of inactivation for these compounds.   
In conclusion, further evidence for mechanism-based inhibition of CYP2C19 by 
esomeprazole, omeprazole sulfone and 5-ODM omeprazole was provided in this chapter in that 
neither glutathione, superoxide dismutase, nor catalase was found to have a significant impact 
on the inactivation of CYP2C19 by these three compounds. In contrast, the alternate CYP2C19 
substrate, pantoprazole, provided significant enzyme protection.  I obtained no 
spectrophotometric evidence to suggest that esomeprazole forms a MIC with CYP2C19 under 
conditions where positive controls did.  The data presented in this chapter also showed that 
tenatoprazole, the only PPI other than omeprazole and esomeprazole with a 5´-methyl 
substituent, is also an MDI of CYP2C19, whereas ilaprazole and rabeprazole are not.  The 
possibility of heme alkylation through the formation of a benzylic radical as a common pathway 
of inactivation of CYP2C19 by esomeprazole, omeprazole sulfone, 5-ODM omeprazole and 
tenatoprazole was also discussed.  Additional experimental approaches to further investigate 
the mechanism of inactivation of CYP2C19 by esomeprazole will be discussed in Chapter 8.  
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Chapter 7. AN INITIAL EVALUATION OF THE ABILITY OF 
ESOMEPRAZOLE TO BIND TO THE HEME OF CYP2C19 BY 
UHPLC/UV/HRMS 
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Abstract 
Studies were undertaken to test the hypothesis that the inactivation of CYP2C19 by 
esomeprazole is the result of the formation of a reactive metabolite that binds covalently to the 
heme moiety.  The results described in this chapter provide tentative support for this hypothesis 
but, perhaps more interestingly, they revealed the potential for an unusual artifact that can result 
when heme-adducts potentially formed from a sulfur-containing drug are analyzed by high-
resolution mass spectrometry with mass-defect filtering.  When incubated with NADPH-fortified 
human liver microsomes (1 mg/mL) for 120 min, esomeprazole (100 µM) caused a ∼50% loss of 
heme (relative to NADPH-fortified HLM in the absence of substrate) as measured by both ultra-
high performance liquid chromatography (UHPLC) with UV/VIS detection at 398 nm and by high 
resolution mass spectrometry (HRMS). Although this finding supported the heme-alkylation 
hypothesis, no new 398 nm-absorbing chromatographic peak could be detected, suggesting the 
missing heme was either covalently cross-linked to the apoprotein (and hence lost during 
protein precipitation) or the heme adduct did not absorb light at 398 nm, or heme was 
fragmented or destroyed, which has been reported for other CYP inactivators. To investigate the 
possibility that an isolable heme adduct was formed but not detectable at 398 nm, heme was 
extracted from esomeprazole-incubated samples and analyzed by UHPLC-UV with HRMS and 
post-acquisition mass-defect filtering. Mass-defect filtered HRMS identified an apparent heme-
associated component (observed m/z = 723.2266) that appeared to have an isotopic distribution 
pattern characteristic of the intact heme if the absence of certain low abundance isotopes were 
attributed to background noise. However, subsequent analysis established that the putative 
heme adduct identified by mass-defect filtering with m/z = 723.2266 and a theoretical elemental 
composition of C41H39FeN4O5 was in fact a dimer of esomeprazole sulfone, which has a 
theoretical m/z = 723.2271 and an elemental composition of C34H39N6O8S2. Compared with the 
abundance of the monoisotope (set to 100%), the +1, +2 and +3 isotopes of omeprazole sulfone 
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dimer were 40%, 9% and 3%, respectively, which were similar to the relative abundance of the 
+1, +2 and +3 isotopes of heme, namely, 40%, 7% and 1%, respectively. A distinguishing 
feature was the absence (<1%) of −1 and −2 isotopes in the mass spectrum of omeprazole 
sulfone dimer and their presence at a relative abundance of 2% and 6%, respectively, in the 
mass spectrum of heme. Analysis of a reference standard solution of omeprazole sulfone 
resulted in the detection of a component within the accurate m/z range of both the theoretical 
dimer and the potential heme adduct at the same retention time of the component observed in 
the esomeprazole-incubation samples.  
In summary, the results presented in this chapter provide tentative support for the 
possibility that, based on the loss of 398 nm-detectable heme, esomeprazole inactivates 
CYP2C19 by alkylating the heme moiety.  Analysis of the putative heme adduct by high 
resolution mass spectrometry with mass-defect filtering did not identify a heme adduct but 
instead revealed an interesting artifact whereby a dimer of omeprazole sulfone had mass 
spectral characteristics remarkably similar to a heme adduct, which should be taken into 
consideration when such studies are performed with other sulfur-containing drugs. 
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Introduction 
In chapters 4-6, I presented evidence that esomeprazole, omeprazole sulfone and 
5-O-desmethyl omeprazole, but not R-omeprazole, are mechanism-based inhibitors of 
CYP2C19.  These studies established that esomeprazole, omeprazole sulfone and 
5-O-desmethyl omeprazole meet the following criteria for mechanism-based inhibition (MBI) of 
CYP2C19: 1) inactivation of CYP2C19 occurs in a concentration-, time- and metabolism-
dependent manner, 2) the efficiency of inactivation is not diminished by glutathione, superoxide 
dismutase nor catalase (exogenous scavengers), 3) the inactivation is irreversible (by 
ultracentrifugation and washing), 4) the inactivation is saturable with respect to inactivator 
concentration, 5) the alternate CYP2C19 substrate pantoprazole protects the enzyme against 
inactivation, and 6) inactivation requires a catalytic event in that it does not occur in the absence 
of the CYP co-factor NADPH.   
In Chapter 6, MIC formation was ruled out as the mechanism of inactivation of CYP2C19 
by esomeprazole.  This suggests the inactivation of CYP2C19 by esomeprazole involves 
formation of a metabolite that alkylates the apoprotein, alkylates the heme prosthetic group or 
cross links these two moieties in a manner that blocks further catalytic activity.  The studies 
described in this chapter were designed to test the hypothesis that esomeprazole inactivates by 
CYP2C19 by alkylating the heme moiety. It is worth noting that studies to investigate the 
possible binding of esomeprazole to the apoprotein moiety of CYP2C19 were not investigated 
because radioactive esomeprazole is not commercially available and because purified 
CYP2C19 (as opposed to cDNA-expressed CYP2C19) was prohibitively expensive. Purified 
CYP2C19 is a more optimal test system than an expressed form of CYP2C19 (e.g., 
Supersomes) because mass spectral analysis of proteins produces an envelope of multiply 
charged ions that must be deconvoluted in order to detect a small change in protein mass due 
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to adduction of a small molecule to the apoprotein.  With the many proteins present in 
expressed recombinant CYP2C19, the protein “envelope” would be particularly difficult to 
deconvolute.   
As noted above, MBI of a CYP enzyme can involve alkylation of the apoprotein or cross-
linking of the heme to the apoprotein.  In the former case (protein alkylation) there is no loss of 
extractable heme and no formation of a new 398 nm-absorbing chromatographic peak indicative 
of a heme adduct.  In the latter case (cross-linking), there is loss of extractable heme but there 
is no formation of new 398 nm-absorbing heme peak.  On the other hand, MBI could involve 
heme alkylation without cross linking to the apoprotein.  In this case, it is possible – but not 
inevitable – that a new 398 nm-absorbing peak will be detected by analysis of the extracted 
heme by HPLC with UV/VIS detection. In order to observe a new peak, the heme adduct must 
be chromatographically distinct from heme and it must absorb light at ~400 nm. Heme adducts 
have been shown to have extinction coefficients at ~400 nm that are essentially zero (they do 
not absorb light at ~400 nm) or are much lower than that of intact heme. For example, 
1-aminobenzotriazole (1-ABT), an MBI that alkylates the heme of numerous CYP enzymes, 
appears to have an extinction coefficient at 398 nm of zero; hence, heme alkylation by 1-ABT 
does not lead to the appearance of a new 398 nm-absorbing chromatographic peak.  In the 
case of gemfibrozil glucuronide, a selective MBI of CYP2C8, the heme adduct has an extinction 
coefficient that is approximately 12% of that for intact heme (159). From these examples it is 
apparent that, when examining the mechanism of CYP inactivation, failure to detect a new 
398 nm-absorbing chromatographic peak does not rule out the possibility that a heme adduct 
formed, as in the case of 1-ABT.  In some cases, such as the cumene hydroperoxide-mediated 
inactivation of CYP3A4, or inactivation of one or more CYPs in rat or human liver microsomes 
by parathion or carbamazepine, heme may be completely destroyed and reactive fragments of 
heme can subsequently bind irreversibly to the apoprotein (181,182).  However, the loss of 
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heme (as evidenced by a decrease in absorbance at 398 nm) is evidence of heme adduct 
formation, cross-linking of heme to apoprotein, or heme destruction. 
In previous studies conducted to examine the mechanism of inactivation of CYP by 
various compounds that modify the prosthetic heme, heme was extracted from cytochrome 
P450 with a strong acid followed by extraction into an organic solvent such as dichloromethane 
or acetone (159,181,183-187).  Strong acids are used in the initial step because heme-protein 
bonds are completely broken at pH≤1.0 (188).  As discussed in Chapter 1, PPIs become 
protonated under acidic conditions, and the resulting cyclic sulfenamide can covalently bind to 
cysteine residues (Figure 1.2).  Omeprazole is rapidly and nearly completely converted to the 
cyclic sulfenamide within 10 to 100 milliseconds at pH 1-4 (189,190).  Free omeprazole and 
omeprazole bound to heme at the benzylic position would also be expected to undergo 
conversion to the cyclic sulfenamide at low pH.  Because the addition of a strong acid (i.e., 1N 
HCl) to facilitate heme extraction catalyzes this rearrangement, UHPLC-UV/HRMS combined 
with post-acquisition mass-defect filtering (MDF) was used to detect the formation of a heme-
associated adduct with an unexpected mass (i.e., an adduct that was not a simple addition of 
esomeprazole or a known inhibitory metabolite to heme, but a rearranged product).  The 
accurate mass defect is the difference between the accurate mass and the nearest whole 
integer mass of the combined elements with a specific molecular formula (126). For example, 
the accurate mass defect for heme (m/z of C34H32FeN4O4 = 616.1773) is +0.1773.  MDF is an in 
silico data filter that screens out all mass spectral peaks that are not associated with the 
accurate mass defect for the analyte of interest, in this case heme.  By constructing a mass-
defect filter within 35 mDa of the mass defect for heme, only heme-associated small-molecule 
components should be detected (126).  UHPLC-UV/HRMS combined with mass-defect filtering 
(MDF) was used to investigate the mechanism of inactivation of CYP2C19 by esomeprazole, 
based on the hypothesis that a lack of detection of a new heme-associated peak by HRMS-
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MDF would suggest that the mechanism of inactivation was covalent modification of the 
apoprotein or cross linking of the heme to the apoprotein.   
For simplicity, the term ‘esomeprazole-incubated sample’ is used throughout this chapter 
to describe in vitro incubations of esomeprazole with human liver microsomes in the presence of 
NADPH. A corresponding term is used for incubations of gemfibrozil glucuronide or 1-ABT with 
NADPH-fortified human liver microsomes.  In addition, for convenience when discussing 
isotopic distributions, the terms ‘lighter’ and ‘heavier’ are used to denote isotopes with less and 
more mass than the monoisotopic mass, respectively.  Finally, for UV-detectable, the term 
398 nm-detectable will be used, even though 398 nm is within the UV spectrum.   
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Results 
7.1. Loss of 398 nm-detectable heme from esomeprazole-treated and 
1-ABT-treated HLM 
In an initial attempt to determine if the mechanism-based inhibition of CYP2C19 involved 
heme modification, the heme extracted from esomeprazole-incubated samples was analyzed by 
UHPLC-UV/HRMS).  The initial hypotheses being tested in these experiments were 1) that 398 
nm-detectable heme would decrease relative to the control if heme were modified or cross 
linked to apoprotein, and 2) that an additional chromatographic peak detectable at 398 nm 
would be evidence of heme modification.  To generate sufficient heme adduct for detection at 
398 nm, a relatively high concentration of HLM (1 mg/mL) supplemented with NADPH was 
incubated for 120 min with a high concentration of esomeprazole (100 µM) or solvent (negative 
control).  Chromatograms of 398 nm-detectable heme from a solvent control and esomprazole-
incubated sample (both containing NADPH) are shown in Figure 7.1a and b, respectively. Under 
the conditions tested, approximately 50% of the 398 nm-detectable heme was lost when HLM 
were incubated with esomeprazole. However, no new 398 nm-absorbing chromatographic peak 
was observed.  It is possible that not all of the heme was extracted from the control sample, 
such that the amount of heme lost may be an over-estimate.    
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Figure 7.1. UV chromatograms (λ = 398 nm) showing the heme extracted from control and 
esomeprazole-treated human liver microsomes 
The chromatograms show the UV peak for heme extracted from NADPH-fortified human liver 
microsomes (1 mg/mL) incubated for 120 min with solvent (i.e., methanol/Tris (pH 9.0) at 
0.4/0.6% v/v final) (chromatogram a) or 100 µM esomeprazole (chromatogram b).   
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As a positive control for the loss of 398 nm-detectable heme, the ubiquitous CYP 
inactivator 1-ABT (2 mM) was incubated with NADPH-fortified HLM (1 mg/mL) for 120 min. As 
shown in Figure 7.2, 1-ABT decreased the amount of 398 nm-detectable heme by more than 
95%. It is possible that not all of the heme was extracted from the control sample, such that the 
amount of heme lost may be an over-estimate.  No new 398 nm-absorbing chromatographic 
peak was observed, as previously reported by others (183,186,191,192).     
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Figure 7.2. UV chromatograms (λ = 398 nm) showing the heme extracted from 
1-aminobenzotriazole- treated human liver microsomes 
The chromatogram shows the UV peak for heme extracted from an incubation of NADPH-
fortified human liver microsomes (1 mg/mL) for 120 min with 1-ABT-treated (2 mM).  The 
corresponding control sample is shown in Figure 7.1a.  
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The heme extracted from esomeprazole- and 1-ABT-incubated samples was also 
quantified by accurate mass spectrometry (m/z = 616.1773 ± 20 mDa) from the in-line analysis 
and chromatographic peaks were integrated and compared against the control.  The results are 
shown in Figure 7.3.  The results were in agreement with the 398 nm-detectable loss of heme, 
with approximately 50% of the heme lost from esomeprazole-incubated samples and >95% lost 
from 1-ABT-incubated samples. No additional mass spectral peaks within 20 mDa of the exact 
mass for heme or small-molecule heme adducts were detected in either the esomeprazole- or 
1-ABT-incubated sample, which is also consistent with the analysis of heme based on UV 
absorbance.  Ion chromatograms were processed by mass-defect filtering for a non-targeted 
evaluation of the heme and associated adducts, as well as by extraction of specific m/z values 
of interest for heme and predicted heme/esomeprazole adducts (data not shown). 
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Figure 7.3. Integrated extracted accurate mass chromatograms of heme extracted from 
incubations of 1-aminobenzotriazole or esomeprazole with human liver microsomes 
The chromatograms show the integrated extracted accurate mass (m/z = 616.1773 ± 20 mDa) 
for heme extracted from NADPH-fortified human liver microsomes (1 mg/mL) incubated for 120 
min with solvent (chromatogram a), 1-ABT (chromatogram b) or esomeprazole (chromatogram 
c).  The results are expressed relative to the solvent control (i.e., NADPH-fortified HLM in the 
absence of substrate). Values of integrated peak areas for the heme peak at ∼7.2 min are 
shown below the retention time in each figure. 
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7.2. The use of mass-defect filtering to examine the potential for heme-associated 
components in treated human liver microsomes 
Figure 7.4 shows the total ion chromatograms (TIC) acquired with the MSE scan type 
across the m/z 50-1200 for heme extracted from solvent-incubated samples (i.e., NADPH-
fortified HLM in the absence of substrate) (chromatogram a) and esomeprazole-incubated 
samples (chromatogram b). A notable difference between the two chromatograms is the large 
peak at ~ 5 min in the TIC for the esomeprazole-incubated sample, which was attributed in part 
to esomeprazole metabolites.  The TIC was searched for specific ions with masses 
corresponding to adducts between heme and either esomeprazole (~m/z 960) or its known 
metabolites (such as ~ m/z 976 for heme + hydroxy-omeprazole and ~m/z 946 for heme + 
desmethylomeprazole).  No such adducts were detected.  Screening for heme adducts based 
on a search for diagnostic fragments of heme was not attempted because, as shown in Figure 
7.5, the product ion spectrum (PIS) for intact heme revealed no suitably diagnostic fragments.  
Therefore, in an attempt to find a heme-associated peak with an unanticipated mass, a 
C-heteroatom mass-defect filter (dynamic with mass range) (127,193) was constructed ±35 
mDa around the mass defect of heme (theoretical m/z of intact heme = 616.1773) and potential 
small molecule heme adducts, as described below.   
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Figure 7.4. Total ion chromatogram for heme extracted from control and esomeprazole-
treated human liver microsomes 
Total ion chromatograms (TICs) are shown for extracts from NADPH-fortified human liver 
microsomes (1 mg/mL) following a 120-min incubation with solvent (i.e., methanol/Tris (pH 9.0) 
at 0.4/0.6% v/v final) (chromatogram a) or 100 µM esomeprazole (chromatogram b). The 
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prominent peak at ~ 5 min in chromatogram b was subsequently identified as omeprazole 
sulfone, the major metabolite formed by CYP3A4.     
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Figure 7.5. Product ion spectrum for heme extracted from esomeprazole-treated human 
liver microsomes 
The product ion spectrum of heme was based on an analysis of intact heme extracted from 
incubations of esomeprazole (100 µM) with NADPH-fortified human liver microsomes 
(1 mg/mL). 
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Figure 7.6 shows the accurate mass-defect filtered chromatograms obtained following a 
120-min incubation of NADPH-fortified HLM (1 mg/ML) with solvent (chromatogram a), 2 mM 
1-ABT (chromatogram b) or 100 µM esomeprazole (chromatogram c).  The marked and partial 
loss of heme following incubation with 1-ABT and esomeprazole, respectively, were similar to 
those shown in Figure 7.1 and Figure 7.2 (based on UV absorbance) and Figure 7.3 (based on 
m/z = 616.1773).  The mass-defect filtered chromatograms show only peaks with a mass defect 
within ±35 mDa of the range of the mass defect for heme and heme-related components. 
Because the C-heteroatom dealkylation algorithm was used to construct the mass filter, at the 
low end of the examined mass range, the specific high and low values of the mass defect filter 
vary to bracket the mass defects of possible fragments of heme (i.e., within 35 mDa).  At the 
high end of the examined mass range, the intact mass defect of heme (+0.1773) is the central 
mass of the filter range. In theory, the majority of component masses not filtered out should be 
related to the heme structure.   
Based on mass-defect filtering, the loss of heme from esomeprazole-treated HLM was 
similar to that in Figure 7.3, but an additional peak was observed at a retention time of 
approximately 5 min.  This additional peak was not detected in the 1-ABT-incubated sample and 
appeared to correspond to a protonated molecule of m/z = 723.2266 (mass error = -0.6 ppm).  A 
heme-containing ion of this m/z would correspond to the mass of intact heme (616.1773) + a 
mass of 107.0493 amu. The additional mass (theoretically caused by the addition of C7H7O, 
with a theoretical mass of 107.0497 amu) does not correspond to the mass of esomeprazole or 
any of its known metabolites, but it seemed possible that the apparent adduct was a fragment of 
esomeprazole (or a metabolite) formed by acid-catalyzed rearrangement during the extraction of 
heme with hydrochloric acid. An extracted accurate mass chromatogram from esomeprazole-
treated HLM at m/z = 723.2270 ± 20 mDa (Figure 7.7) showed two peaks with retention times of 
4.82 min (minor) and 5.09 min (major). Both components were obscured by other ions in the 
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TIC shown in Figure 7.4b, including those within the large peak at approximately the same 
retention time.  
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Figure 7.6. C-Heteroatom accurate mass-defect filtered chromatograms from incubations 
of human liver microsomes with solvent, 1-aminobenzotriazole or esomeprazole  
The mass-defect filter was constructed ±35 mDa around the theoretical accurate mass of heme 
(m/z = 616.1773) to search for heme-associated components in 120-min incubations of 
NADPH-fortified human liver microsomes (1 mg/mL) with solvent (chromatogram a), 2 mM 
1-aminobenzotriazole (chromatogram b) or 100 µM esomeprazole (chromatogram c).  
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Figure 7.7. Extracted accurate mass chromatogram of components with m/z = 723.2270 ± 
20 mDa in esomeprazole-treated human liver microsomes 
The total response is 1000 x relative to the total ion chromatogram shown in Figure 7.4. 
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7.2. Low energy full scan MSE mass spectra for heme extracted from 
control and esomeprazole-treated human liver microsomes 
Isotopic distribution was used to evaluate whether the additional peaks identified in 
esomeprazole-incubated samples by mass-defect filtering were actually associated with heme. 
Isotopic distribution was examined in low energy full scan MSE spectra for intact heme from a 
control sample and the additional peaks found in esomeprazole-incubated samples, and the 
results are shown in Figure 7.8 and Figure 7.9, respectively.  The isotopic distribution of intact 
heme showed the typical pattern for iron-, oxygen- and nitrogen-containing organic compounds 
(discussed later in Section 7.5).  Three peaks containing heavier isotopes than the protonated 
monoisotopic molecule and two peaks containing lighter isotopes were evident in the mass 
spectrum of heme, as shown in Figure 7.8. Relative to the monoisotope with an observed m/z = 
616.1772 (100%), the -2, -1, +1, +2 and +3 isotopes have an abundance of approximately 6, 2, 
40, 7 and 1%, respectively.  As shown in Figure 7.9, the additional peak found in esomeprazole-
incubated samples by mass-defect filtering, and more so its sodium and potassium adducts, 
showed 3 heavier isotopes but no lighter isotopes; the relative abundance of the +1, +2 and +3 
isotopes were approximately 40, 9 and 3% of the monoisotope.   
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Figure 7.8. Low energy full scan MSE mass spectrum of intact heme extracted from 
control human liver microsomes 
The chromatogram shows a protonated molecule of m/z = 616.1772, which is within 0.2 ppm of 
the theoretical value for heme. Relative to the monoisotope (100%), the -2, -1, +1, +2 and +3 
isotopes have an abundance of approximately 6, 2, 40, 7 and 1%, respectively.  
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Figure 7.9. Low energy full scan MSE mass spectrum for the additional mass-defect 
filtered peak found in esomeprazole-treated human liver microsomes 
The chromatogram shows a protonated molecule of m/z = 723.2266 (mass error = -0.6 ppm).  A 
heme-containing ion with this m/z would correspond to the mass of intact heme (616.1773) + a 
mass of 107.0493 amu consistent with the proposed elemental composition indicated in the 
figure).  Corresponding sodium and potassium adducts were also detected, as indicated. 
Relative to the monoisotope (100%), the abundance of the +1, +2 and +3 isotopes were 
approximately 40, 9 and 3%, respectively. 
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7.3. Gemfibrozil glucuronide as a positive control for the use of mass-defect 
filtering to detect heme adducts 
Gemfibrozil glucuronide was chosen as an additional positive control for heme-related 
mass-defect filtering because Baer and colleagues published compelling evidence that the 
mechanism of CYP2C8 inactivation by this glucuronide involved formation of a benzylic radical 
that alkylates the CYP2C8 heme, creating a 398 nm-detectable adduct with an approximate m/z 
of 1040.7, as shown in Figure 6.17 (159).  NADPH-fortified HLM (1 mg/mL) were incubated with 
gemfibrozil glucuronide (100 µM) for 60 minutes, and the heme was extracted and analyzed as 
described in Chapter 3.  Based on the structure of the gemfibrozil glucuronide-heme adduct 
proposed by Baer et al., (159) the protonated molecule would have a theoretical m/z = 
1040.3506.  A UV-absorbing peak corresponding to gemfibrozil glucuronide heme adduct was 
detected at 7.91 min, slightly later than the retention time of intact heme (7.33 min) (Figure 
7.10).  This UV-absorbing peak was very small relative to the remaining intact heme, which is 
attributable to three factors.  First, gemfibrozil glucuronide is highly selective for CYP2C8, which 
comprises only 5-8% of the total drug-metabolizing CYP enzymes in human liver microsomes 
(1,33) and SimCYP.  Second, the intact heme remaining in the microsomal incubations with 
gemfibrozil glucuronide is derived not only from the CYP enzymes that were not inactivated but 
also from cytochrome b5, which accounts for approximately 50% of the heme in human liver 
microsomes (123).  Third, as reported by Baer et al. (159), the absorbance of the gemfibrozil 
glucuronide heme adduct at 407 nm with are consistent with an extinction coefficient that is 
approximately 12% of that of intact heme. Accordingly, when HLM are used as the source of 
CYP2C8, the 398-nm absorbing peak corresponding to gemfibrozil glucuronide-heme adduct is 
predicted to be 0.5% or less of the peak corresponding to intact heme. 
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Figure 7.10. UV chromatograms (λ = 398 nm) of the heme extracted from control and 
gemfibrozil glucuronide-treated pooled human liver microsomes 
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The chromatograms show the 398 nm-absorbing peaks of heme extracted from NADPH-fortified 
human liver microsomes (1 mg/mL) incubated for 60 min with solvent (chromatogram a) or 
100 µM gemfibrozil glucuronide (chromatogram b).  Chromatogram c is a full-scale version of 
chromatogram b.  
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The microsomal samples incubated with gemfibrozil glucuronide were analyzed by 
essentially the same mass-defect filtering procedure described previously for microsomal 
samples incubated with esomeprazole, The mass-defect filter was constructed ± 35 mDa 
around the theoretical mass of gemfibrozil glucuronide-heme adduct (m/z = 1040.3506) using 
the same C-heteroatom dealkylation algorithm.  As shown in Figure 7.11, the extracted accurate 
mass chromatogram, based on m/z = 1040.3506 ± 20 mDa, identified a heme-containing ion at 
7.9 min, the same retention time as the 398 nm-absorbing peak (chromatogram b in Figure 
7.10).  As shown in Figure 7.12, a low energy full scan MSE spectrum of the 7.9-min peak 
revealed an isotopic distribution characteristic of heme (Figure 7.12), with two lighter (-2 and -1) 
and three heavier (+1, +2 and +3) isotopes that were present with a relative abundance of 
approximately 10, 5, 65, 22 and 7%, respectively.  The results demonstrated that the heme 
adduct with gemfibrozil glucuronide could be identified by mass-defect filtering, and the adduct 
identified had the expected accurate mass (within -1.2 ppm) and an isotopic distribution 
characteristic of a heme-containing adduct.  
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Figure 7.11. Extracted accurate mass chromatogram of m/z = 1040.3506 ± 20 mDa for 
gemfibrozil glucuronide-treated human liver microsomes  
The mass-defect filter was constructed ±35 mDa around the theoretical gemfibrozil glucuronide 
heme adduct (m/z = 1040.3506).   
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Figure 7.12. Low energy full scan MSE mass spectrum of gemfibrozil glucuronide heme 
adduct extracted from incubations of gemfibrozil glucuronide with NADPH-fortified 
human liver microsomes 
The spectrum shows a protonated monoisotopic molecule of m/z = 1040.3494, which is within -
1.2 ppm of theoretical, with an isotopic distribution similar to that of intact heme (Figure 7.8). 
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7.4. Evidence that the apparent esomeprazole-heme adduct is an unusual 
artifact 
Because the MS/MS acquisition in the first experiment with heme extracted from either 
control or esomeprazole-treated NADPH-fortified HLM did not provide any useful diagnostic 
fragments, the experiment was repeated.  Similar UV results were obtained (i.e., ~ 50% loss, 
not shown), and MS/MS analysis of control heme again did not show diagnostic fragments (not 
shown).  Mass-defect filtering was employed again to look for possible heme-associated peaks 
(i.e., heme mass defect of 0.1773 ± 35 mDa). As shown in Figure 7.13, the extracted accurate 
mass chromatogram (based on m/z = 723.2270 ± 20 mDa) revealed a major peak at 5.09 min 
and a minor peak at 4.78 min when esomeprazole was incubated with HLM in the presence of 
NADPH but not in the absence of NADPH. As before, because these peaks were dependent on 
the presence of NADPH, and were only detected after mass-defect filtering based on the heme 
mass defect of +0.1773, they were presumed to be associated with both metabolism and heme.  
Accordingly, the 4.78 and 5.09 min peaks were considered candidates for an esomeprazole-
heme adduct. 
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Figure 7.13. Extracted accurate mass chromatogram showing additional peaks from 
esomeprazole-treated HLM (a) –NADPH, and (b) +NADPH, at m/z = 723.2270 ± 20 mDa 
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No significant peaks were detected by mass-defect filtering at m/z = 723.2270 ± 35 mDa in the 
NADPH-free sample (chromatogram a) (maximum scale = 370 counts). The peaks found by 
mass-defect filtering in the NADPH-supplemented sample (chromatogram b) are similar to those 
in Figure 7.7 (maximum scale = 1110 counts).   
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In an attempt to find diagnostic fragments from the peaks detected by mass-defect 
filtering at m/z = 723.2270 ± 35 mDa (Figure 7.13), product ion spectra of the m/z 723 ions were 
acquired for the heme extracts from esomeprazole-incubated samples. The major product ion 
was observed at m/z = 362.1172 (Figure 7.14), which is half the parent ion mass and which 
corresponds to the exact mass of omeprazole sulfone and 5´-hydroxyomeprazole 
(m/z =362.1175) reported by Boix et al. (194).  In other words, if [M2H]+ =723.2270, then 
M =361.1093 and [MH]+ = 362.1172.  In addition, less intense product ions were observed at 
m/z 298.1548, 214.0522, and 150.0895, which are diagnostic for the structure of omeprazole 
sulfone.  Because this was a product ion spectrum for a peak found by mass-defect filtering 
based on the heme mass defect of +0.1773 (and formed only in the presence of NADPH), such 
a finding was entirely unexpected; it seemed remarkable that a heme adduct would fragment 
exactly in half.  Accordingly, it was hypothesized that the proposed heme-associated component 
shown in Figure 7.9, with an observed m/z = 723.2266 and theoretical elemental composition of 
C41H39FeN4O5 was actually a monoprotonated dimer of omeprazole sulfone, which would have a 
theoretical m/z of 723.2271 and an elemental composition of C34H39N6O8S2.  The observed m/z 
= 723.2266 was within -0.1 ppm of such a theoretical dimer. Relatively large amounts of 
omeprazole sulfone would have formed in the 120-min incubation of esomeprazole with 
NADPH-fortified HLM (it is the major metabolite formed by CYP3A4), but the potential for its 
dimerization was not known.  However, dimerization of omeprazole and esomeprazole has been 
previously reported, (195,196).  The product ion spectrum in Figure 7.14 is consistent with 
predominant fragmentation of the labile dimer of omeprazole sulfone to the more stable 
monomer, given the presence of the strong signal at m/z = 362.1172, which is within 0.8 ppm of 
the theoretical m/z for the protonated monomer of omeprazole sulfone of 362.1175. The 
absence of the quadrupole-selected precursor ion of m/z ≈ 723 in the spectrum is consistent 
with fragmentation patterns for labile dimers.  It should also be noted that it is possible that the 
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dimer does not exist in aqueous solution, but rather forms “post-column” during the de-solvation 
phase of electrospray ionization, and this possibility cannot be ruled out. 
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Figure 7.14. Product ion spectrum for the peak at m/z = 723 extracted from esomeprazole-
treated NADPH-fortified human liver microsomes 
The product ion at m/z = 362.1172 corresponds to omeprazole sulfone (i.e., m/z = 362.1175 
theoretical, structure shown) within -0.83 ppm.  
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To test the hypothesis that omeprazole sulfone could dimerize in the matrix as reported 
for omeprazole and esomeprazole, a reference standard solution of omeprazole sulfone (6 mM 
in methanol / Tris buffer, pH 9.0, 60:40 v/v, stored at -20°) was analyzed by MS/MS.  As in 
Figure 7.7 and Figure 7.13, an extracted accurate mass chromatogram at m/z = 723.2270 ± 20 
mDa again revealed a peak at 5.09 min, as shown in Figure 7.15a, consistent with the presence 
of a dimer of omeprazole sulfone.  Furthermore, an extracted accurate mass chromatogram at 
m/z = 362.1175 ± 20 mDa from the solution of omeprazole sulfone also showed a peak at 5.09 
min, as shown in Figure 7.15b, consistent with the presence of monomeric omeprazole sulfone.  
Given the relative abundance of the two chromatographic peaks in the sample when analyzed 
under low energy conditions, the vast majority of the omeprazole sulfone present appeared to 
exist as the dimer.  Importantly, the retention time of omeprazole sulfone is the same as that of 
the predominant peak found in Figure 7.6c and Figure 7.7 in the original experiment.   
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Figure 7.15. Extracted accurate mass chromatograms for a reference standard solution 
of omeprazole sulfone for m/z 723.2270 ± 20 mDa (a) and 362.1172 ± 20 mDa (b), showing 
a peak at 5.09 min 
(a) Maximum scale = 941,000 counts; (b) Maximum scale = 2900 counts.   
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The peak found by mass-defect filtering at m/z = 723.2270 ± 35 mDa with a retention 
time of approximately 5 min in the reference solution of omeprazole sulfone was examined by 
MS/MS, as described in Chapter 3.  The results are shown in Figure 7.16.  The product ion 
spectrum obtained by MS/MS (with quadrupole precursor ion selection at m/z = 723) showed a 
large peak at m/z ≈ 362.12, with less intense product ions observed at m/z 298.1548, ~214, and 
150.0896, which were diagnostic for the structure of omeprazole sulfone.  Importantly, no peaks 
with m/z between 362.12 and 723.24 were observed, consistent with complete dissociation of a 
labile dimer of omeprazole sulfone to the monomer due to the collision energy applied to 
acquire the product ion spectrum.  The low-energy MSE scan in Figure 7.17 shows the isotopic 
distribution of the protonated monoisotopic molecule at m/z = 723.2277 and its sodium and 
potassium adducts (Figure 7.17), which displayed 3 peaks containing heavier isotopes than the 
protonated monoisotopic molecule; relative to the monoisotope (100%), the abundance of the 
+1, +2 and +3 isotopes was approximately 40, 15 and 2%, respectively. The similarity in the 
MS/MS spectra between Figure 7.14 (from esomeprazole-incubated samples) and Figure 7.16 
(a reference standard of omeprazole sulfone), along with the similarity in isotopic distribution of 
the component found by mass-defect filtering in the esomeprazole-incubated samples (Figure 
7.9) and the solution of omeprazole sulfone (Figure 7.17) provide additional evidence that the 
apparent heme-associated peak found by mass-defect filtering in esomeprazole-incubated 
samples was actually due to the metabolic conversion of esomeprazole to the sulfone by 
CYP3A4, and its subsequent dimerization, rather than formation of an adduct with heme.   
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Figure 7.16. Product ion spectrum for the peak at m/z = 723 extracted from a solution of 
omeprazole sulfone 
The ion at 362.1163 corresponds to omeprazole sulfone (theoretical m/z = 362.1175) within -3.3 
ppm.  
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Figure 7.17. Low energy full scan MSE mass spectrum for a proposed omeprazole sulfone 
dimer and its sodium and potassium adducts in a reference standard 
The spectrum shows a protonated monoisotopic molecule of m/z = 723.2277 (mass error from 
the theoretical omeprazole sulfone dimer is 0.8 ppm).  The mass error from the protonated 
monoisotopic molecule of m/z = 723.2266 shown in Figure 7.9 is 1.5 ppm.  Corresponding 
sodium and potassium adducts were also detected, as indicated.  
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7.5. Theoretical accurate mass isotopic distributions for various iron-, 
oxygen- nitrogen- or sulfur-containing organic compounds 
The initial evidence for an esomeprazole-heme adduct relied not only on the discovery of 
an unexpected protonated molecule at m/z = 723.2266 upon mass-defect filtering with the 
heme-based C-heteroatom mass-defect filter, but also the isotopic distribution of the putative 
adduct and its sodium and potassium adducts (Figure 7.9).  The putative esomeprazole-heme 
adduct displayed 3 peaks containing heavier isotopes than the protonated monoisotopic 
molecule but it did not contain peaks with lighter isotopes. It was initially assumed that these 
lighter isotopes were of such low abundance that they were obscured by background noise, a 
common occurrence for lower abundance isotope peaks in high resolution mass spectrometry.  
Given the unexpected finding that a dimer of omeprazole sulfone had many of the mass spectral 
features of a heme adduct, and was initially mistaken as such, a theoretical investigation was 
undertaken to examine the effects of the presence or absence of iron and/or sulfur in various 
compounds on their accurate mass spectra.   
To illustrate the effect of iron on the mass spectrum of heme, theoretical full scan 
accurate mass spectra were constructed for both heme (with iron) and protoporphyrin IX 
(without iron), focusing on peaks with a relative response > 1% of the monoisotope.  The 
theoretical accurate mass spectrum of heme shown in Figure 7.18a is very similar to the 
experimentally determined heme spectrum shown in Figure 7.8. Relative to the monoisotope 
(100%), the abundance of the −2, −1, +1, +2 and +3 isotopes was 6, 2, 40, 7 and 1%, 
respectively (Figure 7.18a). In contrast, the theoretical accurate mass spectrum of 
protoporphyrin IX lacks the two peaks containing lighter isotopes due to the absence of iron, as 
shown in Figure 7.18b.  The abundance of the +1, +2, and +3 isotopic peaks for protoporphyrin 
IX (40, 7 and 1%, respectively) is identical to their abundance in heme (i.e., these peaks are 
independent of iron).  A theoretical full scan accurate mass spectrum was also constructed for 
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the heme adduct with gemfibrozil glucuronide, as shown in Figure 7.19, which again shows an 
isotopic distribution similar to that of the experimentally obtained spectrum of gemfibrozil 
glucuronide-heme adduct (Figure 7.12) and both the theoretical spectrum (Figure 7.18a) and 
experimentally determined spectrum of heme (Figure 7.8).  
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Figure 7.18. Theoretical full scan accurate mass spectra for heme and protoporphyrin IX 
The theoretical m/z for intact heme = 616.1773 (a), differs from the observed protonated 
molecule of m/z = 616.1772 shown in Figure 7.8 by 0.2 ppm.  The theoretical full scan accurate 
mass spectrum for protoporphyrin IX (i.e., iron-depleted heme) is shown in (b).   
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Figure 7.19. Theoretical full scan accurate mass spectrum for the heme adduct with 
gemfibrozil glucuronide 
The theoretical m/z for the gemfibrozil glucuronide heme adduct = 1040.3507 (structure 
proposed by Baer and colleagues (159)) differs from the observed protonated molecule of m/z = 
1040.3494 shown in Figure 7.12 by 1.3 ppm.  
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A theoretical full scan accurate mass spectrum was constructed for ferricrocin iron 
(C28H44FeN9O13) (197), an iron-containing but not a heme-containing organic compound. The 
theoretical spectrum is shown in Figure 7.20.  As with heme, two peaks containing lighter 
isotopes and three peaks containing heavier isotopes than the protonated monoisotopic 
molecule are evident with relative abundance values similar to those in heme.   
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Figure 7.20. Theoretical full scan accurate mass spectrum and structure for ferricrocin 
iron 
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The 5.09-min peak in esomeprazole-incubated samples that was initially mistaken as a 
heme adduct was predicted to have the elemental composition C41H39FeN4O5.   A theoretical full 
scan accurate mass spectrum was constructed for a compound with this elemental composition. 
As shown in Figure 7.21, the theoretical accurate mass spectrum of this proposed heme adduct 
would indeed have two lighter peaks at m/z 721.2317 and 722.2351, which are notably lacking 
from the experimentally determined mass spectrum of the 5.09-min peak, as shown in Figure 
7.9.   
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Figure 7.21. Theoretical full scan accurate mass spectrum for the proposed elemental 
composition of the additional mass-defect filtered peak found in esomeprazole-treated 
human liver microsomes 
The theoretical m/z for the additional mass-defect filtered peak = 723.2270 differs from the 
observed protonated molecule of m/z = 723.2266 (consistent with the proposed elemental 
composition of C41H39FeN4O5) shown in Figure 7.9 by -0.6 ppm. 
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To show how the full scan accurate mass spectrum for a dimer of omeprazole sulfone 
should appear, a theoretical accurate mass spectrum was constructed for a protonated 
molecule with the formula C34H39N6O8S2, as shown in Figure 7.22.  The spectrum shows three 
peaks containing heavier isotopes than the protonated monoisotope, but none with lighter 
isotopes.  Relative to the monoisotope (100%), the abundance of the +1, +2, and +3 isotopes 
was approximately 40, 9 and 3%, respectively (compared with 40, 7 and 1% for heme).  The 
proposed structure of the omeprazole sulfone dimer is based on that described for omeprazole 
and esomeprazole dimers (195,196).  The dimer is proposed to form based on the formation of 
hydrogen bonds between one of the sulfone oxygen atoms (i.e., the proton acceptor) on one 
molecule of omeprazole sulfone and the protonated benzimidazole nitrogen (i.e., the proton 
donor) on the other molecule (195,196).  Importantly, the theoretical m/z for the proposed dimer 
differs from the observed protonated molecule of m/z = 723.2266 shown in Figure 7.9 by only 
0.7 ppm. 
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Figure 7.22. Theoretical full scan accurate mass spectrum and proposed structure for 
omeprazole sulfone dimer 
The theoretical m/z for a dimer of omeprazole sulfone = 723.2271, which differs from the 
observed protonated molecule of m/z = 723.2266 shown in Figure 7.9 by -0.7 ppm.  The 
structure shown is based on that proposed for the omeprazole and esomeprazole dimers by 
Baciocchi et al. and Marom et al. (195,196) with the dashed bonds representing hydrogen 
bonding between the two molecules. 
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Finally, to show how a lack of sulfur affects the full scan accurate mass spectrum for an 
omeprazole-related compound, a theoretical accurate mass spectrum was constructed for a 
protonated molecule of an environmental degradation product of omeprazole that lacks sulfur, 
namely OTP3, with the formula C17H19N3O4 (194). The spectrum (Figure 7.23) shows only two 
peaks containing heavier isotopes than the protonated monoisotopic molecule and no peaks 
containing lighter ones.  This differs from the theoretical isotopic distribution of the proposed 
omeprazole sulfone dimer in that the latter has three peaks containing heavier isotopes (Figure 
7.22).  Importantly, the three peaks at approximately +1, +2, and +3 mass units from the 
monoisotopic mass for the proposed omeprazole sulfone dimer have an abundance of 
approximately 40, 9 and 3% that of the monoisotopic mass (respectively) (Figure 7.22).  In 
contrast the two peaks at approximately +1, +2 mass units from the monoisotopic mass for 
OTP3 (Figure 7.23) have an abundance of only approximately 20, and 2% that of the 
monoisotopic mass, respectively.   
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Figure 7.23. Theoretical full scan accurate mass spectrum and proposed structure of 
omeprazole environmental degradation product OTP3 
The theoretical m/z for OTP3 = 328.1298, which differs from the reported protonated molecule 
of m/z = 328.1313 by 4.6 ppm (m/z and proposed structure reported by Boix et al. (194)). 
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Discussion 
From the studies presented in this chapter, it can be concluded that esomeprazole 
causes a ∼50% loss of heme as measured by both ultra-high performance liquid 
chromatography (UHPLC) with UV/VIS detection at 398 nm and by high resolution mass 
spectrometry (HRMS) in NADPH-fortified pooled human liver microsomes (relative to NADPH-
fortified HLM in the absence of substrate).  Under these conditions, 1-ABT caused more than a 
95% loss of heme and the CYP2C8-selective inactivator gemfibrozil glucuronide formed a new 
398 nm- and HRMS-detectable heme adduct with minimal loss (<1%) of total heme.  In addition 
to the criteria for MBI that esomeprazole was shown to meet in Chapter 6, the loss of 398 nm- 
and HRMS-detectable heme caused by esomeprazole in the presence of NADPH provides 
indirect evidence that CYP holoenzyme content is also reduced (criterion 7 in Chapter 6).  
Because CYP2C19 makes up only approximately 1 to 3 % of the total drug metabolizing CYPs 
in human liver (1) and SimCYP), the 50% loss of heme strongly suggests that CYPs other than 
CYP2C19 were inactivated, likely including CYP3A through the formation of 5-O-desmethyl 
omeprazole, which has been reported to be a metabolism-dependent inhibitor of CYP3A4/5 (75) 
and / or that a portion of the lost heme was also covalently cross-linked to the apoprotein (and 
hence lost during protein precipitation). The experimental conditions used were selected to 
maximize the possibility of finding a heme adduct in human liver microsomes.  Under such 
conditions, omeprazole was found to have a half-life of 14 min (Figure 4.2).  Furthermore, when 
incubating NADPH-fortified HLM with esomeprazole, formation of 5-ODM omeprazole 
contributes nearly 50% to its clearance (Figure 4.9), suggesting that significant amounts of this 
CYP2C19 and CYP3A4 inactivator would be formed. The loss of 398 nm-detectable heme 
without the formation of a new 398 nm-absorbing chromatographic peak suggests 
esomeprazole inactivates CYP2C19 and/or CYP3A4 by cross-linking the heme prosthetic group 
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to the apopotein moiety or by forming a heme adduct that does not absorb light at 398 nm, as is 
the case with 1-ABT.  
When heme is directly modified by a CYP inactivator, the heme adducts may give rise to 
new 398 nm-absorbing chromatographic peaks, as described for heme adducts with gemfibrozil 
glucuronide (159), secobarbital (184,198) and tert-butyl 1-methyl-2-propynyl ether (199).  
However, loss of the heme chromophore due to its fragmentation during CYP inactivation has 
also been previously described, and depending on the exact mechanism, is referred to as heme 
bleaching or destruction (181,200).  1-ABT was used as a positive control for a compound that 
causes extensive loss of 398 nm-detectable heme from pooled human liver microsomes without 
causing the formation of new 398 nm-detectable peaks. The results of the experiments with 
1-ABT were consistent with those reported by several groups (183,186,191).  The mechanism 
of inactivation of CYPs by 1-ABT has been elucidated, and involves the formation of a highly 
reactive metabolite, namely benzyne, upon incubation with CYP enzymes and NADPH, which 
adds directly across two nitrogen atoms within the heme moiety to form an N,N-bridged heme. 
This bridged heme entity can either auto-oxidize to release the N,N-bridged, iron-depleted 
porphyrin, or it can first add to a nitrogen and the iron in the heme, followed by rearrangement to 
the N,N-bridged porphyrin (186,191).  This mechanism is shown in Figure 7.24. 
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Figure 7.24. Mechanism of 1-aminobenzotriazole activation and alternative pathways to 
heme adduct formation by benzyne 
Note that for clarity the peripheral heme substituents have been omitted.  Adapted from 
(16,182,201).   
ABT
Benzyne
Heme
−H2O
+[O]
−Fe
+[O]
−Fe
CYP
225 
 
In the case of the positive control for formation of a 398 nm-detectable heme adduct, 
namely gemfibrozil glucuronide, a new, albeit small, 398 nm-absorbing chromatographic peak 
was detected; one that eluted shortly after intact heme (Figure 7.10b).  The UV peak was small 
relative to that described by Baer et al., who used purified CYP2C8, rather than HLM that I used 
because 1) gemfibrozil glucuronide is highly selective for CYP2C8, which comprises only 5-8% 
of the total drug-metabolizing CYP enzymes, 2) a significant portion of the total heme in HLM 
derives from cytochrome b5, and 3) the extinction coefficient (at ~400 nm) of the heme adduct 
with gemfibrozil glucuronide is ~ 12% of intact heme (159).  In spite of the relatively small 
amount of adduct formed, the use of mass-defect filtering around the mass proposed by Baer et 
al. (159), provided strong evidence for the formation of the gemfibrozil glucuronide heme adduct 
in human liver microsomes (Figure 7.11) which was bolstered by the isotopic pattern in the full 
scan accurate mass spectrum (Figure 7.12), which closely resembled the isotopic distribution of 
intact heme (Figure 7.8).   
In the case of esomeprazole, no new 398 nm-absorbing chromatographic peak was 
identified after incubating a high concentration of esomeprazole (100 µM) with a high 
concentration of HLM (1 mg/mL) in the presence of NADPH for 120 min. Dynamic mass-defect 
filtering within 35 mDa of the heme mass defect (i.e., +0.1773) appeared to demonstrate the 
formation of a heme-associated component with a protonated molecule of m/z = 723.2266.  Low 
energy full scan MSE showed that this component (and its sodium and potassium adducts) had 
an isotopic distribution with three peaks containing heavier isotopes than the protonated 
monoisotopic molecule (see Figure 7.9).  Although the peaks containing lighter isotopes 
observed in intact heme were not found in the putative heme adduct with esomeprazole (see 
Figure 7.8), it seemed reasonable to conclude that these peaks were of such low abundance 
that they were obscured by background noise, as commonly occurs in high resolution mass 
spectrometry.  In addition, in the esomeprazole-incubated sample, the isotopic peaks observed 
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at approximately +1, +2 and +3 mass units from the monoisotopic mass had an abundance of 
approximately 40, 9 and 3% that of the monoisotopic mass, respectively, which was similar but 
not identical to the abundance of the corresponding peaks observed in intact heme (namely 40, 
7 and 1%).  Subsequent analysis provided evidence that the putative esomeprazole-heme 
adduct found by mass-defect filtering was actually a dimer of omeprazole sulfone.  Dimerization 
of omeprazole and esomeprazole has been previously reported (195,196), and it seems likely 
given the data presented in this chapter that omeprazole sulfone can also dimerize.  Evidence 
for the presence of omeprazole sulfone dimer was found not only in microsomal incubations 
with esomeprazole, but also in a solution of omeprazole sulfone (reference standard).  In 
hindsight, the reason that this dimer was not found in NADPH-free microsomal incubation 
samples is obvious: the CYP3A4-mediated formation of omeprazole sulfone from esomeprazole 
simply could not occur in the absence of NADPH.   
The reason that the putative omeprazole sulfone dimer was not excluded by the mass-
deficit filter constructed within 35 mDa around the mass defect for heme is not as obvious.  
False positives rarely occur with mass-defect filtering.  However, because the mass-defect 
filtering algorithm employed is dynamic rather than linear across the mass range of interest, 
false positive and negative results are minimized because of the relatively large mass changes 
(and therefore mass defects) that occur with xenobiotic metabolism such as heteroatom 
dealkylation, hydrolysis or conjugation, etc.  In addition, the dynamic nature of the mass-defect 
filtering algorithm allows a relatively narrow accurate mass defect window to be maintained 
across the mass range of interest (129).  Inspection of the isotopic distribution of the filtered 
component (as described in this chapter) can typically screen out any additional false positives.  
Table 7.1 shows the isotopic masses and natural abundances of carbon, hydrogen, oxygen, 
nitrogen, sulfur and iron. 
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Table 7.1. Isotopic masses and natural abundances of stable isotopes of hydrogen, 
carbon, oxygen, nitrogen, sulfur and iron 
Element Symbol 
Mass of atom  
(amu) 
Representative isotopic composition 
(mole fraction × 100) 
Hydrogen 
1H 1.0079 99.989 
2H 2.0141 0.012 
Carbon 
12C 12.0000 98.930 
13C 13.0034 1.070 
Oxygen 
16O 15.9949 99.757 
17O 16.9991 0.038 
18O 17.9992 0.205 
Nitrogen 
14N 14.0031 99.636 
15N 15.0001 0.364 
Sulfur 
32S 31.9721 94.990 
33S 32.9715 0.750 
34S 33.9679 4.250 
36S 35.9671 0.010 
Iron 
54Fe 53.9396 5.845 
56Fe 55.9349 91.754 
57Fe 56.9354 2.119 
58Fe 57.9333 0.282 
Sources: (202,203). 
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Although the isotopic distribution of the apparent heme adduct (Figure 7.9) did not 
exactly correspond with that of intact heme (Figure 7.8), it was much more similar than a typical 
organic molecule that lacks sulfur or iron (e.g., OTP3, Figure 7.23), which have only two peaks 
containing heavier isotopes than the protonated monoisotopic molecule and no peaks 
containing lighter isotopes.  The experimentally determined (Figure 7.17) and the theoretical 
(Figure 7.22) isotopic distribution for the sulfur-containing dimer of omeprazole sulfone both 
revealed three peaks containing heavier isotopes than the protonated monoisotopic molecule.  
Importantly, because of the presence of sulfur in the molecule, the peaks at approximately +1 
and +2 mass units from the monoisotopic mass for the proposed omeprazole sulfone dimer are 
present at approximately 40 and 9% the abundance of the protonated monoisotopic molecule, 
whereas the corresponding theoretical peaks are present at only approximately 20 and 2% that 
of the protonated monoisotopic OTP3 (Figure 7.23). The effect of iron on the isotopic distribution 
is even more dramatic than the effect of sulfur, with at least two peaks containing lighter 
isotopes and three peaks containing heavier isotopes than the protonated monoisotopic 
molecule (see Figures 7.18a – 7.21).  However, the effects of the presence of sulfur on the 
isotopic distribution observed in full scan accurate mass spectra (Figure 7.9) coupled with the 
low signal intensity led to the mistaken identification of the component found by mass-deficit 
filtering in esomeprazole-incubated samples- as a heme adduct because it was assumed that 
the absence of the two lighter peaks was a consequence of background noise If the component 
found by MDF were to have been OTP3, for instance, inspection of the isotopic distribution 
would led to its rapid identification as a false positive due to the lack of sulfur. 
As discussed in Chapters 1 and 6, of the PPIs, only omeprazole, esomeprazole and 
tenatoprazole have a 5´-methyl substituent (Table 1.1), and these PPIs are all MDIs of 
CYP2C19, whereas those lacking this substituent are not (Table 4.1 and Table 6.3).  The 
conversion of omeprazole or esomeprazole to omeprazole sulfone or 5-ODM omeprazole 
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leaves this substituent intact, and these metabolites are also MBIs of CYP2C19 (and possibly 
CYP3A4 in the case of 5-ODM omeprazole).  As discussed in Chapter 6, it is known that 
omeprazole sulfone can be further metabolized by CYP2C19 to 5´-hydroxyomeprazole sulfone 
(179).  If hydroxylation at the 5´-position partitions between the formation of a non-inhibitory 5´-
hydroxy metabolite by oxygen rebound and a benzylic radical (analogous to that shown for 
gemfibrozil glucuronide, Figure 6.17), then this mechanism would be common to esomeprazole 
and its inhibitory metabolites. However, a 398 nm-detectable peak was not detected that would 
corroborate this mechanism (as it was for gemfibrozil glucuronide).  An alternative to heme 
alkylation that must be considered is that activation of esomeprazole (by the HCl used to extract 
heme) caused an artificial loss of heme.  I considered this possibility when first designing 
experiments to extract heme from HLM, but hypothesized that mass-defect filtering presented a 
novel approach to the problem because it would allow for the detection of a heme-associated 
adduct with an unexpected mass (i.e., an adduct that was not a simple addition of 
esomeprazole to heme accompanied by the loss of two hydrogen atoms, as is the case for 
gemfibrozil glucuronide (159)).  
Under acidic conditions, PPIs become protonated to form a sulfenic acid which then 
hydrolyzes to the active cyclic sulfenamide form of the drug that covalently binds to cysteine 
residues, which is the basis for their pharmacological activity. Heme was extracted from 
esomeprazole-treated HLM with 1N HCl.  If esomeprazole did form an adduct with heme, 
perhaps involving formation of a benzylic radical, it is possible that, following treatment with HCl, 
the adduct would have rearranged and possibly cross-linked the heme to the apoprotein by 
alkylation of a cysteine residue within the active site of the CYP enzyme.  This cross-linking of 
heme to the apoprotein would presumably prevent the extraction of heme. The cross-linked 
heme adduct would end up in the pellet of precipitated protein, making it undetectable by 
UHPLC with either UV of MS analysis.  However, it is important to note that the metabolites of 
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omeprazole or esomeprazole are inactive, and reportedly cannot rearrange to a reactive cyclic 
sulfenamide (57).  Whether this would apply to omeprazole bound to heme via its 5′-methyl 
group is not known. Given the high concentration of HLM (1 mg/mL) and long incubation times 
(60 – 120 min) used in the current study, it is highly likely that most of the esomeprazole that did 
not inactivate CYPs was converted to these inactive metabolites that cannot be converted to an 
active cyclic sulfenamide. In addition, such cross-linking could only occur if this reaction 
occurred more quickly than the heme itself was extracted from the apoprotein upon addition of 
HCl. Nevertheless, the potential for any esomeprazole bound to the heme of CYPs in HLM to 
cross-link to active site cysteine residues is a possibility that needs to be followed up and will be 
discussed in Chapter 8. 
In conclusion, the use of high-resolution mass spectrometry coupled with mass-defect 
filtering appeared to identify an esomeprazole-heme adduct that was subsequently revealed to 
be a dimer of omeprazole sulfone. This artifact should be taken into consideration by others 
using mass-defect filtering to investigate the inactivation of CYP enzymes by sulfur-containing 
compounds. Although compelling evidence for the formation of a heme adduct with 
esomeprazole was not found, under conditions where 1-ABT destroyed >95% of 398 nm-and 
HRMS-detectable heme and gemfibrozil glucuronide formed the expected heme adduct in 
NADPH-fortified HLM, esomeprazole was found to cause a ∼50% loss of the 398 nm- and 
HRMS detectable heme (with no new peaks found), consistent with mechanism-based inhibition 
of CYP through covalent binding to the apoprotein, cross-linking of the heme prosthetic group to 
the apoprotein moiety, or heme destruction.   
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Chapter 8. CONCLUSIONS AND FUTURE DIRECTIONS 
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8.1. Summary and conclusions  
In 2008, the American College of Cardiology Foundation, the American College of 
Gastroenterology and the American Heart Association recommended that certain high risk 
patients prescribed the anti-platelet drug clopidogrel (Plavix) also take a proton pump inhibitor 
(PPI), such as omeprazole, esomeprazole, lansoprazole, rabeprazole or pantoprazole, to 
suppress the production of gastric acid and thereby lessen the severity of upper gastrointestinal 
bleeding commonly associated with clopidogrel therapy (56).  In response to numerous but 
often contradictory reports that PPIs had the unexpected effect of reducing the therapeutic 
effectiveness of clopidogrel, regulatory agencies in Europe (EMA) and America (FDA) cautioned 
against the use of PPIs with clopidogrel.  The FDA and EMA narrowed their recommended 
restrictions to omeprazole and esomeprazole when it was discovered that these PPIs, but not 
lansoprazole or pantoprazole, decreased the anti-platelet effect of clopidogrel (109,140). 
Clopidogrel is a prodrug.  It is converted to its pharmacologically active metabolite H4, 
which covalently binds to the P2Y12 receptor on platelets, by two sequential reactions that are 
catalyzed mainly by CYP2C19.  PPIs are also metabolized by CYP2C19.  in spite of their 
relatively short plasma half-lives, it seemed reasonable to assume, therefore, that PPIs could 
reduce the therapeutic effectiveness of clopidogrel by inhibiting its conversion to H4 by 
CYP2C19.  With the exception of omeprazole and lansoprazole (and their S-enantiomers), 
which have Ki values ≤1.0 µM for direct inhibition of CYP2C19, PPIs are weak inhibitors of 
CYP2C19; hence, direct inhibition of CYP2C19 seemed an unlikely explanation for the clinical 
observation that only certain PPIs compromised the therapeutic effectiveness of clopidogrel. 
For my dissertation research, I tested the hypothesis that omeprazole and 
esomeprazole, but not lansoprazole or pantoprazole, are metabolism-dependent inhibitors of 
CYP2C19 and the selective inactivation of CYP2C19 by omeprazole and esomeprazole is the 
mechanism by which these two PPIs reduce the therapeutic effectiveness of clopidogrel.  The 
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results of my dissertation research provide compelling support for the proposed mechanism and 
provide a scientific rationale for the FDA and EMA’s recommendation that patients prescribed 
clopidogrel should avoid taking omeprazole and esomeprazole and reduce the severity of 
gastrointestinal bleeding by taking other PPIs. 
The key findings of my dissertation research can be summarized as follows. 
As shown in Chapter 4, omeprazole (a racemic mixture of R- and S-enantiomers) and 
esomeprazole (the S-enantiomer) were identified as metabolism-dependent inhibitors (MDIs) of 
CYP2C19 in human liver microsomes (HLM), human hepatocytes and recombinant CYP2C19.  
In contrast, lansoprazole and pantoprazole did not cause MDI of CYP2C19.  In addition to its 
clinical relevance, these observations are important because they underscore the importance of 
using a low concentration of enzyme and a short incubation with the CYP marker substrate in 
order to detect MDI of CYP enzyme in vitro.  In ALL previous studies of CYP2C19 inhibition by 
PPIs, the concentration of HLM was too high and/or the substrate incubation time was too long 
to detect metabolism-dependent inhibition. The kinetic parameters for CYP2C19 inactivation by 
omeprazole, namely kinact the maximum rate of inactivation, and KI, the concentration of inhibitor 
supporting half the maximum rate of inactivation, were used in a physiologically based 
pharmacokinetic (PBPK) model to predict the degree of CYP2C19 inactivation under clinical 
conditions. Omeprazole and esomeprazole were subsequently shown to be irreversible MDIs, 
which also explained the clinical observation that the loss of clopidogrel’s therapeutic 
effectiveness cannot be prevented by separating the doses of clopidogrel and omeprazole or 
esomeprazole. 
In Chapter 5, I demonstrated that, like the parent drug, two of the three major 
metabolites of omeprazole are also irreversible inactivators of CYP2C19.  The kinetic 
parameters for CYP2C19 inactivation were determined and, along with those for omeprazole 
and esomeprazole, used in a mechanistic static model to predict the reduction of H4 formation 
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from clopidogrel under clinical conditions.  The model slightly overpredicted (by a factor of 2) the 
ability of omeprazole to block the conversion of clopidogrel to H4, its pharmacologically active 
metabolites, but otherwise established that inactivation of CYP2C19 is the likely mechanism for 
the clinical interaction between omeprazole/esomeprazole and clopidogrel. 
In Chapter 6, I established that esomeprazole and its two inhibitory metabolites, namely 
omeprazole sulfone and 5-O-desmethylomeprazole, meet the so-called Silverman criteria for 
mechanism-based inhibition (a special case of irreversible MDI).  In this chapter I initiated 
studies to test the hypothesis that the mechanism of CYP2C19 inactivation by esomeprazole 
and its metabolites involves the formation of a benzylic radical (on the 5′-methyl group) that 
binds covalently to the heme moiety.  This hypothesis was based on the observation that the 5′-
methyl group is present on the pyridine ring of those compounds that irreversibly inactivate 
CYP2C19, namely omeprazole, esomeprazole, omeprazole sulfone and 
5-O-desmethylomeprazole, but absent from those compounds that did not inactivate CYP2C19, 
namely lansoprazole, pantoprazole and 5′-hydroxyomeprazole.  (The latter compound contains 
a 5′-methyl group but it is hydroxylated and, hence, cannot be converted to a benzylic radical.)  
Based on this hypothesis, I correctly predicted that tenatoprazole, which contains a 5′-methyl 
group, does cause MDI of CYP2C19 whereas ilaprazole and rabeprazole, which lack a 
5′-methyl group, do not cause MDI of CYP2C19.  Tenatoprazole and ilaprazole have not been 
approved by the FDA for use in the USA but ilaprazole has been approved in other countries.  
The results presented in Chapter 6 suggest that the investigational drug, tenatoprazole, but not 
the clinically used ilaprazole or rabeprazole, will compromise the therapeutic effectiveness of 
clopidogrel and should be added to the list of PPIs to avoid in patients taking clopidogrel, if it is 
approved. 
Chapter 7 describes studies that were performed to provide direct evidence for the 
proposed mechanism of inactivation of CYP2C19 by esomeprazole, namely the formation of a 
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heme adduct.  These studies would have been performed with 14C-labeled omeprazole or 
esomeprazole had they been commercially available, but they are not.  Therefore, formation of 
a heme adduct in incubations of esomeprazole in HLM was evaluated by UHPLC analysis with 
UV/VIS detection (to measure heme at ~400 nm) and by high resolution mass spectrometry 
(HRMS) with post-acquisition mass-defect filtering to identify heme and heme-containing 
adducts.  The results in Chapter 7 show that incubating HLM with esomeprazole results in a 
substantial decrease in the amount of heme detectable by UHPLC coupled with either UV 
absorbance or HRMS and appeared to show the formation of a heme adduct based on mass-
defect filtering.  However, the putative heme adduct was subsequently identified as a dimer of 
esomeprazole sulfone (a metabolite of esomeprazole formed by CYP3A4/5).  Chapter 7 did not 
identify an adduct between heme and a metabolite of esomeprazole but it did reveal the 
potential for an unusual artifact; namely, that sulfur-containing drugs can be converted to 
metabolites that closely resemble a heme adduct based on mass-defect filtering and isotopic 
distribution. 
Overall, the results of my dissertation research support the hypothesis that irreversible 
inactivation of CYP2C19 is the mechanism by which omeprazole and esomeprazole reduce the 
therapeutic effectiveness of clopidogrel.  This property is not shared by lansoprazole, 
pantoprazole, rabeprazole or ilaprazole. These findings support the FDA’s recommendation 
that, in order to reduce the risk of gastrointestinal bleeding, clopidogrel should not be 
coadministered with omeprazole or esomeprazole but should be coadministered with other 
PPIs.    
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8.2. Future directions 
The results of my dissertation research suggest that PPIs containing a 5′-methyl group on the 
pyridine ring, such as omeprazole and esomeprazole, can be converted to a benzylic radical 
that binds covalently to the heme moiety of CYP2C19 leading to irreversible loss of enzyme 
activity. In the future, this proposed mechanism could be evaluated by testing the prediction that 
changing the 5′-methyl group in esomeprazole to a 5′-trifluoromethyl group would block the 
formation of a 5′-benzylic radical and, hence, prevent the irreversible inactivation of CYP2C19.  
Trifluoromethyl-omeprazole, especially trifluoromethyl-R-omeprazole, represents a possible new 
PPI, one that would be (1) metabolized slower than R-omeprazole or esomeprazole (because 
the trifluoromethyl group would block 5′-hydroxylation by CYP2C19), (2) suitable for 
coadministration with clopidogrel (provided it did not, as predicted, inactivate CYP2C19), and (3) 
less susceptible to pharmacokinetic variation due to genetic polymorphisms of CYP2C19.   
Future experiments could also be undertaken to investigate the mechanism of CYP2C19 
inactivation by esomeprazole.  Such studies would be greatly assisted by custom-synthesizing 
14C-esomeprazole to establish whether a metabolite of esomeprazole binds to the heme 
prosthetic group or apoprotein moiety of CYP2C19 (or cross-links the heme to the apoprotein).  
Future studies of the mechanism of CYP2C19 inactivation by esomeprazole would also be 
assisted by the availability of purified CYP2C19, which could be used to detect the covalent 
binding of esomeprazole metabolites to the apoprotein by whole-protein mass spectrometry 
(with suitable deconvolution software).   
An intriguing finding from my dissertation research is the difference between the R- and 
S-enantiomers of omeprazole. Only esomeprazole (the S-enantiomer) inactivated CYP2C19, 
which is surprising because the R-enantiomer not only contains a 5′-methyl group but this 
position is extensively metabolized by CYP2C19 (more so than esomeprazole).  The 
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5′-hydroxylation of R-omeprazole presumably involves the intermediacy of a benzylic radical, 
which begs the question: Why doesn’t R-omeprazole inactivate CYP2C19?  Stereoselective 
inhibition of CYP2C19 has been reported for fluoxetine.  Both the R- and S-enantiomers are 
metabolism-dependent inhibitors but only S-fluoxetine causes irreversible metabolism-
dependent inhibition due to formation of a metabolite that coordinates with the heme iron of 
CYP2C19 (to form a metabolite inhibitory complex or MIC) (as shown in Figure 6.8) (177,178). 
Stereoselective metabolism of mesantoin (racemic mephenytoin) is of historical interest 
because it led to the discovery of CYP2C19, which was identified as the enzyme responsible for 
genetic polymorphisms in the metabolism of S-mephenytoin that had no effect on the disposition 
of R-mephenytoin (1).  Even though mesantoin was withdrawn from the market, S-mephenytoin 
continues to be widely used as a selective in vitro, and even clinical, probe substrate for 
CYP2C19. 
Although stereoselective metabolism and inhibition of CYP2C19 are not unprecedented, 
future studies could be undertaken to explain why esomeprazole irreversibly inactivates 
CYP2C19 and R-omeprazole does not.  CYP2C19 has been crystallized, allowing mapping of 
its substrate-binding site (204).  Future docking experiments might compare the binding of 
esomeprazole and R-omeprazole in the same orientation (with the 5′-methyl group adjacent to 
the heme moiety) to evaluate whether differences in binding can explain why only esomeprazole 
inactivates CYP2C19.  An alternative explanation is that the inactivation of CYP2C19 by 
esomeprazole is not due to the formation of 5′-benzylic radical but is due to O-demethylation of 
methoxy group on the benzimidazole ring (with possible formation of a reactive quinoneimine).  
However, if O-demethylation were responsible for the inactivation of CYP2C19 by 
esomeprazole, then such inactivation would be expected to occur with lansoprazole.  
Nevertheless, future experiments with structural modifications of the methoxy group on the 
238 
 
benzimidazole ring of esomeprazole (such as its replacement with a trifluoromethyl group to 
block metabolism) could be conducted to examine this possibility. 
My dissertation research provided a clinically relevant example of the importance of in 
vitro incubation conditions on the ability to detect metabolism-dependent inhibition of CYP 
enzymes.  Numerous studies of the inhibitory potential of omeprazole failed to detect its ability 
to inactivate CYP2C19, and this can be attributed to the use of high concentrations of HLM 
and/or inappropriately long substrate incubation times. It is possible that the ability of other 
drugs to inactivate CYP enzymes in vitro has also been missed due the use of inappropriate 
incubation conditions. In light of the potential importance of benzylic radicals in the inactivation 
of CYP2C19 by omeprazole, esomeprazole and tenatoprazole, as well as the known role of a 
benzylic radical in the inactivation of CYP2C8 by gemfibrozil glucuronide, it would be of interest 
in the future to evaluate other drugs that undergo benzylic hydroxylation for their ability to cause 
metabolism-dependent inhibition of CYP enzymes under appropriate in vitro conditions.  Such 
drugs include amitriptyline, celecoxib, debrisoquine, desloratadine, glibornuride, gliclazide, 
metoprolol, nortryptyline, salmeterol, reparixin, terodiline, tolazamide, tolbutamide, tolmetin, 
torasemide, tripelennamine, sitaxsentan, and warfarin (those shown in italics are hydroxylated 
at an unsubstituted benzylic methyl group). 
My dissertation research identified tenatoprazole but not ilaprazole or rabeprazole as 
metabolism-dependent inhibitors of CYP2C19.  As such, tenatoprazole (but not ilaprazole or 
rabeprazole) is predicted to inhibit the CYP2C19-dependent conversion of clopidogrel to its 
pharmacologically active metabolite H4.  Tenatoprazole and ilaprazole are not approved PPIs in 
the USA.  Nevertheless, it would be of clinical interest to conduct studies in human subjects to 
examine the potential of tenatoprazole and ilaprazole to inhibit the formation of H4 and thereby 
reduce the therapeutic effectiveness of clopidogrel.   
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Providing a mechanistic rationale for the clinically important interaction between 
clopidogrel and omeprazole and esomeprazole, and the lack of interaction with lansoprazole 
and pantoprazole, and identifying tenatoprazole as a new PPI with the same drug interaction 
potential as omeprazole and esomeprazole are major highlights of my dissertation research. 
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